Back to GetFilings.com
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-K
|
|
|
þ
|
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 |
|
|
|
For the year ended December 31, 2004 |
|
Or |
|
o
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 |
|
|
|
For the transition period
from to . |
Commission File Number 000-31803
Transmeta Corporation
(Exact name of registrant as specified in its charter)
|
|
|
Delaware |
|
77-0402448 |
(State of Incorporation) |
|
(IRS Employer Identification No.) |
3990 Freedom Circle, Santa Clara, CA 95054
(Address of Principal Executive Offices, including zip
code)
(408) 919-3000
(Registrants Telephone Number, including area code)
Securities registered pursuant to Section 12(b) of the
Act:
None
Securities registered pursuant to Section 12(g) of the
Act:
Common Stock, $0.00001 par value per share
Stock Purchase Rights
Indicate by check mark whether the registrant: (1) has
filed all reports required to be filed by Section 13 or
15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has
been subject to such filing requirements for the past
90 days. Yes þ No o
Indicate by check mark if disclosure of delinquent filers
pursuant to Item 405 of Regulation S-K is not
contained herein, and will not be contained, to the best of
Registrants knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this
Form 10-K or any amendment to this
Form 10-K. þ
Indicate by check mark whether the registrant is an accelerated
filer (as defined in Exchange Act
Rule 12b-2). Yes þ No o
As of June 25, 2004, the aggregate market value of the
shares of common stock held by non-affiliates of the Registrant
(based on the closing price of $2.26 for the common stock as
quoted by the NASDAQ National Market on that date) was
approximately $351,200,603.
As of February 28, 2005, there were 189,821,030 shares
of the Registrants common stock, $0.00001 par value
per share, outstanding. This is the only outstanding class of
common stock of the Registrant.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the Registrants definitive Proxy Statement for
its Annual Meeting of Stockholders to be held in 2005 are
incorporated by reference into Parts II and III of
this report on Form 10-K.
TRANSMETA CORPORATION
FISCAL YEAR 2004 FORM 10-K
INDEX
We were incorporated in California in March 1995 and
reincorporated in Delaware in October 2000. Our principal
executive offices are located at 3990 Freedom Circle,
Santa Clara, California 95054, and our telephone number at
that address is (408) 919-3000. Transmeta®, the
Transmeta logo, Crusoe®, the Crusoe logo, Code
Morphing®, LongRun®,
LongRun2tm,
Efficeontm
and
AntiVirusNXtm
are trademarks of Transmeta Corporation in the United States and
other countries. All other trademarks or trade names appearing
in this report are the property of their respective owners.
1
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This Report contains forward-looking statements that are based
upon our current expectations, estimates and projections about
our industry, and that reflect our beliefs and certain
assumptions based upon information made available to us at the
time of this Report. Words such as anticipates,
expects, intends, plans,
believes, seeks, estimates,
may, could, will and
variations of these words or similar expressions are intended to
identify forward-looking statements. Such statements include,
but are not limited to, statements concerning anticipated trends
or developments in our business and the markets in which we
operate, the competitive nature and anticipated growth of those
markets, our expectations for our future performance and the
market acceptance of our products, our ability to develop our
licensing and services business and our future gross margins,
operating expenses and need for additional capital.
Investors are cautioned that such forward-looking statements are
only predictions, which may differ materially from actual
results or future events. These statements are not guarantees of
future performance and are subject to risks, uncertainties and
assumptions that are difficult to predict. Some of the important
risk factors that may affect our business, results of operations
and financial condition are set out and discussed below in the
section entitled Risks That Could Affect Future
Results. You should carefully consider those risks, in
addition to the other information in this Report and in our
other filings with the SEC, before deciding to invest in our
company or to maintain or change your investment. Investors are
cautioned not to place reliance on these forward-looking
statements, which reflect managements analysis only as of
the date of this Report. We undertake no obligation to revise or
update any forward-looking statement for any reason.
PART I
General
In March 2005, as we prepare this Annual Report for our 2004
fiscal year, we are simultaneously completing our evaluation of
our customers requirements for our products and of the
economics and competitive conditions in the market for
x86-compatible microprocessors. We expect to modify our business
model based in part on that evaluation and to announce a related
restructuring plan on or about March 31, 2005. We are also
currently engaged in discussions with other companies regarding
potential strategic alliances for leveraging our microprocessor
design and development capabilities, and we believe that the
outcome of those discussions might also affect the nature and
extent of our restructuring plan.
From Transmetas inception in 1995 through our fiscal year
ended December 31, 2004, our business model was focused
primarily on designing, developing and selling highly efficient
x86-compatible software-based microprocessors. We believe that
our microprocessor products deliver a compelling balance of low
power consumption, high performance, low cost and small size.
These advantages are valuable to a broad range of computing
platforms, especially battery-operated mobile devices and
applications that need high performance, low power consumption
and low heat generation. Such platforms include notebook
computers, ultra-personal computers, or UPCs, tablet PCs, thin
clients, blade servers and embedded computers. We currently
supply our products to a number of the leading companies in the
computer industry, such as Fujitsu, Hewlett-Packard, and Sharp.
Our products include our Crusoe® and
Efficeontm
families of microprocessors.
Although we believe that our products deliver a compelling
balance of low power consumption, high performance, low cost and
small size, we have had negative cash flows and had incurred a
cumulative loss aggregating $649.4 million as of
December 31, 2004. Accordingly, we have focused
increasingly on diversifying our business model by establishing
a revenue stream based upon the licensing of certain of our
intellectual property and advanced computing and semiconductor
technologies developed in the course of Transmetas
research and development programs. Since March 2004, we have
entered into and announced agreements granting licenses to NEC
Electronics, Fujitsu Limited and Sony Corporation to use
Transmetas proprietary
LongRun2tm
technologies for power management and transistor leakage
control. Those licensing agreements include deliverable-based
technology transfer fees, maintenance and service fees, and
subsequent royalties on products incorporating the licensed
technologies.
2
In January 2005, we announced that we are critically evaluating
the economics of our microprocessor product business during the
first quarter of 2005 and that we intend to modify our business
model in 2005 to increase our efforts to license our
intellectual property and advanced technologies. We intend to
continue our efforts to license our advanced power management
technologies to other semiconductor companies, and we are also
contemplating licensing our intellectual property and
microprocessor and computing technologies to other companies in
the future in order to grow our licensing and services revenue.
During the first quarter of 2005, as part of our transition to a
modified business model, we also began taking action to reduce
our operating expenses by discontinuing certain of our products,
increasing prices for our products, and changing our terms and
conditions of sale, which actions we anticipate will improve the
negative gross margins historically associated with our product
business. We currently expect that our modified business model
will further reduce our historic business focus on product
sales, and that we will further reduce operating expenses
associated with our product business as part of a restructuring
plan, including a reduction of our workforce.
Our Product Business
Our product business model has historically focused on
designing, developing and selling x86-compatible microprocessor
products, including products in both our Crusoe® and
Efficeontm
families. Unlike traditional microprocessors that are built
entirely with silicon hardware, our microprocessor products
utilize our innovative combination of software and hardware
technology. A portion of the functionality of our
microprocessors is implemented with software that allows the
remaining functionality to be implemented in hardware with only
a fraction of the number of logic transistors required in a
conventional microprocessor. Because of this reduction in the
number of logic transistors, our microprocessors consume less
power and generate less heat.
In 2004 we derived product revenue from our sales of Crusoe and
Efficeon microprocessor products. In March 2005, as we prepare
this Annual Report for our 2004 fiscal year, we are
simultaneously completing our evaluation of our customers
requirements for those products and of the economics and
competitive conditions in the market for x86-compatible
microprocessors. We have been consulting with our customers and
critical suppliers in that evaluation, and we have announced to
our customers that we will continue to support their critical
product requirements while taking immediate steps to improve our
targeted product margins and positively impact our cash flow.
We announced our first family of microprocessor products in
January 2000 under the brand name Crusoe. The Crusoe product
family evolved multiple models featuring different performance
levels and cost structures. Our current Crusoe models are in the
TM5800 series. We introduced the TM5800 in June 2001 and began
to derive revenue from TM5800 sales during the fourth quarter of
2001. Our TM5800 processors are manufactured at Taiwan
Semiconductor Manufacturing Company, or TSMC, using TSMCs
130 nanometer CMOS technology.
During the first quarter of 2005, we have worked with our
current and potential customers to take steps to improve
Crusoes targeted product margins and to positively impact
Transmetas cash flow. Based on these efforts, we have
advised our customers that we plan to discontinue our Crusoe
products during 2005. We have provided our Crusoe customers in
the first quarter of 2005 an End-of-Life notice on these
products and we will continue to work closely with our customers
during this transition period.
In October 2003, we introduced our second family of
microprocessors, the Efficeon TM8000 series. Our first Efficeon
products were originally manufactured at TSMC, using the TSMC
130 nanometer CMOS manufacturing process that has been used for
our Crusoe TM5800 products. In September 2004, we began building
a new version of our Efficeon processor, the TM8800 series,
using a new 90 nanometer CMOS manufacturing technology at
Fujitsus 90 nanometer foundry in Akiruno, Japan.
3
During the first quarter of 2005, we have taken steps to improve
the product margins for our Efficeon products and positively
impact our cash flow in our product business. Based upon our
review of critical customer needs, we have decided to narrow our
Efficeon product line and announced to our customers in the
first quarter of 2005 that certain versions of the Efficeon
products will be discontinued. These efforts have in some cases
resulted in substantial price increases and other favorable
changes to our terms and conditions of sale. We expect to
continue evaluating the business of designing, developing and
selling our Efficeon processors, and we may decide to
discontinue some or all of our remaining Efficeon products in
2005 as we refine our modified business model.
Our Licensing and Services Business
We began licensing certain of our intellectual property and
advanced computing and semiconductor technologies in 2003, and
we expect to continue building this line of our business in the
future. We have derived most of our revenue in this line of
business from licensing and services agreements relating to our
proprietary LongRun2 technologies for power management and
transistor leakage control. Since March 2004, we have entered
into and announced agreements granting such licenses to NEC
Electronics, Fujitsu Limited and Sony Corporation. Those
licensing agreements include deliverable-based technology
transfer fees, maintenance and service fees, and subsequent
royalties on products incorporating the licensed technologies.
We intend to continue our efforts to license our advanced power
management technologies to other semiconductor companies, and we
are also contemplating licensing our intellectual property and
microprocessor and computing technologies to other companies in
the future in order to increase our revenue in this line of
business.
Customers
We currently sell our products to a number of the computing
industrys leaders. Based on product revenue for the year
ended December 31, 2004, our top two customers were Hewlett
Packard and Sharp.
We have licensed our proprietary LongRun2 and advanced power
management technologies to three companies. During the year
ended December 31, 2004, we entered into such licensing
agreements with NEC Electronics and Fujitsu. In January 2005 we
entered into such an agreement with Sony Corporation. We
continue to work with other semiconductor companies on the
potential for licensing LongRun2 technologies.
Sales and Marketing
We have traditionally sold our x86 microprocessor products
directly to OEMs and through distributors, stocking
representatives and manufacturers representatives. During
the first quarter of 2005, we have evaluated changes required to
align our sales and distribution network with the changes we
have made or contemplate making to our microprocessor product
business model. We have started to consolidate our sales and
distribution network by, for example, terminating our agreements
with certain distributors, stocking representatives and
manufacturers representatives, as appropriate, to reflect
such changes to our business model.
We have traditionally employed direct sales personnel, and we
currently employ direct sales personnel located in the United
States, Japan, Taiwan, Korea and China. Based upon the changes
that we have made or contemplate making to our microprocessor
product business model, we anticipate reducing our sales and
marketing activities and resources worldwide, and we expect to
consolidate our direct sales personnel in the United States and
in Japan in 2005.
We also employ field applications engineers who work directly
with our customers. We currently have field applications
engineers working in our offices in Taiwan, China and Japan, and
in two locations in the United States. Our field applications
engineers assist our potential customers in selecting,
integrating and tuning hardware and software system components
that make up the final computer system. We also provide
potential customers with reference platform designs, which we
believe will enable our customers to achieve easier and faster
transitions from the initial prototype designs through final
production releases. We believe these reference platform designs
also will enhance our targeted customers confidence that
our products will
4
meet their market requirements and product introduction
schedules. Based upon the changes that we have made or
contemplate making to our microprocessor product business model,
we anticipate reducing our field applications engineering
resources in 2005.
Manufacturing
We have traditionally used third-party manufacturers for all of
our wafer fabrication. By subcontracting our manufacturing, we
focus our resources on product design and eliminate the high
cost of owning and operating a semiconductor fabrication
facility. This fabless business model also allows us to take
advantage of the research and development efforts of
manufacturers, and permits us to work with those manufacturers
that offer the most advanced manufacturing processes and
competitive prices.
We currently use Taiwan Semiconductor Manufacturing Company, or
TSMC, to fabricate wafers for our Crusoe microprocessors. We
place orders with TSMC on a purchase order basis. We do not have
a manufacturing agreement with TSMC that guarantees any
particular production capacity or any particular price from
TSMC. TSMC may allocate capacity to other companies and reduce
deliveries to us on short notice.
We currently use Fujitsu Limited in Japan to manufacture our 90
nanometer Efficeon TM8000 products. We began volume shipments
from this process in the second half of 2004. We have yet to
enter into a definitive manufacturing agreement with Fujitsu,
and any agreement we may enter into may not provide us with
guaranteed production capacity.
Advanced Semiconductor Engineering, or ASE, performs the initial
testing of the silicon wafers that contain our microprocessors.
After initial testing, ASE cuts the silicon wafers into
individual semiconductors and assembles them into packages. All
testing is performed on standard test equipment using
proprietary test programs developed by our test engineering
group. We periodically inspect the test facilities to ensure
that their procedures remain consistent with those required for
the assembly of our products. We generally ship our products
from a third party fulfillment center in Hong Kong.
We participate in quality and reliability monitoring through
each stage of the production cycle by reviewing data from our
wafer fabrication plants and assembly subcontractor. We closely
monitor wafer fabrication plant production to enhance product
quality and reliability and yield levels.
Competition
The market for microprocessors is intensely competitive, is
subject to rapid technological change and is currently, and has
been for many years, dominated by Intel. We face intense and
direct competition from Intel, and we face additional
competition from Advanced Micro Devices and VIA Technologies, in
the market for microprocessors. We expect to continue to face
intense competition from these and other competitors in the
various microprocessor markets that we target or may target in
the future. We believe that competition will be intense in the
future in all of the markets in which we compete and may cause
price reductions, reduced gross margins and loss of market
share, any one of which could significantly reduce our future
revenue and increase our losses.
We compete on the basis of a variety of factors, including:
|
|
|
|
|
technical innovation; |
|
|
|
performance of our products, including their speed, power usage,
product system compatibility, reliability and size; |
|
|
|
product price; |
|
|
|
product availability; |
|
|
|
reputation and branding; |
5
|
|
|
|
|
product marketing and merchandising; and |
|
|
|
technical support. |
Many of our current and potential competitors have longer
operating histories, significantly greater financial, technical,
product development and marketing resources, greater name
recognition, significantly greater influence and leverage in the
industry and much larger customer bases than we do. We may not
be able to compete effectively against current and potential
competitors, especially those with significantly greater
resources and market leverage.
In marketing our microprocessors to OEMs, ODMs and distributors,
we depend on third-party companies for the design and
manufacture of core-logic chipsets, graphics chips,
motherboards, BIOS software and other components. All of these
third-party designers and manufacturers produce chipsets,
motherboards, BIOS software and other components to support each
new generation of Intels microprocessors, and Intel has
significant leverage over their business opportunities.
We also expect to face substantial competition in our licensing
and services business, in which we have focused primarily on
licensing our power management and transistor leakage control
technologies. The development of such technologies is an
emerging field subject to rapid technological change, and our
competition is unknown and could increase. Our LongRun2
technologies are highly proprietary and, though the subject of
patents and patents pending, are marketed primarily as trade
secrets subject to strict confidentiality protocols. Although we
are not aware of any other company having developed, offered or
demonstrated any comparable power management or leakage control
technologies, we note that most semiconductor companies have
internal efforts to reduce transistor leakage and power
consumption in current and future semiconductor products.
Indeed, all of our current and prospective licensees are larger,
technologically sophisticated companies, which generally have
significant resources and internal efforts to develop their own
technological solutions. We expect to compete against any
emerging competition on the basis of several factors, including
the following:
|
|
|
|
|
technical innovation; |
|
|
|
performance of our technology, including the nature and extent
of transistor leakage reduction; |
|
|
|
compatibility with other semiconductor design, materials and
manufacturing choices by current and prospective licensees; |
|
|
|
reputation; and |
|
|
|
quality of our services and technical support. |
Intellectual Property
Our success depends in part upon our ability to secure and
maintain legal protection for the proprietary aspects of our
technology and to operate without infringing the proprietary
rights of others. We rely on a combination of patents,
copyrights, trademarks, trade secret laws and contractual
restrictions on disclosure to protect our intellectual property
rights. Our intellectual property rights include numerous issued
U.S. patents, with expiration dates ranging from 2012 to
2025. We also have a number of patent applications pending in
the United States and in other countries. It is possible that no
more patents will issue from patent applications that we have
filed. Our existing patents and any additional patents that may
issue may not provide sufficiently broad protection to protect
our proprietary rights. We hold a number of trademarks,
including Transmeta, Crusoe, Efficeon, LongRun, LongRun2, Code
Morphing, and AntiVirusNX.
Legal protections afford only limited protection for our
technology. Despite our efforts to protect our proprietary
rights, unauthorized parties may attempt to copy aspects of our
products or to obtain and use information that we regard as
proprietary. In addition, the laws of some foreign countries do
not protect our proprietary rights to the same extent as do the
laws of the United States. Attempts may be made to copy or
reverse engineer aspects of our products or to obtain and use
information that we regard as proprietary. Accordingly, we may
not be able to prevent misappropriation of our technology or
deter others from
6
developing similar technology. Furthermore, policing the
unauthorized use of our products or technology is difficult.
Leading companies in the semiconductor industry have extensive
intellectual property portfolios relating to semiconductor
technology. From time to time, third parties, including these
leading companies, may assert exclusive patent, copyright,
trademark and other intellectual property rights to technologies
and related methods that are important to us. We have received,
and may in the future receive, communications from third parties
asserting patent or other intellectual property rights covering
our products. There are currently no such third party claims
that we believe to be material. In the future, however,
litigation may be necessary to defend against claims of
infringement or invalidity, to determine the validity and scope
of the proprietary rights of others, to enforce our intellectual
property rights, or to protect our trade secrets.
Employees
At December 31, 2004, we employed 310 people in the United
States, Japan, Taiwan, China and Korea. Of these employees, 227
were engaged in research and development, 44 were engaged in
sales and marketing and 39 were engaged in general and
administrative functions. None of our employees is subject to
any collective bargaining agreements.
In January 2005, we announced that we expect to announce a
corporate restructuring on or about March 31, 2005. We
expect that our restructuring plan will include a reduction of
our workforce. In January 2005 we gave written notice to our
employees, pursuant to federal and state Worker Adjustment and
Retraining Notification (WARN) Acts and similar statutes
applicable in other countries, that we plan to restructure our
business operations and, depending upon the outcome of
negotiations with third parties for strategic collaborations, we
expect to conduct a mass layoff on or about March 31, 2005.
We currently expect that our restructuring plan will include a
reorganization of our management team and some changes in our
executive officers.
Despite the uncertainty associated with our prospective
restructuring and related workforce reduction, we believe that
our employee relations are good. We believe that our future
success depends in part upon our continued ability to hire and
retain qualified personnel.
Available Information
We make available free of charge on or through our Internet
address located at www.transmeta.com our annual report on
Form 10-K, quarterly reports on Form 10-Q, current
reports on Form 8-K, and amendments to those reports filed
or furnished pursuant to Section 13(a) or 15(d) of the
Securities Exchange Act of 1934, as amended, as soon as
reasonably practicable after we electronically file that
material with, or furnish it to, the Securities and Exchange
Commission. Materials we file with the SEC may be read and
copied at the SECs Public Reference Room at 450 Fifth
Street, NW, Washington, D.C. 20549. This information may
also be obtained by calling the SEC at 1-800-SEC-0330. The SEC
also maintains an Internet website that contains reports, proxy
and information statements, and other information regarding
issuers that file electronically with the SEC at
www.sec.gov. We will provide a copy of any of the
foregoing documents to stockholders upon request.
We lease a total of approximately 126,225 square feet of
office space in Santa Clara, California, under leases
expiring in June 2008. We also lease office space in Taiwan,
Japan and China to support our sales and marketing personnel
worldwide. As a result of our workforce reduction in the third
quarter of fiscal 2002, we vacated approximately
67,730 square feet of office space in Santa Clara,
California. During the fourth quarter of fiscal 2003, we
reassessed our needs for office space and determined that we
will use approximately 20,000 square feet of previously
vacated space in 2004. We have listed the vacated excess office
space with a real estate broker in an effort to secure
subtenants. As of December 31, 2004, approximately
31,100 square feet of vacated office space has been
subleased.
7
|
|
Item 3. |
Legal Proceedings |
The Company is a party to one consolidated lawsuit. Beginning in
June 2001, the Company, certain of its directors and officers,
and certain of the underwriters for its initial public offering
were named as defendants in three putative shareholder class
actions that were consolidated in and by the United States
District Court for the Southern District of New York in In re
Transmeta Corporation Initial Public Offering Securities
Litigation, Case No. 01 CV 6492. The complaints allege
that the prospectus issued in connection with the Companys
initial public offering on November 7, 2000 failed to
disclose certain alleged actions by the underwriters for that
offering, and alleges claims against the Company and several of
its officers and directors under Sections 11 and 15 of the
Securities Act of 1933, as amended, and under
Sections 10(b) and Section 20(a) of the Securities
Exchange Act of 1934, as amended. Similar actions have been
filed against more than 300 other companies that issued stock in
connection with other initial public offerings during 1999-2000.
Those cases have been coordinated for pretrial purposes as In
re Initial Public Offering Securities Litigation, Master
File No. 21 MC 92 (SAS). In July 2002, the Company joined
in a coordinated motion to dismiss filed on behalf of multiple
issuers and other defendants. In February 2003, the Court
granted in part and denied in part the coordinated motion to
dismiss, and issued an order regarding the pleading of amended
complaints. Plaintiffs subsequently proposed a settlement offer
to all issuer defendants, which settlement would provide for
payments by issuers insurance carriers if plaintiffs fail
to recover a certain amount from underwriter defendants.
Although the Company and the individual defendants believe that
the complaints are without merit and deny any liability, but
because they also wish to avoid the continuing waste of
management time and expense of litigation, they accepted
plaintiffs proposal to settle all claims that might have
been brought in this action. Our insurance carriers are part of
the proposed settlement, and the Company and the individual
Transmeta defendants expect that their share of the global
settlement will be fully funded by their director and officer
liability insurance. Although the Company and the Transmeta
defendants have approved the settlement in principle, it remains
subject to several procedural conditions, as well as formal
approval by the Court. It is possible that the parties may not
reach a final written settlement agreement or that the Court may
decline to approve the settlement in whole or part. In the event
that the parties do not reach agreement on the final settlement,
the Company and the Transmeta defendants believe that they have
meritorious defenses and intend to defend any remaining action
vigorously.
|
|
Item 4. |
Submission of Matters to a Vote of Security Holders |
Not applicable.
8
PART II
|
|
Item 5. |
Market for Registrants Common Equity and Related
Stockholder Matters |
Market Information for Common Stock
Our common stock began trading on the NASDAQ National Market on
November 6, 2000 under the symbol TMTA. The
following table shows the high and low sale prices reported on
the NASDAQ National Market for the periods indicated. The market
price of our common stock has been volatile. See
Managements Discussion and Analysis of Financial
Condition and Results of Operations Risks That Could
Affect Future Results. On February 28, 2005, the
closing price of our common stock was $1.05.
|
|
|
|
|
|
|
|
|
|
|
|
High | |
|
Low | |
|
|
| |
|
| |
Fiscal year ended December 31, 2003
|
|
|
|
|
|
|
|
|
|
First quarter
|
|
$ |
1.62 |
|
|
$ |
1.05 |
|
|
Second quarter
|
|
|
1.90 |
|
|
|
0.91 |
|
|
Third quarter
|
|
|
3.59 |
|
|
|
1.41 |
|
|
Fourth quarter
|
|
|
5.51 |
|
|
|
2.75 |
|
Fiscal year ended December 31, 2004
|
|
|
|
|
|
|
|
|
|
First quarter
|
|
$ |
4.44 |
|
|
$ |
3.01 |
|
|
Second quarter
|
|
|
4.20 |
|
|
|
2.00 |
|
|
Third quarter
|
|
|
2.30 |
|
|
|
0.96 |
|
|
Fourth quarter
|
|
|
2.19 |
|
|
|
1.20 |
|
Stockholders
As of February 28, 2005, we had approximately 593 holders
of record of our common stock. This does not include the number
of persons whose stock is in nominee or streetname
accounts through brokers.
Dividends
Transmeta has never declared or paid cash dividends on our
common stock. We currently intend to retain all available funds
and any future earnings to fund the development and growth of
our business and do not anticipate declaring or paying any cash
dividends on our common stock in the foreseeable future.
Securities Authorized For Issuance Under Equity Compensation
Plans
The information required by this item is incorporated by
reference to the caption Equity Compensation Plan
Information in our Proxy Statement for our 2004 Annual
Meeting.
Recent Sales of Unregistered Securities
During the year ended December 31, 2004, we issued and sold
the following unregistered securities:
In March 2004, we issued 9,899 shares of common stock to
Aisys Corporation upon exercise of a warrant that was granted in
March 1999. The exercise price of $3.00 was paid by a net
exercise of the warrant through the surrender of shares issuable
under the warrant.
The sales and issuance of securities listed above were
determined to be exempt from registration under
Section 4(2) of the Securities Act or Regulation D
promulgated under the Securities Act as transactions by an
issuer not involving a public offering.
9
|
|
Item 6. |
Selected Financial Data |
The following table reflects selected unaudited consolidated
financial information for Transmeta for the past five fiscal
years. We have prepared this information using the historical
audited consolidated financial statements of our company for the
five years ended December 31, 2004.
It is important that you read this selected historical financial
data with the historical consolidated financial statements and
related notes contained in this Report as well as the section of
this Report titled Managements Discussion and
Analysis of Financial Condition and Results of Operations.
These historical results are not necessarily indicative of
results to be expected in any future period.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31, | |
|
|
| |
|
|
2004 | |
|
2003 | |
|
2002 | |
|
2001 | |
|
2000 | |
|
|
| |
|
| |
|
| |
|
| |
|
| |
|
|
(In thousands, except per share data) | |
Consolidated Statement of Operations Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product
|
|
$ |
18,776 |
|
|
$ |
16,225 |
|
|
$ |
24,247 |
|
|
$ |
35,590 |
|
|
$ |
16,180 |
|
|
License and service
|
|
|
10,668 |
|
|
|
1,090 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
|
29,444 |
|
|
|
17,315 |
|
|
|
24,247 |
|
|
|
35,590 |
|
|
|
16,180 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenue(1)
|
|
|
37,065 |
|
|
|
16,324 |
|
|
|
17,127 |
|
|
|
48,694 |
|
|
|
9,461 |
|
|
Impairment charge on long-lived assets(4)
|
|
|
1,943 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total cost of revenue
|
|
|
39,008 |
|
|
|
16,324 |
|
|
|
17,127 |
|
|
|
48,694 |
|
|
|
9,461 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit (loss)
|
|
|
(9,564 |
) |
|
|
991 |
|
|
|
7,120 |
|
|
|
(13,104 |
) |
|
|
6,719 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development
|
|
|
52,765 |
|
|
|
48,525 |
|
|
|
63,603 |
|
|
|
67,639 |
|
|
|
61,415 |
|
|
Purchased in-process research and development
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13,600 |
|
|
|
|
|
|
Selling, general and administrative
|
|
|
30,855 |
|
|
|
26,199 |
|
|
|
29,917 |
|
|
|
35,460 |
|
|
|
27,045 |
|
|
Restructuring charges (recovery)(2)
|
|
|
904 |
|
|
|
(244 |
) |
|
|
14,726 |
|
|
|
|
|
|
|
|
|
|
Amortization of patents and patent rights
|
|
|
9,217 |
|
|
|
10,530 |
|
|
|
11,392 |
|
|
|
17,556 |
|
|
|
10,416 |
|
|
Impairment charge of deferred charges(3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16,564 |
|
|
|
|
|
|
Impairment charge on long-lived and other assets(4)
|
|
|
2,544 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock compensation(5)
|
|
|
1,665 |
|
|
|
4,529 |
|
|
|
1,809 |
|
|
|
20,954 |
|
|
|
13,056 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
|
97,950 |
|
|
|
89,539 |
|
|
|
121,447 |
|
|
|
171,773 |
|
|
|
111,932 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating loss
|
|
|
(107,514 |
) |
|
|
(88,548 |
) |
|
|
(114,327 |
) |
|
|
(184,877 |
) |
|
|
(105,213 |
) |
|
Interest income and other, net
|
|
|
827 |
|
|
|
1,389 |
|
|
|
4,962 |
|
|
|
14,686 |
|
|
|
9,174 |
|
|
Interest expense
|
|
|
(111 |
) |
|
|
(477 |
) |
|
|
(601 |
) |
|
|
(1,060 |
) |
|
|
(1,666 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$ |
(106,798 |
) |
|
$ |
(87,636 |
) |
|
$ |
(109,966 |
) |
|
$ |
(171,251 |
) |
|
$ |
(97,705 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share basic and diluted
|
|
$ |
(0.61 |
) |
|
$ |
(0.63 |
) |
|
$ |
(0.82 |
) |
|
$ |
(1.33 |
) |
|
$ |
(2.18 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding basic and diluted
|
|
|
175,989 |
|
|
|
139,692 |
|
|
|
134,719 |
|
|
|
129,002 |
|
|
|
44,741 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated Balance Sheet Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$ |
17,273 |
|
|
$ |
74,765 |
|
|
$ |
16,613 |
|
|
$ |
57,747 |
|
|
$ |
259,744 |
|
Short-term investments
|
|
|
36,395 |
|
|
|
46,000 |
|
|
|
112,837 |
|
|
|
183,941 |
|
|
|
83,358 |
|
Working capital
|
|
|
40,661 |
|
|
|
99,290 |
|
|
|
116,033 |
|
|
|
217,152 |
|
|
|
343,004 |
|
Total assets
|
|
|
89,613 |
|
|
|
171,590 |
|
|
|
197,555 |
|
|
|
309,024 |
|
|
|
412,536 |
|
Long-term obligations, net of current Portion
|
|
|
5,000 |
|
|
|
356 |
|
|
|
18,116 |
|
|
|
29,295 |
|
|
|
20,950 |
|
Total stockholders equity
|
|
|
58,000 |
|
|
|
131,418 |
|
|
|
140,847 |
|
|
|
244,965 |
|
|
|
364,916 |
|
|
|
(1) |
Cost of revenue includes $9.0 million, $1.5 million,
$2.6 million and $28.1 million, respectively, related
to charges taken to decrease the value of our inventory to its
fair market value in fiscal 2004, 2003, 2002 and 2001,
respectively, which was partially offset by the sale of
previously written down inventory and the reversal of previously
accrued inventory charges of $0.6 million,
$0.5 million, $1.9 million and |
10
|
|
|
$2.5 million, respectively. There were no similar charges
in fiscal 2000. In fiscal 2004, when we became aware of factors
indicating that inventory associated with non-cancelable
purchase orders would be sold to customers at a loss, we
recorded a charge of $8.4 million in cost of revenue
related to these non-cancelable orders. |
|
(2) |
Restructuring charge in fiscal 2004 and restructuring recovery
in fiscal 2003 primarily relate to adjustments in the costs
related to excess facilities. Restructuring charges recorded in
fiscal 2002 primarily consist of $8.9 million for excess
facilities, $1.6 million for equipment and prepaid software
maintenance write-offs and $4.1 million related to a
reduction in workforce. |
|
(3) |
During the fourth quarter of 2001, we wrote-off
$16.6 million of long-lived asset balances related to
deferred charges under licensing agreements. |
|
(4) |
During the fourth quarter of 2004, we performed an impairment
assessment of long-lived and other assets due to the emergence
of indicators of impairment in the fourth quarter of 2004. As a
result of this assessment, we recorded a charge in operating
expenses of $2.5 million to write off certain long-lived
and other asset balances, comprised of $1.7 million for
property and equipment and $0.8 million for software
maintenance prepayments. This charge was included in operating
expenses. Additionally, we recorded a charge in cost of revenue
of $1.9 million for prepaid manufacturing tools. |
|
(5) |
Stock compensation includes $0.7 million,
$1.8 million, $3.6 million, $16.8 million and
$13.1 million in amortization of deferred stock
compensation for the years ended December 31, 2004, 2003,
2002, 2001 and 2000, respectively. Stock compensation also
includes $1.0 million, $2.7 million,
$(1.8) million and $4.2 million in variable stock
compensation for the years ended December 31, 2004, 2003,
2002 and 2001, respectively. There was no variable compensation
for the year ended December 31, 2000. |
11
|
|
Item 7. |
Managements Discussion and Analysis of Financial
Condition and Results of Operations |
NOTE: For a more complete understanding of our financial
condition and results of operations, and some of the risks that
could affect future results, see Risks That Could Affect
Future Results. This section should also be read in
conjunction with the Consolidated Financial Statements and
related Notes, which immediately follow this section.
Overview
In March 2005, as we prepare this Annual Report for our 2004
fiscal year, we are simultaneously completing our evaluation of
our customers requirements for our products and of the
economics and competitive conditions in the market for
x86-compatible microprocessors. We expect to modify our business
model based in part on that evaluation and to announce a related
restructuring plan on or about March 31, 2005. We are also
currently engaged in discussions with other companies regarding
potential strategic alliances for leveraging our microprocessor
design and development capabilities, and we believe that the
outcome of those discussions might also affect the nature and
extent of our restructuring plan. No assurance can be given that
any of these discussions will be concluded successfully.
Accordingly, the potential impact of these discussions has not
been considered in the preparation of the financial statements
presented with this Annual Report.
From Transmetas inception in 1995 through our fiscal year
ended December 31, 2004, our business model was focused
primarily on designing, developing and selling highly efficient
x86-compatible software-based microprocessors. Since introducing
our first family of microprocessor products in January 2000, we
have derived the majority of our revenue from selling our
microprocessor products. Although we believe that our products
deliver a compelling balance of low power consumption, high
performance, low cost and small size, we have had negative cash
flows and had incurred a cumulative loss aggregating
$649.4 million as of December 31, 2004. Accordingly,
we have diversified our business model to establish a revenue
stream based upon the licensing of certain of our intellectual
property and advanced computing and semiconductor technologies
developed in the course of Transmetas research and
development programs. Since March 2004, we have entered into and
announced agreements granting licenses to NEC Electronics,
Fujitsu Limited and Sony Corporation to use Transmetas
proprietary LongRun2 technologies for power management and
transistor leakage control. Those licensing agreements include
deliverable-based technology transfer fees, maintenance and
service fees, and subsequent royalties on products incorporating
the licensed technologies. In January 2005, we announced that we
are critically evaluating the economics of our microprocessor
product business during the first quarter of 2005 and that we
intend to modify our business model in 2005 to increase our
efforts to license our intellectual property and advanced
technologies. During the first quarter of 2005, we increased our
focus on our licensing and services business and initiated
actions to improve the negative gross margins associated with
our product business. We currently expect that our modified
business model will further reduce our historic business focus
on product sales, and that we will further reduce operating
expenses associated with our product business as part of a
restructuring plan, including a reduction of our workforce.
Our total revenue in fiscal 2004 was $29.4 million,
compared to $17.3 million in fiscal 2003. Our total revenue
increased primarily due to an increase in license and service
revenue of $9.6 million, to $10.7 million in fiscal
2004 from $1.1 million in fiscal 2003. The increase in our
license and service revenue can be substantially attributed to
an agreement that we entered into during fiscal 2004 to license
our advanced power management and transistor leakage control
technologies to another company. Additionally, our product
revenue increased 15.7% in fiscal 2004 compared to fiscal 2003.
The increase in our product revenue can be attributed to
increases in net units shipped for the Efficeon products, which
was introduced in October 2003 and had a full year of sales in
fiscal 2004. We expect our licensing and service revenue to
increase in 2005, based on our technology licensing agreements
with NEC, Fujitsu and Sony as well as other prospective activity
toward our licensing of our intellectual property and
proprietary technologies. We expect our product revenue to
decline in 2005, based on our announced modification of our
business model to focus on intellectual property and technology
licensing.
As a percent of product revenue, our product gross margin was
negative 103.8% for fiscal 2004, compared to 0.3% for fiscal
2003. The decrease in our gross margin was primarily attributed
to our transition to our new
12
90 nanometer Efficeon products, pricing pressure, lower than
expected sales volumes and higher than expected manufacturing
costs. Gross margin in fiscal 2004 was additionally adversely
affected by higher inventory and inventory-related charges and
an impairment charge on long-lived assets that are used in the
manufacturing process. We have historically reported negative
cash flows from operations because the gross profit, if any,
generated from our product and licensing revenues has not been
sufficient to cover our operational cash requirements. Our total
operating expenses were $98.0 million in fiscal 2004,
compared to $89.5 million in fiscal 2003. Our net loss was
$106.8 million in fiscal 2004, compared to
$87.6 million in fiscal 2003. The higher net loss in fiscal
2004 was primarily the result of a negative product gross
margin, higher operating expenses related to the development and
promotion for our Efficeon TM8000 family of microprocessors and
an impairment charge on long-lived and other assets.
Historically we have incurred significant losses, and as of
December 31, 2004, we had an accumulated deficit of
$649.4 million. We anticipate improved gross margins in
2005, based on expected growth in our licensing and service
revenue, and lower negative gross margins associated with
reduced product sales. We expect to reduce our overall operating
expenses in 2005 based on our anticipated restructuring of our
organization and operations in accordance with our modified
business model.
In January 2004, we received net proceeds of $10.2 million
when our underwriters exercised their over-allotment option to
purchase an additional 3.75 million shares of our common
stock relating to a public offering of our common stock in
December 2003. In November 2004, we received net proceeds, after
expenses, of $15.4 million related to an issuance of
11.1 million shares of common stock.
We believe that our existing cash and cash equivalents and
short-term investment balances and cash from operations will be
sufficient to fund our operations, planned capital and
R&D expenditures for the next twelve months on the
modified business model that we are currently developing and
expect to announce with a related restructuring plan on or about
March 31, 2005. We expect that our restructuring plan and
related restructuring charge may vary depending upon the outcome
of our current discussions with other companies regarding
potential strategic alliances for leveraging our microprocessor
design and development capabilities.
For ease of presentation, the accompanying financial information
has been shown as of December 31 for all annual financial
statement captions. Fiscal year 2004 consisted of 53 weeks
an ended on December 31. Fiscal years 2003 and 2002 each
consisted of 52 weeks and ended on December 26 and
December 27, respectively.
On February 25, 2005, our Board of Directors resolved to
change the fiscal year from one ending on the last Friday in
December to a fiscal year ending the last calendar day in
December. This change is not deemed a change in fiscal year for
purposes of reporting subject to Rule 13a-10 or 15d-10
because our fiscal year 2005 commenced with the end of its
fiscal year 2004.
Critical Accounting Policies
The process of preparing financial statements requires the use
of estimates on the part of our management. The estimates used
by management are based on our historical experiences combined
with managements understanding of current facts and
circumstances. Certain of our accounting policies are considered
critical as they are both important to the portrayal of our
financial condition and results and require significant or
complex judgments on the part of management.
We believe the following critical accounting policies include
our more significant judgments and estimates used in the
preparation of the consolidated financial statements:
|
|
|
|
|
License and service revenue recognition; |
|
|
|
Estimation of inventory valuations; |
|
|
|
Valuation of long-lived and intangible assets; |
|
|
|
Restructuring charges; and |
|
|
|
Loss contingencies |
13
License and Service Revenue Recognition. We enter into
technology and trademark license agreements, some of which may
contain multiple elements, including technology licenses and
support services, or non-standard terms and conditions. As a
result, interpretation on these agreements, in accordance with
Emerging Issues Task Force (EITF) Issue No. 00-21,
Revenue Arrangements with Multiple Deliverables and
the Securities and Exchange Commissions Staff Accounting
Bulletin No. 104, Revenue Recognition, is
required to determine the appropriate accounting, including
whether deliverables specified in a multiple element arrangement
should be treated as separate units of accounting for revenue
recognition purposes, and if so, how the price should be
allocated among the deliverable elements and when to recognize
revenue for each element. We recognize revenue from license
agreements when earned, which generally occurs when agreed-upon
deliverables are provided, customer acceptance criteria has been
met, or milestones are met and accepted by licensees and
relative fair values of multiple elements can be determined.
Additionally, license, and maintenance and service revenues are
recognized if collectibility is reasonably assured and if we are
not subject to any future performance obligation. Royalty
revenue is recognized upon receipt of royalty payments from
customers.
Estimation of Inventory Valuations. Our inventory
valuation policy stipulates that we write-down or write-off our
inventory for estimated obsolescence or unmarketable inventory
at the end of each reporting period. The amount of the
write-down or write-off is equal to the difference between the
cost of the inventory and the estimated market value of the
inventory based upon reasonable assumptions about future demand
and market conditions. If actual market conditions are less
favorable than those projected by management, additional
inventory write-downs or write-offs may be required. Conversely,
if demand for estimated excess or obsolete materials exceeds our
original estimates, or the sales prices for previously written
down materials are higher than anticipated, our gross margins
would benefit to the extent that the associated revenue exceeds
the materials adjusted value. Additionally, as we
introduce product enhancements and new products, and improve our
manufacturing processes, demand for our existing products in
inventory may decrease. Inventory on hand in excess of
forecasted demand is not valued. In computing inventory
valuation adjustments as a result of lower of cost or market
considerations, we review not only the inventory on hand but
also inventory in the supply chain pursuant to the
non-cancelable purchase orders. If we become aware of factors
that indicate that inventory associated with these
non-cancelable purchase orders will be sold to customers below
its cost, we accrue such loss as an additional cost of revenue
and as an additional accrued liability on the balance sheet. At
the end of the second quarter of 2001, consistent with this
policy, we recorded a charge of $28.1 million primarily to
write-off certain older inventory products as a result of an
actual decrease of future demand for these older products.
Additionally, we made adjustments of $18.5 million and
$1.5 million for fiscal 2004 and 2003, respectively. For
fiscal 2004 and 2003, the Companys gross margins included
a benefit of $0.6 million and $0.5 million,
respectively, resulting from the sale of previously written down
inventory.
Valuation of Long-Lived and Intangible Assets. Our policy
for the valuation and impairment of long lived assets stipulates
that, whenever events or changes in circumstances indicate that
the carrying amount of long-lived assets may not be recoverable,
we evaluate our long-lived and intangible assets for impairment.
Recoverability of assets to be held and used is determined by
comparing the carrying amount of an asset to the future cash
flows expected to be generated by the asset. If the carrying
amount of an asset exceeds the future cash flows the asset is
considered to be impaired and the impairment charge recognized
is measured by the amount by which the carrying amount of the
asset exceeds the fair value of the asset. During the fourth
quarter of 2004, consistent with this policy, we recorded an
impairment charge of $4.5 million related to certain
long-lived and other assets associated with our product sales.
We continue to periodically evaluate our long-lived assets for
impairment in accordance with SFAS 144 and acknowledge it
is at least possible that such evaluation might result in future
adjustments for impairment. Such an impairment might adversely
affect our operating results.
Determining the expected future cash flows requires management
to make significant estimates. We base our estimates on
assumptions that we believe to be reasonable but that are
unpredictable and inherently uncertain. Actual future results
may differ from these estimates. If these estimates or their
related assumptions change in the future, it could result in
lower estimated future cash flows that may not support the
current carrying value of these assets, which would require us
to record impairment charges for these assets.
14
Restructuring Charges. In fiscal 2002, in accordance with
EITF Issue No. 94-3, Liability Recognition for
Certain Employee Termination Benefits and Other Costs to Exit an
Activity (including Certain Costs Incurred in a
Restructuring), we accrued for restructuring costs when we
made a commitment to a firm exit plan that specifically
identified all significant actions to be taken in conjunction
with our response to a change in our strategic plan, product
demand, increased costs or other environmental factors. As part
of the 2002 restructuring plan, we recorded restructuring
charges of $10.6 million primarily related to lease costs
and equipment write-offs. We recorded restructuring charges of
$4.1 million related to a reduction in workforce during the
third quarter of fiscal 2002. Our assumptions used in
determining the estimation of restructuring expenses include the
determination of the period that it will take to sublet our
vacated premises, the market price that we would be able to
command for the subleased space and the interest rate used to
determine the present value of our future lease obligations. Any
significant variation in these estimates compared to actual
results may have a material impact on our restructuring expenses
and our operating results. We reassess the restructuring
accruals on a quarterly basis to reflect changes in the costs of
the restructuring activities. The most significant variables of
our accrued restructuring costs are the period that it will take
to sublet our vacated premises and the market price at which we
believe that we will be able to sublet our vacated facilities.
For example, if it is determined that the rate for which we are
able to sublease our vacated space is less than our assumed
rate, our restructuring charges could significantly increase as
a result. Additionally, if it takes longer than expected to
sublease our vacated space, additional restructuring charges may
be incurred. When reassessing our estimates, we incorporate the
most recently available industry data regarding relevant
occupancy and lease cost rates. We have found that these
variables are often difficult to predict as there are many
uncertainties related to the commercial real estate market in
which we are attempting to sublet our vacated facilities. During
the fourth quarter of fiscal 2003, we adjusted the balance in
our accrued restructuring costs and recorded a recovery of
$0.2 million of previously recorded restructuring charges.
This adjustment was the result of an update in assumptions
regarding the Companys internal use of previously vacated
office space, as well as the anticipated length of time before
our vacated facilities are sublet to others. During the third
quarter of fiscal 2004, we adjusted the balance in our accrued
restructuring costs and recorded a charge of $0.9 million
to restructuring charges. This adjustment was the result of an
update to certain underlying assumptions regarding the sublease
of our vacant facilities in future periods. The assumption had
been revised such that we no longer assume that we will be able
to sublease our previously vacated space that remained unused as
of September 30, 2004.
Loss Contingencies. We are subject to the possibility of
various loss contingencies arising in the normal course of
business. In accordance with SFAS No. 5,
Accounting for Contingencies, we accrue for a loss
contingency when it is probable that a liability has been
incurred and we can reasonably estimate the amount of loss. We
regularly assess current information available to determine
whether changes in such accruals are required.
Description of Operating Accounts
Total Revenue. Total revenue currently consists of
product sales, net of returns and allowances, and revenue from
licensing and services agreements.
Gross Margin. Cost of revenue consists of the costs of
manufacturing, assembly and testing of our silicon chips, and
compensation and associated costs related to manufacturing
support, logistics and quality assurance personnel. Cost of
revenue may additionally include a component for adjustments to
the valuation of certain inventories based on lower demand and
average selling prices expected in future periods. Cost of
revenue also includes the costs of providing services under the
maintenance agreements with the licenses of our power management
and other technologies. Gross margin is the percentage derived
from dividing gross profit by product revenue. Our gross margin
each quarter is affected by a number of factors, including
competitive pricing, mix, foundry pricing, yields, production
flow costs and speed distribution of our products.
Research and Development. Research and development
expenses consist primarily of salaries and related overhead
costs associated with employees engaged in research, design and
development activities for products and related technologies, as
well as the cost of masks, wafers and other materials and
related test services and equipment used in the development
process.
15
Selling, General & Administrative. Selling,
general and administrative expenses consist of salaries and
related overhead costs for sales, marketing and administrative
personnel and legal and accounting services.
Restructuring Charges. Restructuring charges resulted
from our decision in 2002 to cease development and
productization of a previous generation of microprocessors. The
restructuring charges consisted primarily of lease costs,
employee severance and termination costs, equipment write-offs
and other costs.
Amortization of Patents and Patent Rights. These charges
primarily relate to various patents and patent rights acquired
from Seiko Epson and others during fiscal 2001.
Impairment Charge on Long-Lived and Other Assets. The
impairment charge on long-lived and other assets was recorded in
fiscal 2004 after the emergence of indicators of impairment in
the fourth quarter of fiscal 2004 related to the expected
negative operating margin related to the Companys product
sales. This led to the recording of an impairment charge for
assets for which the carrying amount exceeded their fair value.
Stock Compensation. There were two components to stock
compensation expense during these periods. The first component
is the amortization of deferred stock compensation associated
with options granted prior to November 2000, net of
cancellations. The second component is the application of
variable accounting for certain stock option grants. During the
fourth quarter of fiscal 2001, we did not enforce the recourse
provisions of certain employee notes associated with option
exercises. Therefore, we account for all other outstanding notes
as if they had terms equivalent to non-recourse notes, even
though the terms of these notes were not in fact changed from
recourse to non-recourse. As a result, we have and will continue
to record adjustments related to variable stock option
accounting on the associated stock awards until the notes are
paid. This variable stock compensation charge is based on the
excess, if any, of the current market price of our stock as of
the period-end over the purchase price of the stock award,
adjusted for vesting and prior stock compensation expense
recognized on the stock award.
Interest Income and Other, Net and Interest Expense.
Interest income and other, net consist of the interest income on
our average cash balances over a given period of time. Interest
expense is primarily based on the accretion of long-term
property lease obligations related to office space that was
vacated as part of our 2002 restructuring.
Results of Operations
Our products are targeted at a broad range of computing
platforms, particularly battery-operated mobile devices and
applications that need high performance, low power consumption
and low heat generation. Such platforms include notebook
computers, ultra-personal computers, or UPCs, tablet PCs, thin
clients, blade servers and embedded computers. Total revenue,
which includes product and license and service revenue, for each
computing market, is presented as a percentage of total revenue
in the following table:
|
|
|
|
|
|
|
|
|
|
Years Ended |
|
|
December 31, |
|
|
|
|
|
2004 |
|
2003 |
|
2002 |
|
|
|
|
|
|
|
Product:
|
|
|
|
|
|
|
|
Thin client desktop
|
|
30% |
|
17% |
|
6% |
|
Notebook computers
|
|
19% |
|
42% |
|
82% |
|
Embedded/servers
|
|
8% |
|
6% |
|
5% |
|
Tablet PCs
|
|
4% |
|
27% |
|
6% |
|
UPCs
|
|
3% |
|
2% |
|
1% |
License and service:
|
|
36% |
|
6% |
|
n/a |
Thin client desktop revenues increased with the ramp of
Crusoe-based systems. Notebook revenues declined as our TM5800
product line matured and customers transitioned to our TM8000
Efficeon products. Tablet PCs revenues declined as a
result of a product line transition within a major customer
account.
16
During fiscal 2004 and fiscal 2003, we recognized
$10.7 million and $1.1 million of license and service
revenue, respectively, related to certain license agreements
that we entered into during those years. Most of our license and
service revenue in fiscal 2004 derived from our LongRun2
licensing agreement with NEC Electronics. In November 2004, we
entered into a licensing agreement with Fujitsu Limited. As of
December 31, 2004, we have not recognized revenue
associated with this agreement, because we had not completed
delivery of all the required deliverables. In January 2005, we
also entered into a licensing agreement with Sony Corporation.
We continue to explore additional opportunities for licensing
our advanced power management technologies to other companies in
the integrated circuit industry.
We have derived the majority of our revenue from a limited
number of customers. Additionally, we derive a significant
portion of our revenue from customers located in Asia, which
subjects us to economic cycles in that region as well as the
geographic areas in which they sell their products containing
our microprocessors. The following table represents our sales to
customers, each of which is located in Asia, that accounted for
more than 10% of total revenue for fiscals 2004, 2003 and 2002:
|
|
|
|
|
|
|
|
|
|
Years Ended |
|
|
December 31, |
|
|
|
|
|
2004 |
|
2003 |
|
2002 |
|
|
|
|
|
|
|
Customer:
|
|
|
|
|
|
|
|
NEC Electronics Corp.
|
|
33% |
|
*% |
|
*% |
|
Hewlett Packard International Pte Inc.
|
|
27% |
|
14% |
|
% |
|
Sharp Trading Corporation
|
|
12% |
|
20% |
|
*% |
|
Uniquest Hong Kong**
|
|
*% |
|
21% |
|
*% |
|
Fujitsu America Inc.
|
|
*% |
|
16% |
|
26% |
|
Sony Trading International Corp.
|
|
% |
|
*% |
|
37% |
|
|
|
|
* |
represents less than 10% of total revenue. |
|
|
** |
Uniquest Hong Kong made these purchases acting as the
distributor of our product for the Hewlett Packard Tablet PC
program. |
Total revenue for the comparative periods is summarized in the
following table:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31, | |
|
|
| |
|
|
2004 | |
|
2003 | |
|
2002 | |
|
|
| |
|
| |
|
| |
|
|
(In thousands) | |
Product
|
|
$ |
18,776 |
|
|
$ |
16,225 |
|
|
$ |
24,247 |
|
License and service
|
|
|
10,668 |
|
|
|
1,090 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
$ |
29,444 |
|
|
$ |
17,315 |
|
|
$ |
24,247 |
|
|
|
|
|
|
|
|
|
|
|
Fiscal 2004 Compared to Fiscal 2003. Total revenue was
$29.4 million for fiscal 2004 compared to
$17.3 million for fiscal 2003, representing an increase of
$12.1 million, or 69.9%. License and service revenue
increased $9.6 million, primarily due to the recognition of
$9.0 million in technology transfer and license fees and
$0.8 million in service revenue pursuant to a technology
and professional services agreement executed in March 2004.
Product revenue increased $2.5 million, mostly due to
revenue from the Efficeon product offset by a decrease in the
revenue from the TM5800 product. The Efficeon product, which
began shipment in the fourth quarter of fiscal 2003 and
represented less than 5% of total fiscal 2003 revenue, had a
full year of sales in fiscal 2004 and represented 18.2% of total
fiscal 2004 revenue. Pricing pressure on the TM5800 continued to
increase as the product has matured and continues to sell into
market segments and geographies, such as China and Taiwan, that
traditionally demand lower average selling prices, or ASPs.
Fiscal 2003 Compared to Fiscal 2002. Total revenue was
$17.3 million for fiscal 2003 compared to
$24.2 million for fiscal 2002, representing a decrease of
$6.9 million, or 28.5%. Excluding the effects of a certain
sale of previously written down inventory in the third quarter
of fiscal 2002, this decline can be attributed to a decrease in
average selling prices, or ASPs, of 36.0% from fiscal 2002 to
fiscal 2003, partially
17
offset by an increase in unit volume of 8%. The increase in
volume primarily resulted from an increase of our products into
the tablet PC and thin client markets and an expansion of our
international sales, particularly into China, Hong Kong and
Taiwan. See Gross Margin section below for further
discussion on the effects of decreases in ASPs and increases in
volume.
We experienced pricing pressure on the TM5800 in fiscal 2003 as
the product had matured and transitioned into geographies and
market segments that traditionally demand lower ASPs. We
continued to manufacture the TM5800 as we have begun to migrate
the processor into market segments such as the embedded, thin
client, and ultra personal computer markets, from which we
expect the processor to derive the majority of its future
revenue. The Efficeon product was targeted at the high-volume
notebook market, which traditionally demands higher ASPs. We
started shipping the Efficeon product in the fourth quarter of
fiscal 2003. Revenue recognized from sales of this product
represented less than 5% of total fiscal 2003 revenue.
Revenue recognized in fiscal 2003 also included license and
service revenue, which was earned in connection with technology
and trademark license agreements during the year. Total
licensing revenue was $1.1 million for fiscal 2003. Fiscal
2002 did not include any license and service revenues.
Our product gross margin is comprised of the components
displayed in the following table, shown as a percentage of
product revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31, | |
|
|
| |
|
|
2004 | |
|
2003 | |
|
2002 | |
|
|
| |
|
| |
|
| |
Product revenue
|
|
|
100.0 |
% |
|
|
100.0 |
% |
|
|
100.0 |
% |
|
|
|
|
|
|
|
|
|
|
Product cost
|
|
|
90.3 |
% |
|
|
80.8 |
% |
|
|
60.3 |
% |
Underabsorbed overhead
|
|
|
7.5 |
% |
|
|
12.8 |
% |
|
|
7.3 |
% |
Charges for inventory and other adjustments
|
|
|
98.7 |
% |
|
|
9.0 |
% |
|
|
10.8 |
% |
Benefits to gross margin from the sale of previously written
down inventory
|
|
|
(3.0 |
)% |
|
|
(2.9 |
)% |
|
|
(7.8 |
)% |
Impairment charges for long-lived assets
|
|
|
10.3 |
% |
|
|
|
% |
|
|
|
% |
|
|
|
|
|
|
|
|
|
|
|
Cost of product revenue
|
|
|
203.8 |
% |
|
|
99.7 |
% |
|
|
70.6 |
% |
|
|
|
|
|
|
|
|
|
|
|
Gross margin
|
|
|
(103.8 |
)% |
|
|
0.3 |
% |
|
|
29.4 |
% |
|
|
|
|
|
|
|
|
|
|
Fiscal 2004 Compared to Fiscal 2003. Product gross margin
was negative 103.8% for fiscal 2004 compared to 0.3% for fiscal
2003.
As a percent of product revenue, our product costs increased
9.5 percentage points, from 80.8% in fiscal 2003 to 90.3%
in fiscal 2004. We experienced higher product costs with the
introduction of our 130 nanometer Efficeon TM8000 processors
during the first quarter of fiscal 2004. This was followed by
the introduction of and transition to our 90 nanometer Efficeon
TM8800 processors during the third quarter of fiscal 2004. Our
initial production costs of these new products were higher than
the ongoing costs of mature products. In addition to overall
higher product costs, we experienced downward pressures on our
average selling prices, which is used as a component of the
denominator in this calculation.
Gross margin was also adversely affected during both periods by
unabsorbed overhead costs as our production-related
infrastructure exceeded our needs. For fiscal 2004, these
unabsorbed costs were $1.4 million, or 7.5% of product
revenue, compared to $2.1 million, or 12.8% of product
revenue, for the same period in the prior year. The decrease in
unabsorbed overhead costs was due to increased utilization of
our manufacturing overhead as we shifted our product mix to the
Efficeon TM8000, and as the volume of shipments of our Crusoe
TM5800 product increased.
In fiscal 2004, we recorded inventory-related charges of
$17.4 million consisting of charges related to excess
quantities and net realizable value of inventory on hand and on
non-cancelable purchase orders. Of these charges,
$9.0 million was for inventory on hand, primarily related
to our Crusoe and 130 nanometer
18
Efficeon processors. The remaining $8.4 million in charges
was for non-cancelable orders for substrates and wafers,
primarily related to both our 130 nanometer and 90 nanometer
Efficeon processors. In computing inventory valuation
adjustments as a result of lower of cost or market
considerations, we review the inventory on hand and inventory on
order. If we become aware of factors that indicate that
inventory associated with these non-cancelable purchase orders
will be sold to customers below its cost, we accrue such loss as
an additional cost of revenue and as an additional accrued
liability on the balance sheet. The Efficeon-related charges for
both inventory on hand and on order was the result of the
manufacturing costs of these products exceeding the price at
which we expect to be able to sell them, as well as lower than
expected yields. Additionally, we believe that the initial
availability of our first limited production 90 nanometer
Efficeon processors in September 2004 had a greater than
expected adverse effect on the demand for our 130 nanometer
Efficeon microprocessors, and as a result, we recorded
inventory-related charges for the 130 nanometer product on hand
and on order that are in excess of our anticipated demand for
that product.
Gross margin from our 130 and 90 nanometer parts on hand and on
order may have a benefit from future sales only to the extent
that the associated revenue exceeds their currently adjusted
values. Similarly, our gross margins could be adversely affected
if the products are sold at a price lower than their currently
estimated market value. The $8.4 million charge in
connection with the non-cancelable orders for substrates and
wafers mentioned above includes a $3.3 million charge
related to a conditional purchase order for a minimum quantity
of units for which mandatory yields were lower than expected for
the product specification required by the customer.
Consequently, we were unable to ship the minimum quantity and
therefore have recorded a write down. If we are successful in
our current efforts to obtain approval from the customer for a
change in the product specifications such that these products
will be accepted by the customer, we may record in future
periods a benefit to gross margins to the extent that the
revenue exceeds their adjusted values.
In addition to the $17.4 million charges noted above, gross
margin in fiscal 2004 was also additionally adversely affected
by a $1.1 million charge related to non-cancelable
obligations that we had made to a third party suppliers for
goods and services from which we do not anticipate seeing any
economic benefits.
Of the $5.4 million and $8.8 million net inventory on
hand at December 31, 2004 and December 31, 2003,
respectively, $2.4 million and $2.6 million of net
inventory, respectively, were adjusted to their net realizable
value, which was lower than cost. Accordingly, gross margin may
be impacted from future sales of these parts to the extent that
the associated revenue exceeds or fails to achieve their
currently adjusted values. Benefits to gross margin as a result
of products being sold at ASPs in excess of their previously
written down values were $0.6 million and $0.5 million
for fiscal 2004 and fiscal 2003, respectively.
During the fourth quarter of 2004, due to the emergence of
indicators of impairment, we performed an assessment of our
long-lived and other assets. The conclusion of the assessment
was that the carrying value of certain assets was in excess of
their expected future undiscounted cash flows. As a result, we
recorded a $1.9 million charge in cost of revenue to
write-off prepaid tools that are used in the manufacturing of
our products.
Fiscal 2003 Compared to Fiscal 2002. Product gross margin
was 0.3% for fiscal 2003 compared to 29.4% for fiscal 2002. Our
benefits from the sale of previously written down inventory were
2.9% and 7.8% of product revenue in fiscal 2003 and fiscal 2002,
respectively. Before taking into consideration such benefits,
our cost of product revenue was 102.6% of product revenue for
fiscal 2003, and 78.4% of product revenue for fiscal 2002. As a
percent of product revenue, our product costs increased
20.5 percentage points, from 60.3% to 80.8%, mostly as a
result of a decrease in average selling prices, which is used as
a component of the denominator in this calculation. Partially
offsetting this decline in average selling prices was a reduced
average dollar cost of products sold in fiscal 2003 as compared
to fiscal 2002. The reduced average product cost is attributed
to reduced costs to manufacture our Crusoe TM5800 product.
Additionally, we experienced production difficulties in fiscal
2002 which increased our costs to manufacture product during
that period.
Gross margin was adversely affected during both years by
unabsorbed overhead costs as our production-related
infrastructure exceeded our needs. For fiscal 2003, these
unabsorbed costs were $2.1 million, or 12.8% of product
revenue, compared to $1.8 million, or 7.3% of product
revenue, for the same period in the prior year.
19
In fiscal 2003 and fiscal 2002 our gross margin was adversely
affected by adjustments to our inventory valuation in response
to lower demand and lower average selling prices expected in
future periods for some of our products. For the year ended
December 31, 2003, these adjustments totaled
$1.5 million, or 9.0% of product revenue compared to
$2.6 million, or 10.8% of product revenue for the same
period in the prior year. Of the $8.8 million and
$10.9 million of inventory on hand at December 31,
2003 and 2002, respectively, $2.6 million and
$2.8 million of net inventory, respectively, were stated at
net realizable value. Accordingly, gross margin may benefit from
future sales of these parts to the extent that the associated
revenue exceeds their currently adjusted values. In fiscal 2003,
the Companys gross margin included a benefit of
$0.5 million resulting from the sale of previously written
down inventory. In fiscal 2002 the Company recognized
$0.7 million in gross margin related to the sale of
inventory for which the value had been written down in previous
periods at amounts in excess of the average selling prices used
to record their lower of cost or market valuation. In fiscal
2002 we additionally recorded a benefit to gross margin sold in
the amount of $1.2 million related to the reversal of
previously accrued inventory-related purchase commitments due to
favorable settlements of such purchase commitments.
Fiscal 2004 Compared to Fiscal 2003. Research and
development (R&D) expenses were $52.8 million for
fiscal 2004 compared to $48.5 million for fiscal 2003,
representing an increase of $4.3 million, or 8.9%. The
increase in R&D expenses was due to increased
headcount-related expenses of $2.9 million and
non-recurring engineering charges of $2.8 million,
partially offset by decreased depreciation expenses of
$1.4 million. The increased headcount-related and
engineering expenses in fiscal 2004 were primarily the result of
our increased efforts devoted to the development of the 90
nanometer and 130 nanometer manufacturing technology for our
Efficeon TM8000 family of microprocessors, as well as our
LongRun2 power management technologies. The decreases in
depreciation expenses were primarily due to certain property and
equipment being fully depreciated throughout the last fiscal
year. We anticipate that our research and development spending
in future periods will be invested to further develop our
LongRun2 power management and other computing technologies.
Fiscal 2003 Compared to Fiscal 2002. Research and
development expenses were $48.5 million for fiscal 2003
compared to $63.6 million for fiscal 2002, representing a
decrease of $15.1 million, or 23.7%. The majority of the
decrease for the year can be attributed to our workforce
reduction in the third quarter of fiscal 2002, which resulted in
lower compensation and benefit costs and consultant fees. We
additionally incurred less non-recurring engineering charges in
fiscal 2003, in part due to a $1.6 million charge in the
second quarter of 2002 for engineering related silicon and mask
sets for products that the Company ceased development. The
majority of research and development spending in fiscal 2003 was
for the Efficeon TM8000 family of microprocessors. We also
devoted additional research and development resources towards
our next generation 90 nanometer manufacturing technology as
well as our LongRun2 power management technology. The remaining
portion of the fiscal 2003 research and development expenditure
was used for sustaining engineering efforts on our TM5800
microprocessor in fiscal 2003.
|
|
|
Selling, General and Administrative |
Fiscal 2004 Compared to Fiscal 2003. Selling, general and
administrative (SG&A) expenses were $30.9 million for
fiscal 2004 compared to $26.2 million for fiscal 2003,
representing an increase of $4.7 million, or 17.9%. The
increase in SG&A expenses was due to increases in consultant
and accounting expenses of $2.5 million, headcount-related
expenses of $1.4 million, facilities expenses of
$0.8 million, and travel and tradeshow expenses of
$0.7 million. The increases in these expenses were
partially offset by decreases in insurance expenses of
$0.6 million and depreciation expenses of
$0.6 million. The increased consultant and accounting
expenses were primarily due to costs incurred in relation to
efforts to comply with Section 404 Managements
Internal Controls and Procedures for Financial Reporting
of the Sarbanes Oxley Act of 2002. The increased
headcount-related expenses and travel and tradeshow expenses in
fiscal 2004 were primarily the result of our continued efforts
to hire additional personnel, to expand our presence in the
Asia-Pacific market with new offices and to promote awareness of
our Efficeon TM8000 processor. The increased
20
facilities expenses were primarily the result of our increased
building occupancy at our offices in Santa Clara. The
decrease in depreciation expenses were primarily due to certain
property and equipment being fully depreciated throughout the
last fiscal year. The decrease in insurance expense was
primarily due to the receipt of certain refunds related to
overpayment of our estimated insurance premiums.
Fiscal 2003 Compared to Fiscal 2002. Selling, general and
administrative expenses were $26.2 million for fiscal 2003
compared to $29.9 million for fiscal 2002, representing a
decrease of $3.7 million, or 12.4%. A significant portion
of this decrease was due to lower compensation and benefit
costs, consultant fees and recruiting costs related to our
reduction in workforce in the third quarter of fiscal 2002.
Additionally, as a result of our 2002 restructuring charge, for
fiscal 2003 we recorded lower facilities-related charges,
including rent and building maintenance costs. These decreases
were partly offset by increases in other areas, including higher
corporate insurance costs and expenditures for patent protection
of our inventions. In fiscal 2003 the primary focus of our
marketing expenses was to promote the awareness of our new
Efficeon TM8000 processor. In fiscal 2003, we had anticipated on
increasing our selling costs as we planned to initiate a
marketing alliance program specifically designed and structured
to promote our customers products, to drive awareness,
foster market opportunities, and help generate sales.
During fiscal 2002, we recorded restructuring charges of
$14.7 million. We recorded charges of $10.6 million in
the second quarter of fiscal 2002 consisting primarily of lease
costs, equipment write-offs and other costs as we identified a
number of leased facilities and leased equipment that were no
longer required. We recorded severance and termination charges
of $4.1 million in the third quarter of fiscal 2002 related
to the reduction in workforce. Approximately 195 employees and
contractors were terminated on July 18, 2002. Other than
future lease payments for our vacated facilities, the majority
of our restructuring activities have been completed.
As a result of our workforce reduction completed in the third
quarter of fiscal 2002, we vacated a total of approximately
67,730 square feet of office space in Santa Clara,
California. As part of our quarterly reassessment of
restructuring accruals, during the fourth quarter of fiscal
2003, we adjusted the accrued restructuring balance as a result
of an update in assumptions regarding our internal use of
previously vacated office space, as well as the anticipated
length of time before vacated facilities are sublet to others.
As a result of this update, we adjusted the balance in accrued
restructuring costs and recorded a benefit of $0.2 million
to restructuring charges.
During the third quarter of fiscal 2004, we adjusted our accrued
restructuring costs as a result of an update to certain
underlying assumptions. We had previously anticipated subleasing
our vacant facilities in future periods. In view of market
conditions, this assumption had been revised such that we no
longer assume that we will be able to sublease our previously
vacated space that remained unused as of September 30,
2004. As a result of this update in assumptions, we adjusted the
accrued restructuring costs and recorded a charge of
$0.9 million in restructuring charges. We may need to
adjust our restructuring accruals in the future as circumstances
change and as we make our quarterly reassessment. See
Note 7 in the Notes to Consolidated Financial
Statements for further discussion of our restructuring
charges.
|
|
|
Amortization of Patents and Patent Rights |
Amortization charges for fiscal 2004, 2003 and fiscal 2002
relate to various patents and patent rights acquired from Seiko
Epson and others during fiscal 2001. See Note 5 and
Note 6 in the Notes to Consolidated Financial
Statements for further discussion of our technology
license agreements and patents and patent rights.
Fiscal 2004 Compared to Fiscal 2003. Amortization of
patents and patent rights was $9.2 million for fiscal 2004
compared to $10.5 million for fiscal 2003, representing a
decrease of $1.3 million, or 12.4%. This decrease can be
attributed to a reduction in payments due under our patents and
patent rights and our technology license agreement with IBM, as
amended. Amounts due under the agreements decreased
$18.5 million, from $23.5 million at December 31,
2003 to $5.0 million at December 31, 2004.
21
Fiscal 2003 Compared to Fiscal 2002. Amortization of
patents and patent rights was $10.5 million for fiscal 2003
compared to $11.4 million for fiscal 2002, representing a
decrease of $0.9 million, or 7.9%. This decrease can be
attributed to a reduction in payments due under our patents and
patent rights and our technology license agreement with IBM, as
amended. Amounts due under the agreements decreased
$16.0 million, from $39.5 million at December 31,
2002 to $23.5 million at December 31, 2003.
|
|
|
Impairment Charge on Long-Lived and Other Assets |
During the fourth quarter of 2004, due to the emergence of
indicators of impairment, we performed an assessment of our
long-lived and other assets. The assessment was performed in
connection with our internal policies and pursuant to
SFAS 144. The conclusion of the assessment was that the
carrying value of certain assets was in excess of their expected
future undiscounted cash flows. As a result, we recorded a
charge of $2.5 million to write-off such assets based on
the amount by which the carrying amount of these assets exceeded
their fair value, which was deemed to be zero and was based on
the expected future discounted cash flows for the Companys
product sales. The assumptions supporting the estimated future
discounted cash flows reflect managements best estimates
and may be affected by future events. The $2.5 million
charge related to long-lived and other assets associated with
the product business and was comprised of $1.7 million for
property and equipment and $0.8 million for software
maintenance prepayments.
Fiscal 2004 Compared to Fiscal 2003. Stock compensation
was $1.7 million for fiscal 2004 compared to
$4.5 million for fiscal 2003, representing a decrease of
$2.8 million. The two components of stock compensation were
the amortization of deferred stock compensation and variable
stock compensation. Net amortization of deferred stock
compensation for fiscal 2004 was $0.7 million compared to
$1.8 million for fiscal 2003. This decrease was primarily a
result of amortizing the deferred charge on an accelerated
method in accordance with our accounting policy. The
amortization of the deferred stock compensation, calculated in
connection with stock options granted prior to November 2000,
was completed in fiscal 2004. Variable stock compensation for
fiscal 2004 was $1.0 million, compared to $2.7 million
for the same period last year. Variable stock compensation in
fiscal 2004 is comprised of expenses of $0.5 million
related to adjustments made for certain notes receivable from
stockholders that had been fully paid and expenses of
$0.5 million primarily related to the higher market price
of our common stock at the time of repayment of notes from
stockholders. The decrease in the variable stock compensation
component in fiscal 2004 compared to fiscal 2003 primarily
resulted from a higher repayment amount of notes from which such
variable stock accounting is applied, as well as a lower market
price of our stock as of December 31, 2004 compared to the
same period in the prior year.
Fiscal 2003 Compared to Fiscal 2002. Stock compensation
was $4.5 million for fiscal 2003 compared to
$1.8 million for fiscal 2002, representing an increase of
$2.7 million. The two components of stock compensation were
the amortization of deferred stock compensation and variable
stock compensation. Net amortization of deferred stock
compensation for fiscal 2003 was $1.8 million compared to
$3.6 million for fiscal 2002. This decrease was primarily a
result of amortizing the deferred charge on an accelerated
method in accordance with our accounting policy, as well as a
decrease in the number of outstanding options affecting the
compensation charge as a result of cancellations in connection
with our reduction in workforce in the third quarter of fiscal
2002. In connection with stock options granted prior to November
2000, we expect to record amortization of deferred stock
compensation of $0.7 million in 2004. Variable stock
compensation for fiscal 2003 was $2.7 million, compared to
a credit of $1.8 million for the same period last year.
This charge is based on the excess, if any, of the current
market price of our stock as of the period-end over the purchase
price of the stock award, adjusted for vesting and prior stock
compensation expense recognized on the stock award. The increase
in the variable stock compensation component primarily resulted
from a higher market price of our stock as of December 31,
2003, compared to the same period in the prior year.
22
|
|
|
Interest Income and Other, Net and Interest Expense |
Fiscal 2004 Compared to Fiscal 2003. Interest income and
other, net for fiscal 2004 was $0.8 million compared to
$1.4 million compared for fiscal 2003, representing a
decrease of $0.6 million, or 42.9%. This decrease was due
to lower average invested cash balances during fiscal 2004 as we
continued to use cash to fund operations. Interest expense for
fiscal 2004 was $0.1 million compared to $0.5 million
for fiscal 2003, representing a decrease of $0.4 million,
or 80.0%. This decrease was primarily the result of lower
average debt balances due to several debt arrangements expiring
during fiscal 2003.
Fiscal 2003 Compared to Fiscal 2002. Interest income and
other, net for fiscal 2003 was $1.4 million compared to
$5.0 million for fiscal 2002, representing a decrease of
$3.6 million, or 72.0%. This decrease was due to lower
average invested cash balances during fiscal 2003 as we
continued to use cash to fund operations, as well as a decrease
in interest rates earned on investments during the period.
Interest expense for fiscal 2003 was $0.5 million compared
to $0.6 million for fiscal 2002, representing a decrease of
$0.1 million, or 16.7%. This decrease was primarily the
result of lower average debt balances due to several
lease-financing arrangements expiring during 2002, offset by
increases in certain accretion expenses related to our
facilities lease commitments.
Liquidity and Capital Resources
We have historically reported negative cash flows from our
operations because the gross profit, if any, generated from our
product revenues and our license and service revenues has not
been sufficient to cover our operating cash requirements. From
our inception in 1995 through the end of fiscal year 2004, we
incurred a cumulative loss aggregating $649.4 million,
which included net losses of $106.8 million in fiscal 2004,
$87.6 million in fiscal 2003 and $110.0 million in
fiscal 2002, which losses have reduced stockholders equity
to $58.0 million at December 31, 2004.
At December 31, 2004, we had $53.7 million in cash,
cash equivalents and short-term investments compared to
$120.8 million and $129.5 million at December 31,
2003 and December 31, 2002, respectively.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31, | |
|
|
| |
|
|
2004 | |
|
2003 | |
|
2002 | |
|
|
| |
|
| |
|
| |
|
|
(In thousands) | |
Net cash used in operating activities
|
|
$ |
(77,687 |
) |
|
$ |
(64,467 |
) |
|
$ |
(93,918 |
) |
Net cash provided by/(used in) investing activities
|
|
|
(11,301 |
) |
|
|
49,556 |
|
|
|
49,679 |
|
Net cash provided by financing activities
|
|
|
31,496 |
|
|
|
73,063 |
|
|
|
3,105 |
|
|
|
|
|
|
|
|
|
|
|
Increase/(Decrease) in cash and cash equivalents
|
|
$ |
(57,492 |
) |
|
$ |
58,152 |
|
|
$ |
(41,134 |
) |
|
|
|
|
|
|
|
|
|
|
We believe that our existing cash and cash equivalents and
short-term investment balances and cash from operations would
not be sufficient to fund our operations, planned capital and
R&D expenditures for the next twelve months under the
business model that we pursued during and through our fiscal
year ended December 31, 2004, which business model was
primarily focused on designing, developing and selling
software-based x86-compatible microprocessor products.
Accordingly, and as we announced publicly in January 2005, we
are currently evaluating and modifying our business model and
developing a related restructuring plan, and we currently expect
to announce that modified business model and related
restructuring plan on or about March 31, 2005. During the
first quarter of 2005, we began to modify our business model to
leverage our intellectual property rights and increase our
business focus on licensing our advanced power management and
other proprietary technologies to other companies. By increasing
our focus on our licensing and service business, we hope to
increase revenue from our licensing and service activities in
2005 and beyond. During the first quarter of 2005, as part of
our transition to a modified business model, we also began
taking action to reduce our operating expenses by discontinuing
certain of our products, increasing prices for our products, and
changing our terms and conditions of sale, which actions we
anticipate will improve the negative gross margins historically
associated with our product business. We currently expect that
our modified business model will further reduce our
23
historic business focus on product sales, and that we will
further reduce operating expenses associated with our product
business as part of a restructuring plan. We expect that our
restructuring plan will include a reduction of our workforce,
and in January 2005 we gave written notice to our employees,
pursuant to federal and state Worker Adjustment and Retraining
Notification (WARN) Acts and similar statutes applicable in
other countries, that we plan to restructure our business
operations and to conduct a mass layoff on or about
March 31, 2005. Under the currently anticipated
restructuring plan, we expect to restructure our operations so
as to reduce our overall operating expenses in accordance with a
modified business model and, as a result, we believe that our
existing cash and cash equivalents and short-term investment
balances and cash from operations will be sufficient to fund our
operations, planned capital and R&D expenditures for the
next twelve months under the modified business model that we are
currently developing and expect to announce with a related
restructuring plan on or about March 31, 2005. The
accompanying financial statements have been prepared assuming
that we will continue as a going concern; however, the above
conditions raise substantial doubt about our ability to continue
as a going concern. The financial statements do not include any
adjustments to reflect the possible future effects on the
recoverability and classification of assets or the amounts and
classifications of liabilities that may result should we be
unable to continue as a going concern.
In addition to the currently expected modifications of our
business model referred to above, we are currently engaged in
discussions with other companies regarding certain potential
strategic alliances that could enable us to leverage our
microprocessor design and development capabilities in order to
raise operating capital and to improve or enhance our business
in other ways. We believe that the outcome of some of those
discussions might affect the nature of our restructuring plan
and the extent of any related reduction in our workforce.
Although it is possible that we might raise additional operating
capital or create new prospects by means of one or more
strategic alliances with other companies, we have no assurance
that we will achieve any such strategic alliance or that any
such strategic alliance, if achieved, will prove favorable for
us or our business.
To date, we have financed our operational expenses and working
capital requirements primarily with funds that we raised from
the sale of our common stock. Although it is possible that we
might raise additional capital by means of one or more strategic
alliances, or through public or private equity or debt
financing, we have no assurance that any additional funds will
be available on terms favorable to us or at all.
Despite these several disclosed contingencies relating to our
planned modification of our business model, we believe that our
existing cash and cash equivalents and short-term investment
balances and cash from operations will be sufficient to fund our
operations, planned capital and R&D expenditures for the
next twelve months under the modified business model that we are
currently developing and expect to announce with a related
restructuring plan on or about March 31, 2005.
Net cash used in operating activities was $77.7 million for
the year ended December 31, 2004, compared to
$64.5 million for the year ended December 31, 2003 and
$93.9 million for the year ended December 31, 2002.
The cash usage during fiscal 2004 was primarily the result of a
net loss of $106.8 million, as well as a $1.7 million
cash usage related to the building leasehold cost component of
our restructuring charges. This usage in cash was partially
offset by the $8.8 million increase in accounts payable and
accrued liabilities and the $3.4 million decrease in
inventory. The net loss and changes in operating assets and
liabilities were partially offset by non-cash charges related to
amortization of patents and patent rights of $9.2 million,
impairment charges on certain assets of $4.5 million,
depreciation of $3.6 million and stock compensation of
$1.7 million.
The cash usage during fiscal 2003 was primarily the result of a
net loss of $87.6 million, as well as a $2.5 million
net cash drawdown of accrued restructuring charges related to
building leasehold costs during the period. This usage in cash
was partially offset by the $2.2 million decrease in
accounts receivable and the $2.1 million decrease in
inventory. The net loss and changes in operating assets and
liabilities were partially
24
offset by non-cash charges related to amortization of patents
and patent rights of $10.5 million, depreciation and
amortization of $6.0 million, and amortization of deferred
stock compensation of $4.5 million.
Net cash used in investing activities was $11.3 million for
the year ended December 31, 2004, compared to net cash
provided by investing activities of $49.6 million for the
year ended December 31, 2003 and $49.7 million for the
year ended December 31, 2002.
The change in net cash used in investing activities was
primarily due to decreased net proceeds from the maturity of
available for-for-sale investments, which totaled
$9.5 million in fiscal 2004, compared to $66.7 million
in fiscal 2003 and $70.5 million in fiscal 2002. Offsetting
the net proceeds from the maturity of available-for-sale
investments were payments related to the purchase of patents and
patent rights and payments to our development partner, which
totaled $18.5 million, $16.0 million and
$15.0 million for fiscals 2004, 2003 and 2002,
respectively. As of December 31, 2004, a payment to our
development partner for $5.0 million remains and will be
due on June 30, 2006. Additional cash used in investing
activities included the purchase of property and equipment,
which amounted to $2.3 million, $1.1 million and
$5.6 million for fiscals 2004, 2003 and 2002, respectively.
Capital equipment purchases increased in fiscal 2004 compared to
fiscal 2003 as we invested in our next generation 90 nanometer
manufacturing technology and further developed our LongRun2
power management technology.
Net cash provided by financing activities was $31.5 million
for the year ended December 31, 2004, compared to
$73.1 million for the year ended December 31, 2003 and
$3.1 million for the year ended December 31, 2002.
Cash provided by financing activities in fiscal 2004 was
primarily due to net proceeds from the public offering of common
stock. In January 2004, we received $10.2 million when our
underwriters exercised their over-allotment option in relation
to our December 2003 common stock offering and purchased
3.75 million shares of our common stock. We also received
$15.4 million in November 2004 when we completed a public
offering of 11.1 million shares of common stock. This
compares to $67.5 million in net proceeds received in
fiscal 2003 related to the issuance of 25.0 million shares
of common stock in December 2003. Additionally, we received
$5.3 million in net proceeds from sales of common stock
under our employee stock purchase and stock option plans for
fiscal 2004, compared to $6.1 million for fiscal 2003 and
$4.2 million for fiscal 2002.
These proceeds from stock issuances were partially offset by
payments for debt and capital lease obligations of
$0.4 million for fiscal 2004, compared to $0.7 million
for fiscal 2003 and $2.7 million for fiscal 2002. The
decrease in payments for debt and capital lease obligations was
primarily the result of the expiration of these leases in
fiscals 2002 and 2003.
Since our inception, we have financed our operations primarily
through sales of equity securities and, to a lesser extent, from
lease financing. It is reasonably possible that we may continue
to seek financing through these sources of capital as well as
other types of financing, including but not limited to debt
financing. Additional financing might not be available on terms
favorable to us, or at all.
At December 31, 2004, we had $17.3 million in cash and
cash equivalents and $36.4 million in short-term
investments. We lease our facilities under non-cancelable
operating leases expiring in 2008, and we lease equipment and
software under non-cancelable leases with terms ranging from 12
to 36 months.
As part of our 2002 restructuring plan, we recorded charges
primarily for excess facilities costs for which we expect cash
expenditures of approximately $5.8 million through June
2008. Of this amount, $5.2 million was recorded on our
consolidated balance sheets at December 31, 2004 and
$0.6 million will be expensed as interest expense in future
periods as the costs are incurred or the requirements to record
the costs as a liability
25
are met. See Note 7 in the Notes to Consolidated
Financial Statements for further discussion of our
restructuring charges.
At December 31, 2004, we had the following contractual
obligations:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments Due by Period |
|
|
|
|
|
|
|
Less Than | |
|
|
|
After |
Contractual Obligations |
|
Total | |
|
1 Year | |
|
1-3 Years | |
|
4 Years |
|
|
| |
|
| |
|
| |
|
|
|
|
(In thousands) |
Capital Lease Obligations
|
|
$ |
371 |
|
|
$ |
371 |
|
|
$ |
|
|
|
$ |
|
|
Operating Leases
|
|
$ |
16,328 |
|
|
$ |
4,603 |
|
|
$ |
11,725 |
|
|
$ |
|
|
Unconditional Purchase Obligations(1)
|
|
$ |
6,173 |
|
|
$ |
4,876 |
|
|
$ |
1,297 |
|
|
$ |
|
|
Other Obligations(2)
|
|
$ |
5,000 |
|
|
$ |
|
|
|
$ |
5,000 |
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$ |
27,872 |
|
|
$ |
9,850 |
|
|
$ |
18,022 |
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
Purchase obligations include agreements to purchase goods or
services that are enforceable and legally binding on Transmeta
and that specify all significant terms, including: fixed or
minimum quantities to be purchased; fixed, minimum or variable
price provisions; and the approximate timing of the transaction. |
|
(2) |
Other obligations include payments to our development partner. |
|
|
|
Off-Balance Sheet Arrangements |
As part of our ongoing business, we do not participate in
transactions that generate relationships with unconsolidated
entities or financial partnerships, such as entities often
referred to as structured finance or special purpose entities
(SPEs), which would have been established for the
purpose of facilitating off-balance sheet arrangements or other
contractually narrow or limited purposes. As of
December 31, 2004, we are not involved in SPE transactions.
Recent Accounting Pronouncements
In March 2004, the Financial Accounting Standards Board
(FASB) approved the consensus reached on the Emerging
Issues Task Force (EITF) Issue No. 03-1, The
Meaning of Other-Than-Temporary Impairment and Its Application
to Certain Investments. EITF 03-1 provides guidance
for identifying other-than-temporarily impaired investments.
EITF 03-1 also provides new disclosure requirements for
investments that are deemed to be temporarily impaired. In
September 2004, the FASB issued a FASB Staff Position
(FSP) EITF 03-1-1 that delays the effective date of
the measurement and recognition guidance in EITF 03-1 until
further notice. Once the FASB reaches a final decision on the
measurement and recognition provisions, we will evaluate the
impact of the adoption of the accounting provisions of
EITF 03-1.
In November 2004, the FASB issued Statement of Financial
Accounting Standards (SFAS) 151, Inventory Costs, an
amendment of ARB No. 43, Chapter 4.
SFAS 151 amends ARB No. 43, Chapter 4, to clarify
that abnormal amounts of idle facility expense, freight,
handling costs and wasted materials (spoilage) should be
recognized as current period charges. Additionally,
SFAS 151 requires that the allocation of fixed production
overheads to the costs of conversion be based on the normal
capacity of the production facilities. SFAS 151 is
effective for fiscal years beginning after June 15, 2005.
The adoption of this pronouncement is not expected to have a
material impact on our statements of operations.
In December 2004, the FASB issued SFAS 123(R),
Share-Based Payment. SFAS 123(R) requires
employee stock options and rights to purchase shares under stock
participation plans to be accounted for under the fair value
method, and eliminates the ability to account for these
instruments under the intrinsic value method prescribed by APB
Opinion No. 25, and allowed under the original provisions
of SFAS 123. SFAS 123(R) requires the use of an option
pricing model for estimating fair value, which is amortized to
expense over the service periods. The requirements of
SFAS 123(R) are effective for fiscal periods beginning
26
after June 15, 2005. SFAS 123(R) allows for either
prospective recognition of compensation expense or retrospective
recognition, which may be back to the original issuance of
SFAS 123 or only to interim periods in the year of
adoption. We are currently evaluating the impact of the adoption
of SFAS 123(R).
In December 2004, the FASB issued SFAS No. 153,
Exchanges of Nonmonetary Assets, an amendment of APB
Opinion No. 29. SFAS 153 amends APB Opinion
No. 29 to eliminate the exception for nonmonetary exchanges
of similar productive assets and replaces it with a general
exception for exchanges of nonmonetary assets that do not have
commercial substance. A nonmonetary exchange has commercial
substance if the future cash flows of the entity are expected to
change significantly as a result of the exchange. The Company is
required to adopt SFAS 153, on a prospective basis, for
nonmonetary exchanges beginning after June 15, 2005. The
adoption of SFAS No. 153 is not expected to have an
impact on our consolidated result of operations.
Risks that Could Affect Future Results
The factors discussed below are cautionary statements that
identify important risk factors that could cause actual results
to differ materially from those anticipated in the
forward-looking statements in this Form 10-K. If any of the
following risks actually occurs, our business, financial
condition and results of operations would suffer. In this case,
the trading price of our common stock could decline and
investors might lose all or part of their investment in our
common stock.
We have a history of losses, expect to incur further
significant losses and must develop and successfully execute on
a modified business model and restructuring plan if we are to
sustain our operations.
We have historically reported negative cash flows from
operations because the gross profit, if any, generated from our
product revenue and our licensing and service revenue has not
been sufficient to cover our operating cash requirements. From
our inception through the end of fiscal 2004, we have incurred a
cumulative loss aggregating $649.4 million, which includes
net losses of $106.8 million in fiscal 2004,
$87.6 million in fiscal 2003 and $110.0 million in
fiscal 2002, which losses have reduced stockholders equity
to $58.0 million at December 31, 2004.
At the end of 2004 we determined that our existing cash and cash
equivalents and short-term investment balances and cash from
operations would not be sufficient to fund our operations,
planned capital and R&D expenditures for the next twelve
months under the business model that we pursued during and
through the end of 2004, which business model was primarily
focused on designing, developing and selling software-based
x86-compatible microprocessor products. See
Managements Discussion and Analysis of Financial
Condition and Results of Operations Liquidity and
Capital Resources. Accordingly, we undertook a critical
evaluation of our customers requirements for our products
and of the economics and competitive conditions in the market
for x86-compatible microprocessors, and we announced that we
expected to modify our business model based in part on that
evaluation and to announce a related restructuring plan on or
about March 31, 2005. Although the nature and extent of our
restructuring plan may vary depending upon the resolution of
pending discussions with other companies regarding potential
strategic alliances for leveraging our microprocessor design and
development capabilities, we must in any case develop and begin
executing on a modified business model in order to permit us to
continue to operate for a period that extends at least through
December 31, 2005.
We have announced that we are modifying our business model in
2005. We may fail to develop a viable new business model and
restructuring plan, and we might fail to execute our
restructuring plan or to operate successfully under our modified
business model.
In January 2005 we announced our intent to modify our business
model during 2005, for example, by leveraging our intellectual
property assets and by focusing on our strategy of licensing our
advanced power management and other technologies to other
companies. Any modification of our business model entails
significant risks and costs, and even if we define a viable new
business model, we might not succeed in operating within that
model or under our restructuring plan for many reasons. These
reasons include the risks that we might not be able to develop
viable products or technologies, achieve market acceptance for
our
27
products or technologies, earn adequate revenues from the sale
of our products or from our licensing and services business, or
achieve profitability. Employee concern about changes in our
business model or the effect of such changes on their workloads
or continued employment might cause our employees to seek or
accept other employment, depriving us of the human and
intellectual capital that we need in order to succeed. Because
we necessarily lack historical operating and financial results
for any modified business model, it will be difficult for us, as
well as for investors, to predict or evaluate our business
prospects and performance. Our business prospects would need to
be considered in light of the uncertainties and difficulties
frequently encountered by companies undergoing a business
transition or in the early stages of development. The
modification of our business model might also create
uncertainties and cause our stock price to fall and impair our
ability to raise additional capital.
Our anticipated restructuring plan and related reductions in
our workforce may adversely affect the morale and performance of
our personnel, the rate of attrition among our personnel, our
ability to hire new personnel and our ability to conduct our
business operations.
As part of our effort to reduce operating expenses under our
modified business model, we expect to announce a financial
restructuring and related reduction in our workforce on or about
March 31, 2005. Our restructuring plan may include the
termination of employment of some or substantially all of our
employees and contractors. We currently expect that our
restructuring plan will include a reorganization of our
management team and some changes in our executive officers. We
also expect that our restructuring plan and any related
workforce reduction will cause us to incur substantial costs
related to severance and other employee-related costs. Our
workforce reduction may also subject us to litigation risks and
expenses. In addition, our restructuring plan may yield
unanticipated consequences, such as attrition beyond our planned
reduction in workforce. As a result of these reductions, our
ability to respond to unexpected challenges may be impaired and
we may be unable to take advantage of new opportunities. In
addition, some of the employees who were terminated had specific
and valuable knowledge or expertise, the loss of which may
adversely affect our operations. Further, the reduction in force
may reduce employee morale and may create concern among existing
employees about job security, which may lead to increased
attrition or turnover. As a result of these factors, our
remaining personnel may decide to seek other employment,
including opportunities with more established companies or with
smaller, private companies, and we may have difficulty
attracting new personnel that we might wish to hire in the
future.
We might not be able to execute on our modified business
model and restructuring plan if we lose key management or
technical personnel, on whose knowledge, leadership and
technical expertise we rely.
Our success under our modified business model and restructuring
plan will depend heavily upon the contributions of our key
management and technical personnel, whose knowledge, leadership
and technical expertise would be difficult to replace. Many of
these individuals have been with us for several years and have
developed specialized knowledge and skills relating to our
technology and lines of business. We have recently lost some of
our executive management. For instance, Ray Holzworth, our Vice
President of Operations since August 2002, left the Company in
February 2005. Others have joined us in key management roles
only recently. In September 2004, Mark R. Kent joined us as our
Chief Financial Officer. All of our executive officers and key
personnel are employees at will. We have no employment contracts
and do not maintain key person insurance on any of our
personnel. We might not be able to execute on our modified
business model or restructuring plan if we were to lose the
services of any of our key personnel. If any of these
individuals were to leave our company unexpectedly, we could
face substantial difficulty in hiring qualified successors and
could experience a loss in productivity while any such successor
develops the necessary training and experience.
We may not be able to raise any more financing, or financing
may only be available on terms unfavorable to us or our
stockholders.
Although we believe that our existing cash and cash equivalents
and short-term investment balances and cash from operations will
be sufficient to fund our operations, planned capital and
R&D expenditures for the next twelve months under the
modified business model that we are currently developing and
expect to
28
announce with a related restructuring plan on or about
March 31, 2005, it is possible that we may need to raise
significant additional funds through public or private equity or
debt financing in order to continue operations under our
modified business model. Further, as we continue to develop new
technologies or to enhance our products or service competencies
in accordance with our modified business model, we might require
more cash to fund our operations. In addition, we may begin to
generate positive cash flow from operations later than
anticipated or we may never generate positive cash flow from
operations. A variety of other business contingencies could
contribute to our need for funds in the future, including the
need to:
|
|
|
|
|
fund expansion; |
|
|
|
fund marketing expenditures; |
|
|
|
develop new products or enhance existing products; |
|
|
|
enhance our operating infrastructure; |
|
|
|
hire additional personnel; |
|
|
|
respond to customer concerns about our viability; |
|
|
|
respond to competitive pressures; or |
|
|
|
acquire complementary businesses or technologies. |
If we were to raise additional funds through the issuance of
equity or convertible debt securities, the percentage ownership
of our stockholders would be reduced, and these newly issued
securities might have rights, preferences or privileges senior
to those of our then-existing stockholders. For example, in
order to raise equity financing, we may decide to sell our stock
at a discount to our then current trading price, which may have
an adverse effect on our future trading price. Additional
financing might not be available on terms favorable to us, or at
all. If we are unable to raise additional funds or to sustain
our operations on a modified business model in the future, then
substantial doubt may develop as to our ability to continue to
operate our business as a going concern, with substantial
adverse effects on the value of our common stock and our ability
to raise additional capital. This uncertainty may also create
concerns among our current and future customers, vendors and
licensees as to whether we will be able to fulfill our
obligations or, in the case of customers, fulfill their future
product or service needs. As a result, our current and
prospective customers, licensees and strategic partners might
decide not to do business with us, or only do so on less
favorable terms and conditions. Employee concern about the
future of the business and their continued prospects for
employment may cause employees to seek employment elsewhere,
depriving us of the human and intellectual capital we need to be
successful.
Our product revenue and our product business may be
negatively impacted by modifications to our business model that
we have recently implemented or are contemplating.
During the first quarter of 2005, as part of our transition to a
modified business model, we began taking action to reduce our
operating expenses by discontinuing certain of our products,
increasing prices for our products, and changing our terms and
conditions of sale, which actions we anticipate will improve the
negative gross margins historically associated with our product
business. Accordingly, we have advised our customers that we
plan to discontinue production of our Crusoe products during
2005. We have provided our Crusoe customers an End-of-Life
notice and we will continue to work closely with our customers
during this transition period. Based upon our review of critical
customer needs, we have also decided to narrow our Efficeon
product line and announced to our customers that certain
versions of the Efficeon products will be discontinued. We
currently expect that our modified business model will further
reduce our historic business focus on product sales, and that we
will further reduce operating expenses associated with our
product business as part of a restructuring plan, including a
reduction of our workforce. The actions that we have taken or
contemplate taking likely will result in lost sales as target
customers design a competitors microprocessor into their
product, to replace our own microprocessors. We expect to
continue evaluating the business of designing, developing and
selling our Efficeon processors, and we may decide to
discontinue some or all of our remaining Efficeon products in
2005 as we refine our modified business model.
29
The success of our licensing and service business depends on
maintaining and increasing our LongRun2 licensing revenue.
Our licensing and service revenue was $10.7 million in
fiscal year 2004 and $1.1 million in fiscal year 2003. In
2005, our licensing and service revenue will depend upon revenue
that we receive from existing licensing agreements and our
entering into new licensing agreements. Our ability to enter
into new LongRun2 licensing agreements depends in part upon the
adoption of our LongRun2 technology by our licensees and
potential licensees and the success of the products
incorporating our technology sold by licensees. While we
anticipate that we will continue our efforts to license our
technology to licensees, we cannot predict the timing or the
extent of any future licensing revenue, and recent levels of
license revenues may not be indicative of future periods.
We have limited visibility regarding when and to what extent
our licensees will use our LongRun2 or other licensed
technologies.
We have not yet earned or received any royalties under any of
our LongRun2 licensees. Our receipt of royalties from our
LongRun2 licenses depends on our licensees incorporating our
technology into their manufacturing and products, their bringing
their products to market, and the success of their products. Our
licensees are not contractually obligated to manufacture,
distribute or sell products using our licensed technologies.
Thus, our entry into and our full performance of our obligations
under our LongRun2 licensing agreements does not necessarily
assure us of any future royalty revenue. Any royalties that we
are eligible to receive are based upon our licensees use
of our licensed technologies and, as a result, we do not have
direct access to information that would enable us to forecast
the timing and amount of any future royalties. Factors that
negatively affect our licensees and their customers could
adversely affect our future royalties. The success of our
licensees is subject to a number of factors, including:
|
|
|
|
|
the competition these companies face and the market acceptance
of their products; |
|
|
|
the pricing policies of our licensees for their products
incorporating our technology and whether those products are
competitively priced; |
|
|
|
the engineering, marketing and management capabilities of these
companies and technical challenges unrelated to our technology
that they face in developing their products; and |
|
|
|
the financial and other resources of our licensees. |
Because we do not control the business practices of our
licensees and their customers, we have little influence on the
degree to which our licensees promote our technology.
Our licensing and services revenue cycle is long and
unpredictable, which makes it difficult to predict future
revenues, which may cause us to miss analysts estimates
and may result in unexpected changes in our stock price.
It is difficult to predict accurately our future revenues from
either the granting of new licenses or the generation of
royalties by our licensees under our existing licenses. In
addition, engineering services are dependent upon the varying
level of assistance desired by licensees and, therefore, revenue
from these services is also difficult to predict. There can be
no assurance that we can accurately estimate the amount of
resources required to complete projects, or that we will have,
or be able to expend, sufficient resources required to complete
a project. Furthermore, there can be no assurance that the
development schedules of our licensees will not be changed or
delayed. Our licensees are not obligated to continue using our
licensed technology or to use future generations of our
technologies in future manufacturing processes, and therefore
our past contract revenue may not be indicative of the amount of
such revenue in any future period. All of these factors make it
difficult to predict future licensing and service revenue, which
may result in us missing analysts estimates and may cause
unexpected changes in our stock price.
30
We could encounter a variety of technical and manufacturing
problems that could delay or prevent us from satisfying customer
demand for Efficeon TM8000 series microprocessors manufactured
using a 90 nanometer process.
We are using Fujitsu Limited to manufacture our 90 nanometer
Efficeon TM8000 series microprocessors. Manufacturing on an
advanced 90 nanometer CMOS process involves a variety of
technical and manufacturing challenges. Fujitsu Limited has
limited experience with the 90 nanometer CMOS process and,
although we have achieved production of our Efficeon TM8800
product on the Fujitsu Limited 90 nanometer CMOS process, we
cannot be sure that Fujitsu Limiteds 90 nanometer foundry
will achieve production shipments on our planned schedule or
that other manufacturing challenges might later arise. For
example, during 2001 and again in 2004, we experienced yield
problems as we migrated our products to smaller geometries,
which caused increases in our product costs, delays in product
availability and diversion of engineering personnel. If we
encounter problems with the manufacture of the Efficeon TM8000
series microprocessors using the 90 nanometer process that are
more significant or take longer to resolve than we anticipate,
our ability to fulfill our customer demand would suffer and we
could incur significant expenses.
Our restructuring plan will very likely reduce our resources
and ability to pursue opportunities and support customers in
emerging markets for our microprocessor products.
We currently expect that our modification of our business model
will further reduce our historical business focus on product
sales, and that we will further reduce operating expenses
associated with our product business as part of a restructuring
plan, including a reduction of our workforce. Our restructuring
plan will likely substantially limit our resources and ability
to pursue opportunities in emerging markets for which our
products are suited, including new classes of computing devices
such as UPCs and other unique PC form factors, which require
newly developed technologies, extensive development time, and
marketing support.
We face intense competition in the x86-compatible
microprocessor and power management markets. Many of our
competitors are much larger than we are and have significantly
greater resources. We may not be able to compete effectively.
The market for microprocessors is intensely competitive. We may
not be able to compete effectively against current and potential
competitors, especially those with significantly greater
resources and market leverage. Competition may cause price
reductions, reduced gross margins and loss of market share, any
one of which could significantly reduce our future revenue and
increase our losses. For example, we may determine to lower the
prices of our products in order to increase or maintain market
share, which would likely increase our losses.
Significant competitors in the x86-compatible microprocessor
product market include Intel, Advanced Micro Devices and VIA
Technologies. Our current and potential competitors have longer
operating histories, significantly greater financial, technical,
product development and marketing resources, greater name
recognition and significantly larger customer bases than we do.
Our competitors may be able to develop products comparable or
superior to those we offer, adapt more quickly than we do to new
technologies, evolving industry trends and customer
requirements, and devote greater resources to the development,
promotion and sale of their products than we can. Many of our
competitors also have well-established relationships with our
existing and prospective customers and suppliers. As a result of
these factors, many of our competitors, either alone or with
other companies, have significant influence in our target
markets that could outweigh any advantage that we may possess.
For example, negotiating and maintaining favorable customer and
strategic relationships are and will continue to be critical to
our business. If our competitors use their influence to
negotiate strategic relationships on more favorable terms than
we are able to negotiate, or if they structure relationships
that impair our ability to form strategic relationships, our
competitive position and our business would be substantially
damaged.
In particular, Intel has dominated the market for x86-compatible
microprocessors for many years. We may be adversely affected by
Intels pricing decisions, product mix and introduction
schedules, marketing strategies and influence over industry
standards and other market participants and the loyalty of
consumers to
31
the Intel brand. We cannot be sure that we can compete
effectively against Intel even in the market segments that we
intend to target.
In 2003, Intel introduced a new microprocessor that is focused
on the notebook computer market segment and designed to consume
less power than its prior microprocessors. We expect that Intel,
and potentially other microprocessor companies, will
increasingly seek to offer microprocessors specifically targeted
at many of the same market segments that we have served and
intend to serve, which could adversely affect our ability to
compete successfully.
Furthermore, our competitors may merge or form strategic
relationships that might enable them to offer, or bring to
market earlier, products that are superior to ours in terms of
features, quality, pricing or other factors. We expect
additional competition from other established and emerging
companies and technologies.
We also expect to face substantial competition in our licensing
and services business, in which we have focused primarily on
licensing our power management and transistor leakage control
technologies. The development of such technologies is an
emerging field subject to rapid technological change, and our
competition is unknown and could increase. Our LongRun2
technologies are highly proprietary and, though the subject of
patents and patents pending, are marketed primarily as trade
secrets subject to strict confidentiality protocols. Although we
are not aware of any other company having developed, offered or
demonstrated any comparable power management or leakage control
technologies, we note that most semiconductor companies have
internal efforts to reduce transistor leakage and power
consumption in current and future semiconductor products.
Indeed, all of our current and prospective licensees are larger,
technologically sophisticated companies, which generally have
significant resources and internal efforts to develop their own
technological solutions.
We may experience manufacturing difficulties that could
increase the cost and reduce the supply of our products.
The fabrication of wafers for our microprocessors is a highly
complex and precise process that requires production in a
tightly controlled, clean room environment. Minute impurities,
difficulties in the fabrication process, defects in the masks
used to print circuits on a wafer or other factors can cause
numerous die on each wafer to be nonfunctional. The proportion
of functional die expressed as a percentage of total die on a
wafer is referred to as product yield. Semiconductor
companies frequently encounter difficulties in achieving
expected product yields, particularly when introducing new
products. Yield problems may not be identified and resolved
until a product has been manufactured and can be analyzed and
tested, if ever. As a result, yield problems are often
difficult, time-consuming and expensive to correct. We have
experienced yield problems in the past, and we may experience
yield problems in the future that impair our ability to deliver
our products to our customers, increase our costs, adversely
affect our margins and divert the efforts of our engineering
personnel. Difficulties in achieving the desired yields often
occur in the early stages of production of a new product or in
the migration of manufacturing processes to smaller geometries.
We could experience difficulties in achieving desired yields or
other manufacturing problems in the production of our Efficeon
TM8000 series products that could delay our ability to deliver
Efficeon TM8000 series products, adversely affect our costs and
gross margins and harm our reputation. Even with functional die,
normal variations in wafer fabrication can cause some die to run
faster than others. Variations in speed yield could lead to
excess inventory of the slower, less valuable die, a resulting
unfavorable impact on gross margins and an insufficient
inventory of faster products, depending upon customer demand.
Our lengthy and variable product sales cycles make it
difficult for us to predict when and if a design win will result
in volume shipments.
We depend upon other companies designing our microprocessors
into their products, which we refer to as design wins. Many of
our targeted customers consider the choice of a microprocessor
to be a strategic decision. Thus our targeted customers may take
a long time to evaluate our products, and many individuals may
be involved in the evaluation process. We anticipate that the
length of time between our initial contact with a customer and
the time when we recognize revenue from that customer will vary.
We expect our sales cycles to
32
range typically from six to 12 months, or more, from the
time we achieve a design win to the time the customer begins
volume production of products that incorporate our
microprocessors. We do not have historical experience selling
our products that is sufficient for us to determine accurately
how our sales cycles will affect the timing of our revenue.
Variations in the length of our sales cycles could cause our
revenue to fluctuate widely from period to period. While
potential customers are evaluating our products and before they
place an order with us, we may incur sales and marketing
expenses and expend significant management and engineering
resources without any assurance of success. The value of any
design win depends upon the commercial success of our
customers products. If our customers cancel projects or
change product plans, we could lose anticipated sales. We can
offer no assurance that we will achieve further design wins or
that the products for which we achieve design wins will
ultimately be introduced or will, if introduced, be commercially
successful.
If we fail to forecast demand for our products accurately, we
could lose sales and incur inventory losses.
The demand for our products depends upon many factors and is
difficult to forecast. Many shipments of our products may be
made near the end of the fiscal quarter, which makes it
difficult to estimate demand for our products. Significant
unanticipated fluctuations in demand have caused, and in the
future could cause, problems in our operations. The lead-time
required to fabricate large volumes of wafers is often longer
than the lead-time our customers provide to us for delivery of
their product requirements. As a result, we have only a limited
ability to react to fluctuations in demand for our products,
which could cause us to have either too much or too little
inventory of a particular product. If demand does not develop as
we expect, we could have excess production. Excess production
would result in excess inventories of product, which would use
cash and could result in inventory write-downs and write-offs.
For example, we recorded a $6.8 million inventory-related
charge for the third quarter of fiscal 2004. We have limited
capability to reduce ongoing production once wafer fabrication
has commenced. Conversely, if demand exceeds our expectations,
Taiwan Semiconductor Manufacturing Company, or TSMC, or Fujitsu
Limited might not be able to fabricate wafers as quickly as we
need them. Also, Advanced Semiconductor Engineering, or ASE,
might not be able to increase assembly functions in a timely
manner. In that event, we would need to increase production and
assembly rapidly or find, qualify and begin production and
assembly at additional manufacturers or providers of assembly
and test services, which may not be possible within a time frame
acceptable to our customers. The inability of our product
manufacturer or ASE to increase production rapidly enough could
cause us to fail to meet customer demand. In addition, rapid
increases in production levels to meet unanticipated demand
could result in higher costs for manufacturing and other
expenses. These higher costs could lower our gross margins.
We currently derive a substantial portion of our product
revenue from a small number of customers, and our revenue would
decline significantly if any major customer were to cancel,
reduce or delay a purchase of our products.
Our customer base for product sales is highly concentrated. For
example, sales to three customers in the aggregate accounted for
72% of total revenue in fiscal 2004. We expect that a small
number of customers will continue to account for a significant
portion of our revenue. Our future revenue will depend upon the
timing and size of future purchase orders, if any, from these
customers and new customers and, among other things, the success
of our customers in marketing products that incorporate our
products, the product requirements of our customers; and the
financial and operational success of our customers.
We expect that our sales to OEM customers will continue to be
made on the basis of purchase orders rather than long-term
commitments. Many of our customers and potential customers are
significantly larger than we are and have sufficient bargaining
power to demand changes in terms and conditions of sale. The
loss of any major customer, or the delay of significant orders
from these customers, could reduce or delay our recognition of
revenue.
33
If our customers are not able to obtain the other components
necessary to build their systems, sales of our products could be
delayed or cancelled.
Suppliers of other components incorporated into our
customers systems may experience shortages, which could
reduce the demand for our products. For example, from time to
time, the computer and semiconductor industries have experienced
shortages of some materials and devices, such as memory
components, displays, and storage devices. Our customers could
defer or cancel purchases of our products if they are not able
to obtain the other components necessary to build their systems.
We rely on an independent foundry that has no obligation to
provide us with fixed pricing or production capacity for the
fabrication of our wafers, and our business will suffer if we
are unable to obtain sufficient production capacity on favorable
terms.
We do not have our own manufacturing facilities and, therefore,
must rely on third parties to manufacture our products. We
currently rely on TSMC in Taiwan to fabricate the wafers for our
current 130 nanometer products, and we rely on Fujitsu Limited
in Japan to manufacture our 90 nanometer Efficeon TM8000 series
products. We do not have manufacturing contracts with TSMC or
Fujitsu Limited, and therefore we cannot be assured that we will
have any guaranteed production capacity. These foundries may
allocate capacity to other companies products while
reducing the capacity available to us on short notice. Foundry
customers that are larger than we and have greater economic
resources, that have long-term agreements with these foundries
or that purchase in significantly larger volumes than we may
cause these foundries to reallocate capacity to them, decreasing
the capacity available to us. In addition, these foundries
could, with little or no notice, refuse to continue to fabricate
all or some of the wafers that we require. If these foundries
were to stop manufacturing for us, we would likely be unable to
replace the lost capacity in a timely manner. Transferring to
another manufacturer would require a significant amount of time
and money. As a result, we could lose potential sales and fail
to meet existing obligations to our customers. These foundries
could also, with little or no notice, change the terms under
which they manufacture for us, which could cause our
manufacturing costs to increase substantially.
Our reliance on TSMC and Fujitsu Limited to fabricate our
wafers limits our ability to control the production, supply and
delivery of our products.
Our reliance on third-party manufacturers exposes us to a number
of risks outside our control, including the following:
|
|
|
|
|
unpredictability of manufacturing yields and production costs; |
|
|
|
interruptions in shipments; |
|
|
|
inability to control quality of finished products; |
|
|
|
inability to control product delivery schedules; |
|
|
|
potential lack of access to key fabrication process
technologies; and |
|
|
|
potentially greater exposure to misappropriation of our
intellectual property. |
We depend on ASE to provide assembly and test services. If
ASE were to cease providing services to us in a timely manner
and on acceptable terms, our business would suffer.
We rely on ASE, which is located in Taiwan, for the majority of
our assembly and test services. We do not have a contract with
ASE for test and assembly services, and we typically procure
these services from ASE on a per order basis. ASE could cease to
perform all of the services that we require, or could change the
terms upon which it performs services for us. If we were
required to find and qualify alternative assembly or testing
services, we could experience delays in product shipments,
increased product costs or a decline in product quality. In
addition, as a result of our reliance on ASE, we do not directly
control our product delivery schedules. If ASE were not to
provide high quality services in a timely manner, our costs
could increase, we could experience delays in the delivery of
our products and our product quality could suffer.
34
If our products are not compatible with industry standards,
hardware that our customers design into their systems or that is
used by end-users or software applications or operating systems
for x86-compatible microprocessors, market acceptance of our
products and our ability to maintain or increase our revenues
would suffer.
Our products are designed to function as components of a system.
If our customers experience system-level incompatibilities
between our products and the other components in their systems,
we could be required to modify our products to overcome the
incompatibilities or delay shipment of our products until the
manufacturers of other components modify their products or until
our customers select other components. These events would delay
purchases of our products, cause orders for our products to be
cancelled or result in product returns.
In addition, to gain and maintain market acceptance, our
microprocessors must not have significant incompatibilities with
software for x86-compatible microprocessors, and in particular,
the Windows operating systems, or hardware used by end-users.
Software applications, games or operating systems with
machine-specific routines programmed into them can result in
specific incompatibilities. If a particular software
application, game or operating system is programmed in a manner
that makes it unable to respond correctly to our microprocessor,
it will appear to users of that software that our microprocessor
is not compatible with that software. Software or hardware
incompatibilities that are significant or are perceived to be
significant could hinder our products from achieving or
maintaining market acceptance and impair our ability to increase
our revenues.
In an effort to test and ensure the compatibility of our
products with hardware and software for x86-compatible
microprocessors, we rely on the cooperation of third-party
hardware and software companies, including manufacturers of
graphics chips, motherboards, BIOS software and other
components. All of these third-party designers and manufacturers
produce chipsets, motherboards, BIOS software and other
components to support each new generation of Intels
microprocessors, and Intel has significant leverage over their
business opportunities. If these third parties were to cease
supporting our microprocessor products, our business would
suffer.
Our products may have defects that could damage our
reputation, decrease market acceptance of our products, cause us
to lose customers and revenue and result in liability to us.
Highly complex products such as our microprocessors may contain
hardware or software defects or bugs for many reasons, including
design issues or defective materials or manufacturing processes.
Often, these defects and bugs are not detected until after the
products have been shipped. If any of our products contains
defects, or has reliability, quality or compatibility problems,
our reputation might be damaged significantly and customers
might be reluctant to buy our products, which could result in
the loss of or failure to attract customers. In addition, these
defects could interrupt or delay sales. We may have to invest
significant capital and other resources to correct these
problems. If any of these problems is not found until after we
have commenced commercial production of a new product, we might
incur substantial additional development costs. If we fail to
provide solutions to the problems, such as software patches, we
could also incur product recall, repair or replacement costs.
These problems might also result in claims against us by our
customers or others. In addition, these problems might divert
our technical and other resources from other development
efforts. Moreover, we would likely lose, or experience a delay
in, market acceptance of the affected product or products, and
we could lose credibility with our current and prospective
customers. This is particularly significant as we are a new
entrant to a market dominated by large well-established
companies.
If we fail to meet the continued listing requirements of the
NASDAQ Stock Market, our common stock could be delisted, which
would reduce the liquidity of our stock and would likely result
in a further decrease in the trading price of our stock.
Our common stock is listed on the NASDAQ National Market. The
NASDAQ Stock Markets Marketplace Rules impose requirements
for companies listed on the NASDAQ National Market to maintain
their listing status. One of these requirements is that we must
maintain a minimum closing bid price of
35
$1.00 per share for our common stock. If we fail to meet
this requirement for 30 consecutive business days, the NASDAQ
would issue a deficiency notice to us. If we were to receive
such a notice, we would then have 90 calendar days to comply,
and during this period the minimum closing bid price per share
must be above $1.00 per share for 10 consecutive business
days during this period to comply. Following this period, we
could appeal to NASDAQ for a hearing regarding the determination
to delist our common stock from the NASDAQ National Market. If
our common stock were to be delisted, holders of our common
stock would be less able to purchase or sell shares as quickly
and as inexpensively as they have done historically. For
instance, failure to obtain listing on another market or
exchange may make it more difficult for traders to sell our
securities. Broker-dealers may be less willing or able to sell
or make a market in our common stock. The loss or
discontinuation of our NASDAQ National Market listing may result
in a decrease in the trading price of our common stock due to a
decrease in liquidity, reduced analyst coverage and less
interest by institutions and individuals in investing in our
common stock.
If we fail to constitute an independent Board of Directors by
the time of our next annual stockholders meeting, our common
stock could be delisted, which would reduce the liquidity of our
stock and would likely result in a further decrease in the
trading price of our stock.
In order to maintain our NASDAQ continued listing requirements,
we also must satisfy the specific requirement that a majority of
the members of our Board of Directors are independent, within
the meaning of NASDAQ rules, by the time of our next annual
meeting of stockholders. We expect that our meeting of
stockholders for 2005 will be held in May or June 2005. Our
Board of Directors, as currently constituted, would not satisfy
this requirement, and we must adjust the membership of our Board
of Directors in order to achieve that requirement by the time of
our annual meeting of stockholders. If we are unable to meet the
Board independence requirement for any reason, our common stock
may be delisted. If our common stock were to be delisted,
holders of our common stock would be less able to purchase or
sell shares as quickly and as inexpensively as they have done
historically. For instance, failure to obtain listing on another
market or exchange may make it more difficult for traders to
sell our securities. Broker-dealers may be less willing or able
to sell or make a market in our common stock. Not maintaining a
listing on a major stock market may result in a decrease in the
trading price of our common stock due to a decrease in
liquidity, reduced analyst coverage and less interest by
institutions and individuals in investing in our common stock.
We are subject to general economic and market conditions.
Our business is subject to the effects of general economic
conditions in the United States and worldwide and, in
particular, market conditions in the semiconductor and computer
industries. In 2001, 2002 and through parts of 2003, our
operating results were adversely affected by unfavorable global
economic conditions and reduced information technology spending,
particularly in Japan, where we currently generate a substantial
portion of our revenue. These adverse conditions resulted in
decreased demand for notebook computers and, as a result, our
products, which are components of notebook computers. Further,
demand for our products decreases as computer manufacturers seek
to manage their component and finished product inventory levels.
If the economic conditions in Japan and worldwide do not
improve, or worsen, we may continue to experience material
adverse effects on our business, operating results and financial
condition.
If we do not keep pace with technological change, our
products may not be competitive and our revenue and operating
results may suffer.
The semiconductor industry is characterized by rapid
technological change, frequent new product introductions and
enhancements, and ongoing customer demands for greater
performance. In addition, the average selling price of any
particular microprocessor product has historically decreased
substantially over its life, and we expect that trend to
continue. As a result, our products may not be competitive if we
fail to introduce new products or product enhancements that meet
evolving customer demands. It may be difficult or costly for us,
or we may not be able, to enhance existing products to fully
meet customer demands, particularly in view of our anticipated
restructuring plan.
36
Advances in battery design, cooling systems and power
management systems could adversely affect our ability to achieve
widespread market acceptance for our products.
We believe that our ability to achieve widespread market
acceptance for our products will depend in large part on whether
potential purchasers of our products believe that the low power
usage of our products is a substantial benefit. Advances in
battery technology, or energy technologies such as fuel cell
technologies, that offer increased battery life and enhanced
power capacity, as well as the development and introduction of
more advanced cooling systems, may make microprocessor power
consumption a less important factor to our customers and
potential customers. These developments, or developments in
power management systems by third parties, may adversely affect
our ability to market and sell our products.
Our products and technologies may infringe the intellectual
property rights of others, which may cause us to become subject
to expensive litigation, cause us to incur substantial damages,
require us to pay significant license fees or prevent us from
selling our products.
Our industry is characterized by the existence of a large number
of patents and frequent claims and related litigation regarding
patent and other intellectual property rights. We cannot be
certain that our products and technologies do not and will not
infringe issued patents, patents that may be issued in the
future, or other intellectual property rights of others. In
addition, leading companies in the semiconductor industry have
extensive intellectual property portfolios with respect to
semiconductor technology. From time to time, third parties,
including these leading companies, may assert exclusive patent,
copyright, trademark and other intellectual property rights to
technologies and related methods that are important to us. We
expect that we may become subject to infringement claims as the
number of products and competitors in our target markets grows
and the functionality of products overlaps. We have received,
and may in the future receive, communications from third parties
asserting patent or other intellectual property rights covering
our products. Litigation may be necessary in the future to
defend against claims of infringement or invalidity, to
determine the validity and scope of the proprietary rights of
others, to enforce our intellectual property rights, or to
protect our trade secrets. We may also be subject to claims from
customers for indemnification. Any resulting litigation,
regardless of its resolution, could result in substantial costs
and diversion of resources.
If it were determined that our products infringe the
intellectual property rights of others, we would need to obtain
licenses from these parties or substantially reengineer our
products and technologies in order to avoid infringement. We
might not be able to obtain the necessary licenses on acceptable
terms, or at all, or to reengineer our products and technologies
successfully. Moreover, if we are sued for infringement and lose
the suit, we could be required to pay substantial damages or be
enjoined from licensing or using the infringing products or
technology. Any of the foregoing could cause us to incur
significant costs and prevent us from selling our products.
Any dispute regarding our intellectual property may require
us to indemnify certain licensees, the cost of which could
severely hamper our business operations and financial
condition.
In any potential dispute involving our patents or other
intellectual property, our licensees could also become the
target of litigation. Our LongRun2 license agreements provide
limited indemnities. Our indemnification obligations could
result in substantial expenses. In addition to the time and
expense required for us to supply such indemnification to our
licensees, a licensees development, marketing and sales of
licensed products incorporating our LongRun2 technology could be
severely disrupted or shut down as a result of litigation, which
in turn could severely hamper our business operations and
financial condition.
If we are unable to protect our proprietary rights
adequately, our competitors might gain access to our technology
and we might not compete successfully in our markets.
We believe that our success will depend in part upon our
proprietary technology. We rely on a combination of patents,
copyrights, trademarks, trade secret laws and contractual
obligations with employees and third parties to protect our
proprietary rights. These legal protections provide only limited
protection and may be time consuming and expensive to obtain and
enforce. If we fail to protect our proprietary rights
37
adequately, our competitors might gain access to our technology.
As a result, our competitors might offer similar products and we
might not be able to compete successfully in our market.
Moreover, despite our efforts to protect our proprietary rights,
unauthorized parties may copy aspects of our products and obtain
and use information that we regard as proprietary. Also, our
competitors may independently develop similar, but not
infringing, technology, duplicate our products, or design around
our patents or our other intellectual property. In addition,
other parties may breach confidentiality agreements or other
protective contracts with us, and we may not be able to enforce
our rights in the event of these breaches. Furthermore, the laws
of many foreign countries do not protect our intellectual
property rights to the same extent as the laws of the United
States. We may be required to spend significant resources to
monitor and protect our intellectual property rights.
Our pending patent and trademark applications may not be
approved. Our patents, including any patents that may result
from our patent applications, may not provide us with any
competitive advantage or may be challenged by third parties. If
challenged, our patents might not be upheld or their claims
could be narrowed. We may initiate claims or litigation against
third parties based on our proprietary rights. Any litigation
surrounding our rights could force us to divert important
financial and other resources from our business operations.
The evolution of our business could place significant strain
on our management systems, infrastructure and other resources,
and our business may not succeed if we fail to manage it
effectively.
Our ability to implement our business plan in a rapidly evolving
market requires effective planning and management process.
Changes in our business plans could place significant strain on
our management systems, infrastructure and other resources. In
addition, we expect that we will continue to improve our
financial and managerial controls and procedures. We will also
need to expand, train and manage our workforce worldwide.
Furthermore, we expect that we will be required to manage an
increasing number of relationships with suppliers,
manufacturers, customers and other third parties. If we fail to
manage change effectively, our employee-related costs and
employee turnover could increase and our business may not
succeed.
We have significant international operations, which exposes
us to risk and uncertainties.
We have sold, and in the future we expect to sell, most of our
products to customers in Asia. In addition, TSMC and ASE are
located in Taiwan, and the Fujitsu Limited foundry we use for
our 90 nanometer product is located in Japan. In addition,
we generally ship our products from a third-party warehouse
facility located in Hong Kong. In attempting to conduct and
expand business internationally, we are exposed to various risks
that could adversely affect our international operations and,
consequently, our operating results, including:
|
|
|
|
|
difficulties and costs of staffing and managing international
operations; |
|
|
|
fluctuations in currency exchange rates; |
|
|
|
unexpected changes in regulatory requirements, including
imposition of currency exchange controls; |
|
|
|
longer accounts receivable collection cycles; |
|
|
|
import or export licensing requirements; |
|
|
|
problems in the timeliness or quality of product deliveries; |
|
|
|
potentially adverse tax consequences; |
|
|
|
major health concerns, such as SARS; |
|
|
|
political and economic instability, for example as a result of
tensions between Taiwan and the Peoples Republic of
China; and |
|
|
|
potentially reduced protection for intellectual property rights. |
38
Our operating results are difficult to predict and fluctuate
significantly. A failure to meet the expectations of securities
analysts or investors could result in a substantial decline in
our stock price.
Our operating results fluctuate significantly from quarter to
quarter, and we expect that our operating results will fluctuate
significantly in the future as a result of one or more of the
risks described in this section or as a result of numerous other
factors. You should not rely on quarter-to-quarter comparisons
of our results of operations as an indication of our future
performance. Our stock price has declined substantially since
our stock began trading publicly. If our future operating
results fail to meet or exceed the expectations of securities
analysts or investors, our stock price would likely decline from
current levels.
A large portion of our expenses, including rent and salaries, is
fixed or difficult to reduce. Our expenses are based in part on
expectations for our revenue. If our revenue does not meet our
expectations, the adverse effect of the revenue shortfall upon
our operating results may be acute in light of the fixed nature
of our expenses. We often make many shipments of our products at
or near the end of the fiscal quarter, which makes it difficult
to estimate or adjust our operating activities quickly in
response to a shortfall in expected revenue.
We might experience payment disputes for amounts owed to us
under our LongRun2 licensing agreements, and this may harm our
results of operations.
The standard terms of our LongRun2 license agreements require
our licensees to document the royalties owed to us from the sale
of products that incorporate our technology and report this data
to us on a quarterly basis. While standard license terms give us
the right to audit books and records of our licensees to verify
this information, audits can be expensive, time consuming, and
potentially detrimental to our ongoing business relationship
with our licensees. Our failure to audit our licensees
books and records may result in us receiving more or less
royalty revenues than we are entitled to under the terms of our
license agreements. The result of such royalty audits could
result in an increase, as a result of a licensees
underpayment, or decrease, as a result of a licensees
overpayment, to previously reported royalty revenues. Such
adjustments would be recorded in the period they are determined.
Any adverse material adjustments resulting from royalty audits
or dispute resolutions may result in us missing analyst
estimates and causing our stock price to decline. Royalty audits
may also trigger disagreements over contract terms with our
licensees and such disagreements could hamper customer
relations, divert the efforts and attention of our management
from normal operations and impact our business operations and
financial condition.
The price of our common stock has been volatile and is
subject to wide fluctuations.
The market price of our common stock has been volatile and is
likely to remain subject to wide fluctuations in the future.
Many factors could cause the market price of our common stock to
fluctuate, including:
|
|
|
|
|
variations in our quarterly results; |
|
|
|
market conditions in our industry, the industries of our
customers and the economy as a whole; |
|
|
|
announcements of technological innovations by us or by our
competitors; |
|
|
|
introductions of new products or new pricing policies by us or
by our competitors; |
|
|
|
acquisitions or strategic alliances by us or by our competitors; |
|
|
|
recruitment or departure of key personnel; |
|
|
|
the gain or loss of significant orders; |
|
|
|
the gain or loss of significant customers; and |
|
|
|
changes in the estimates of our operating performance or changes
in recommendations by securities analysts. |
In addition, the stock market generally and the market for
semiconductor and other technology-related stocks in particular
experienced a decline during 2000, 2001 and through 2002, and
could decline from current
39
levels, which could cause the market price of our common stock
to fall for reasons not necessarily related to our business,
results of operations or financial condition. The market price
of our stock also might decline in reaction to events that
affect other companies in our industry even if these events do
not directly affect us. Accordingly, you may not be able to
resell your shares of common stock at or above the price you
paid. Securities litigation is often brought against a company
following a period of volatility in the market price of its
securities, and we have been subject to such litigation in the
past. Any such lawsuits in the future will divert
managements attention and resources from other matters,
which could also adversely affect our business and the price of
our stock.
Our California facilities and the facilities of third parties
upon which we rely to provide us critical services are located
in regions that are subject to earthquakes and other natural
disasters.
Our California facilities, including our principal executive
offices, are located near major earthquake fault lines. If there
is a major earthquake or any other natural disaster in a region
where one of our facilities is located, our business could be
materially and adversely affected. In addition, TSMC, upon which
we currently rely to fabricate our wafers, and ASE, upon which
we currently rely for the majority of our assembly and test
services, are located in Taiwan. Fujitsu Limited, which we
expect will fabricate a significant amount of our wafers in the
future, is located in Japan. Taiwan and Japan have experienced
significant earthquakes and could be subject to additional
earthquakes in the future. Any earthquake or other natural
disaster in these areas could materially disrupt our
manufacturers production capabilities and ASEs
assembly and test capabilities and could result in our
experiencing a significant delay in delivery, or substantial
shortage, of wafers and possibly in higher wafer prices.
Our certificate of incorporation and bylaws, stockholder
rights plan and Delaware law contain provisions that could
discourage or prevent a takeover, even if an acquisition would
be beneficial to our stockholders.
Provisions of our certificate of incorporation and bylaws, as
well as provisions of Delaware law, could make it more difficult
for a third party to acquire us, even if doing so would be
beneficial to our stockholders. These provisions include:
|
|
|
|
|
establishing a classified board of directors so that not all
members of our board may be elected at one time; |
|
|
|
providing that directors may be removed only for
cause and only with the vote of
662/3%
of our outstanding shares; |
|
|
|
requiring super-majority voting to amend some provisions in our
certificate of incorporation and bylaws; |
|
|
|
authorizing the issuance of blank check preferred
stock that our board could issue to increase the number of
outstanding shares and to discourage a takeover attempt; |
|
|
|
limiting the ability of our stockholders to call special
meetings of stockholders; |
|
|
|
prohibiting stockholder action by written consent, which
requires all stockholder actions to be taken at a meeting of our
stockholders; and |
|
|
|
establishing advance notice requirements for nominations for
election to our board or for proposing matters that can be acted
upon by stockholders at stockholder meetings. |
In addition, the stockholder rights plan, which we implemented
in 2002, and Section 203 of the Delaware General
Corporation Law may discourage, delay or prevent a change in
control.
40
Our reported financial results may be adversely affected by
changes in accounting principles generally accepted in the
United States.
Generally accepted accounting principles in the United States
are subject to interpretation by the Financial Accounting
Standards Board (FASB), the American Institute of Certified
Public Accountants, the Securities and Exchange Commission
(SEC) and various bodies formed to promulgate and interpret
appropriate accounting principles. A change in these principles
or interpretations could have a significant effect on our
reported financial results, and could affect the reporting of
transactions completed before the announcement of a change. For
example, we currently are not required to record stock-based
compensation charges if an employees stock option exercise
price is equal to or exceeds the deemed fair value of our common
stock at the date of grant. However, several companies have
recently elected to change their accounting policies and begun
to record the fair value of stock options as an expense. The
FASB published a pronouncement in December 2004 that would
require us to record expense for the fair value of stock options
granted. The effective date of the proposed standard is for
periods beginning after June 15, 2005. Our future operating
expenses may be adversely affected in connection with the
issuance of stock options.
We have identified material weaknesses in our internal
control over financial reporting, which contributed to our need
to amend our financial statements for the second quarter of
fiscal 2004.
In the course of preparing our financial statements for the
third quarter of fiscal 2004, material weaknesses, as defined in
Public Company Accounting Oversight Board Standard No. 2,
were identified in our internal control over financial
reporting. Specifically, material weaknesses were identified
with respect to our financial statement close process and our
contract administration. These material weaknesses contributed
to post-closing adjustments and the resulting need to amend our
financial statements for the second quarter of fiscal 2004. Our
amendment of our previously released financial statements could
diminish public confidence in the reliability of our financial
statements, which could harm our business and our stock price.
In addition, we cannot assure you that we will not in the future
identify further material weaknesses or significant deficiencies
in our internal control over financial reporting.
In order to comply with the Sarbanes-Oxley Act of 2002, we are
currently completing our system and process evaluation and
testing required for our management to assess the effectiveness
of our system of internal control over financial reporting as of
December 31, 2004, the end of our current fiscal year. In
our evaluation, we have identified certain material weaknesses
as set forth below in Item 9A. Controls and
Procedures. Our independent registered public accounting
firm must attest to and report on that assessment by our
management. If we fail to complete our evaluation and testing in
order to allow for this assessment by our management, or if our
independent registered public accounting firm cannot timely
attest to our managements assessment, then we could be
subject to regulatory scrutiny and a loss of public confidence
in our internal controls, which could harm our business and our
publicly traded stock price. Further, if our independent
registered public accounting firm are not satisfied with our
internal control over financial reporting or with the level at
which it is documented, designed, operated or reviewed, they may
decline to attest to managements assessment or may issue a
qualified report identifying further material weaknesses in our
internal controls. This could result in significant additional
expenditures responding to the Section 404 internal control
audit, a diversion of management attention and potentially an
adverse reaction to our publicly traded stock price.
Changes in securities laws and regulations have increased our
costs.
The Sarbanes-Oxley Act of 2002 has required and will require
changes in some of our corporate governance, public disclosure
and compliance practices. The Act also requires the SEC to
promulgate new rules on a variety of subjects. In addition to
final rules and rule proposals already made by the SEC, the
National Association of Securities Dealers has adopted revisions
to its requirements for companies, such as us, that are listed
on the NASDAQ National Market. These developments have increased
our legal and financial compliance costs and have made some
activities, such as SEC reporting requirements, more difficult.
Additionally, we expect these developments to make it more
difficult and more expensive for us to obtain director and
officer liability insurance, and we may be required to accept
reduced coverage or incur
41
substantially higher costs to obtain coverage. These
developments could make it more difficult for us to attract
qualified executive officers and attract and retain qualified
members of our board of directors, particularly to serve on our
audit committee. We are presently evaluating and monitoring
regulatory developments and cannot estimate the timing or
magnitude of additional costs we may incur as a result.
|
|
Item 7A. |
Quantitative and Qualitative Disclosures About Market
Risk |
Interest Rate Risk. Our cash equivalents and short-term
investments are exposed to financial market risk due to
fluctuations in interest rates, which may affect our interest
income. As of December 31, 2004, our cash equivalents and
short-term investments included money market funds and short and
medium term corporate bonds and earned interest at an average
rate of 2.1%. Due to the relative short-term nature of our
investment portfolio, our interest income is vulnerable to
sudden changes in market interest rates. We do not use our
investment portfolio for trading or other speculative purposes.
The table below presents principal amounts and related weighted
average interest rates by year of maturity for our investment
portfolio as of December 31, 2004 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2005 | |
|
2006 | |
|
Thereafter | |
|
Total | |
|
Fair Value | |
|
|
| |
|
| |
|
| |
|
| |
|
| |
Cash equivalents
|
|
$ |
17,273 |
|
|
|
|
|
|
|
|
|
|
$ |
17,273 |
|
|
$ |
17,273 |
|
|
Average rate
|
|
|
2.0 |
% |
|
|
|
|
|
|
|
|
|
|
2.0 |
% |
|
|
|
|
Short term investments
|
|
$ |
21,569 |
|
|
$ |
15,000 |
|
|
|
|
|
|
$ |
36,569 |
|
|
$ |
36,395 |
|
|
Average rate
|
|
|
2.0 |
% |
|
|
2.5 |
% |
|
|
|
|
|
|
2.2 |
% |
|
|
|
|
Foreign Currency Exchange Risk. All of our sales and
substantially all of our expenses are denominated in
U.S. dollars. As a result, we have relatively little
exposure to foreign currency exchange risk. We do not currently
enter into forward exchange contracts to hedge exposures
denominated in foreign currencies or any other derivative
financial instruments for trading or speculative purposes.
However, in the event our exposure to foreign currency risk
increases, we may choose to hedge those exposures.
42
|
|
Item 8. |
Financial Statements and Supplementary Data |
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
The following financial statements are filed as part of this
Report:
43
TRANSMETA CORPORATION
CONSOLIDATED BALANCE SHEETS
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, | |
|
|
| |
|
|
2004 | |
|
2003 | |
|
|
| |
|
| |
|
|
(In thousands, except For | |
|
|
share and per share data) | |
ASSETS |
Current assets:
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$ |
17,273 |
|
|
$ |
74,765 |
|
|
Short-term investments
|
|
|
36,395 |
|
|
|
46,000 |
|
|
Accounts receivable, net of allowances for doubtful accounts of
$9 and $215, in 2004 and 2003, respectively
|
|
|
2,290 |
|
|
|
1,719 |
|
|
Inventories
|
|
|
5,410 |
|
|
|
8,796 |
|
|
Prepaid expenses and other current assets
|
|
|
2,218 |
|
|
|
3,671 |
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
63,586 |
|
|
|
134,951 |
|
Property and equipment, net
|
|
|
2,187 |
|
|
|
5,305 |
|
Patents and patent rights, net
|
|
|
22,926 |
|
|
|
29,771 |
|
Other assets
|
|
|
914 |
|
|
|
1,563 |
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$ |
89,613 |
|
|
$ |
171,590 |
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS EQUITY |
Current liabilities:
|
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$ |
6,224 |
|
|
$ |
1,900 |
|
|
Accrued compensation and related compensation liabilities
|
|
|
4,189 |
|
|
|
4,986 |
|
|
Accrued inventory-related charges
|
|
|
4,876 |
|
|
|
|
|
|
Other accrued liabilities
|
|
|
5,723 |
|
|
|
5,360 |
|
|
Current portion of accrued restructuring costs
|
|
|
1,557 |
|
|
|
1,916 |
|
|
Current portion of long-term payables
|
|
|
|
|
|
|
21,129 |
|
|
Current portion of long-term debt and capital lease obligations
|
|
|
356 |
|
|
|
370 |
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
22,925 |
|
|
|
35,661 |
|
Long-term accrued restructuring costs, net of current portion
|
|
|
3,688 |
|
|
|
4,155 |
|
Long-term payables, net of current portion
|
|
|
5,000 |
|
|
|
|
|
Long-term debt and capital lease obligations, net of current
portion
|
|
|
|
|
|
|
356 |
|
Commitments and contingencies
|
|
|
|
|
|
|
|
|
Stockholders equity:
|
|
|
|
|
|
|
|
|
|
Convertible preferred stock, $0.00001 par value, at amounts
paid in; Authorized shares 5,000,000. None issued in
2004 and 2003
|
|
|
|
|
|
|
|
|
|
Common stock, $0.00001 par value, at amounts paid in;
Authorized shares 1,000,000,000. Issued and
outstanding shares 187,773,293 in 2004 and
167,528,493 in 2003
|
|
|
709,926 |
|
|
|
677,093 |
|
Treasury stock 796,875 shares in 2004 and 2003
|
|
|
(2,439 |
) |
|
|
(2,439 |
) |
Deferred stock compensation
|
|
|
|
|
|
|
(696 |
) |
Accumulated other comprehensive income (loss)
|
|
|
(125 |
) |
|
|
24 |
|
Accumulated deficit
|
|
|
(649,362 |
) |
|
|
(542,564 |
) |
|
|
|
|
|
|
|
|
|
Total stockholders equity
|
|
|
58,000 |
|
|
|
131,418 |
|
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders equity
|
|
$ |
89,613 |
|
|
$ |
171,590 |
|
|
|
|
|
|
|
|
(See accompanying notes)
44
TRANSMETA CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31, | |
|
|
| |
|
|
2004 | |
|
2003 | |
|
2002 | |
|
|
| |
|
| |
|
| |
|
|
(In thousands, except for per share data) | |
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product
|
|
$ |
18,776 |
|
|
$ |
16,225 |
|
|
$ |
24,247 |
|
|
License and service
|
|
|
10,668 |
|
|
|
1,090 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
|
29,444 |
|
|
|
17,315 |
|
|
|
24,247 |
|
|
|
|
|
|
|
|
|
|
|
Cost of revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenue
|
|
|
37,065 |
|
|
|
16,324 |
|
|
|
17,127 |
|
|
Impairment charge on long-lived assets
|
|
|
1,943 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total cost of revenue
|
|
|
39,008 |
|
|
|
16,324 |
|
|
|
17,127 |
|
|
|
|
|
|
|
|
|
|
|
Gross profit (loss)
|
|
|
(9,564 |
) |
|
|
991 |
|
|
|
7,120 |
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development(1)(2)
|
|
|
52,765 |
|
|
|
48,525 |
|
|
|
63,603 |
|
|
Selling, general and administrative(3)(4)
|
|
|
30,855 |
|
|
|
26,199 |
|
|
|
29,917 |
|
|
Restructuring charges (recovery)(5)
|
|
|
904 |
|
|
|
(244 |
) |
|
|
14,726 |
|
|
Amortization of patents and patent rights
|
|
|
9,217 |
|
|
|
10,530 |
|
|
|
11,392 |
|
|
Impairment charge on long-lived and other assets
|
|
|
2,544 |
|
|
|
|
|
|
|
|
|
|
Stock compensation
|
|
|
1,665 |
|
|
|
4,529 |
|
|
|
1,809 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
|
97,950 |
|
|
|
89,539 |
|
|
|
121,447 |
|
|
|
|
|
|
|
|
|
|
|
Operating loss
|
|
|
(107,514 |
) |
|
|
(88,548 |
) |
|
|
(114,327 |
) |
|
Interest income and other, net
|
|
|
827 |
|
|
|
1,389 |
|
|
|
4,962 |
|
|
Interest expense
|
|
|
(111 |
) |
|
|
(477 |
) |
|
|
(601 |
) |
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$ |
(106,798 |
) |
|
$ |
(87,636 |
) |
|
$ |
(109,966 |
) |
|
|
|
|
|
|
|
|
|
|
Net loss per share basic and diluted
|
|
$ |
(0.61 |
) |
|
$ |
(0.63 |
) |
|
$ |
(0.82 |
) |
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding basic and diluted
|
|
|
175,989 |
|
|
|
139,692 |
|
|
|
134,719 |
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
Excludes $445, $1,118 and $4,364 in amortization of deferred
stock compensation for the year ended December 31, 2004,
2003 and 2002, respectively. |
|
(2) |
Excludes $330, $128 and $(408) in variable stock compensation
for the year ended December 31, 2004, 2003 and 2002,
respectively. |
|
(3) |
Excludes $232, $657 and $950 in amortization of deferred stock
compensation for the year ended December 31, 2004, 2003 and
2002, respectively. |
|
(4) |
Excludes $658, $2,626 and $(1,360) in variable stock
compensation for the year ended December 31, 2004, 2003 and
2002, respectively. |
|
(5) |
Excludes $(1,737) of deferred stock compensation related to
employee terminations for the year ended December 31, 2002. |
(See accompanying notes)
45
TRANSMETA CORPORATION
CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated | |
|
|
|
|
|
|
|
|
Common Stock | |
|
|
|
Deferred | |
|
Other | |
|
|
|
Total | |
|
|
Shares of | |
|
at Amounts | |
|
Treasury | |
|
Stock | |
|
Comprehensive | |
|
Accumulated | |
|
Stockholders | |
|
|
Common Stock | |
|
Paid-in | |
|
Stock | |
|
Compensation | |
|
Income/(Loss) | |
|
Deficit | |
|
Equity | |
|
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
|
(In thousands, except for share and per share data) | |
Balance at December 31, 2001
|
|
|
132,234,558 |
|
|
$ |
603,464 |
|
|
$ |
(2,439 |
) |
|
$ |
(11,818 |
) |
|
$ |
720 |
|
|
$ |
(344,962 |
) |
|
$ |
244,965 |
|
Issuance of common stock to employees under option exercises and
employee stock purchase plan, net of repurchases
|
|
|
3,511,101 |
|
|
|
4,168 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,168 |
|
Issuance of common stock in connection with the purchase of
patents and patent rights at $2.94 per share
|
|
|
340,483 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock compensation
|
|
|
|
|
|
|
(5,201 |
) |
|
|
|
|
|
|
8,779 |
|
|
|
|
|
|
|
|
|
|
|
3,578 |
|
Repayment of notes from stockholders
|
|
|
|
|
|
|
456 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
456 |
|
Variable stock compensation
|
|
|
|
|
|
|
(1,768 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1,768 |
) |
Other comprehensive income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(586 |
) |
|
|
|
|
|
|
(586 |
) |
Net loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(109,966 |
) |
|
|
(109,966 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(110,552 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2002
|
|
|
136,086,142 |
|
|
$ |
601,119 |
|
|
$ |
(2,439 |
) |
|
$ |
(3,039 |
) |
|
$ |
134 |
|
|
$ |
(454,928 |
) |
|
$ |
140,847 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock in public offering at $2.90 per
share, net of issuance costs of $5.1 million
|
|
|
25,000,000 |
|
|
|
67,450 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
67,450 |
|
Issuance of common stock to employees under option exercises and
employee stock purchase plan, net of repurchases
|
|
|
5,423,213 |
|
|
|
6,136 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,136 |
|
Issuance of common stock in connection with the purchase of
patents and patent rights at $1.26 per share
|
|
|
796,178 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock in connection with net warrant
exercises at exercise price of $1.25 per share
|
|
|
222,960 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock compensation
|
|
|
|
|
|
|
(568 |
) |
|
|
|
|
|
|
2,343 |
|
|
|
|
|
|
|
|
|
|
|
1,775 |
|
Repayment of notes from stockholders
|
|
|
|
|
|
|
202 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
202 |
|
Variable stock compensation
|
|
|
|
|
|
|
2,754 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,754 |
|
Other comprehensive income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(110 |
) |
|
|
|
|
|
|
(110 |
) |
Net loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(87,636 |
) |
|
|
(87,636 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income/(loss)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(87,746 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2003
|
|
|
167,528,493 |
|
|
$ |
677,093 |
|
|
$ |
(2,439 |
) |
|
$ |
(696 |
) |
|
$ |
24 |
|
|
$ |
(542,564 |
) |
|
$ |
131,418 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock at $2.90 per share, in connection
with the over allotment option exercised by the underwriters
related to the December 2003 common stock offering, net of
issuance costs of $0.7 million
|
|
|
3,750,000 |
|
|
|
10,289 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10,289 |
|
Issuance of common stock at $1.50 per share in public
offering, net of issuance costs of $1.2 million
|
|
|
11,083,333 |
|
|
|
15,441 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15,441 |
|
Issuance of shares of common stock to employees under option
exercises and employee stock purchase plan, net of repurchases
|
|
|
5,401,568 |
|
|
|
5,277 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,277 |
|
Issuance of common stock in connection with net warrant
exercises at exercise price of $3.00 per share
|
|
|
9,899 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock compensation
|
|
|
|
|
|
|
(19 |
) |
|
|
|
|
|
|
696 |
|
|
|
|
|
|
|
|
|
|
|
677 |
|
Repayment of notes from stockholders
|
|
|
|
|
|
|
857 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
857 |
|
Variable stock compensation
|
|
|
|
|
|
|
988 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
988 |
|
Other comprehensive income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(149 |
) |
|
|
|
|
|
|
(149 |
) |
Net loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(106,798 |
) |
|
|
(106,798 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income/(loss)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(106,947 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2004
|
|
|
187,773,293 |
|
|
$ |
709,926 |
|
|
$ |
(2,439 |
) |
|
$ |
|
|
|
$ |
(125 |
) |
|
$ |
(649,362 |
) |
|
$ |
58,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(See accompanying notes)
46
TRANSMETA CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31, | |
|
|
| |
|
|
2004 | |
|
2003 | |
|
2002 | |
|
|
| |
|
| |
|
| |
|
|
(In thousands) | |
Cash flows from operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$ |
(106,798 |
) |
|
$ |
(87,636 |
) |
|
$ |
(109,966 |
) |
|
Adjustments to reconcile net loss to net cash used in operating
activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock compensation
|
|
|
1,665 |
|
|
|
4,529 |
|
|
|
1,809 |
|
|
|
Depreciation
|
|
|
3,639 |
|
|
|
5,586 |
|
|
|
5,888 |
|
|
|
Loss on disposal of fixed assets, net
|
|
|
|
|
|
|
138 |
|
|
|
148 |
|
|
|
Allowance for doubtful accounts
|
|
|
(206 |
) |
|
|
125 |
|
|
|
90 |
|
|
|
Amortization of other assets
|
|
|
|
|
|
|
413 |
|
|
|
201 |
|
|
|
Amortization of patents and patent rights
|
|
|
9,217 |
|
|
|
10,530 |
|
|
|
11,392 |
|
|
|
Impairment charge on long-lived assets for cost of revenue
|
|
|
1,943 |
|
|
|
|
|
|
|
|
|
|
|
Impairment charge on long-lived and other assets
|
|
|
2,544 |
|
|
|
|
|
|
|
|
|
|
|
Non cash restructuring charges (recovery)
|
|
|
904 |
|
|
|
(244 |
) |
|
|
1,629 |
|
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
(365 |
) |
|
|
2,216 |
|
|
|
(2,401 |
) |
|
|
Inventories
|
|
|
3,386 |
|
|
|
2,141 |
|
|
|
(9,549 |
) |
|
|
Prepaid expenses and other current assets
|
|
|
(649 |
) |
|
|
1,122 |
|
|
|
2,320 |
|
|
|
Other non-current assets
|
|
|
|
|
|
|
101 |
|
|
|
(103 |
) |
|
|
Accounts payable and accrued liabilities
|
|
|
8,763 |
|
|
|
(1,015 |
) |
|
|
(3,381 |
) |
|
|
Accrued restructuring charges
|
|
|
(1,730 |
) |
|
|
(2,473 |
) |
|
|
8,005 |
|
|
|
|
|
|
|
|
|
|
|
Net cash used in operating activities
|
|
|
(77,687 |
) |
|
|
(64,467 |
) |
|
|
(93,918 |
) |
|
|
|
|
|
|
|
|
|
|
Cash flows from investing activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase of available-for-sale investments
|
|
|
(74,994 |
) |
|
|
(102,775 |
) |
|
|
(178,596 |
) |
|
Proceeds from sale or maturity of available-for-sale investments
|
|
|
84,450 |
|
|
|
169,502 |
|
|
|
249,114 |
|
|
Purchase of property and equipment
|
|
|
(2,257 |
) |
|
|
(1,112 |
) |
|
|
(5,581 |
) |
|
Payment to development partner
|
|
|
(11,000 |
) |
|
|
(7,000 |
) |
|
|
(6,000 |
) |
|
Payment of previously acquired patents and patent rights
|
|
|
(7,500 |
) |
|
|
(9,000 |
) |
|
|
(9,000 |
) |
|
Other assets
|
|
|
|
|
|
|
(59 |
) |
|
|
(258 |
) |
|
|
|
|
|
|
|
|
|
|
Net cash provided by/(used in) investing activities
|
|
|
(11,301 |
) |
|
|
49,556 |
|
|
|
49,679 |
|
|
|
|
|
|
|
|
|
|
|
Cash flows from financing activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net proceeds from public offering of common stock
|
|
|
25,730 |
|
|
|
67,450 |
|
|
|
|
|
|
Common stock issued under stock option plans and employee stock
purchase programs
|
|
|
5,277 |
|
|
|
6,136 |
|
|
|
4,168 |
|
|
Repayment of notes from stockholders
|
|
|
857 |
|
|
|
202 |
|
|
|
456 |
|
|
Proceeds from debt and capital lease obligations
|
|
|
|
|
|
|
|
|
|
|
1,140 |
|
|
Repayment of debt and capital lease obligations
|
|
|
(368 |
) |
|
|
(725 |
) |
|
|
(2,659 |
) |
|
|
|
|
|
|
|
|
|
|
Net cash provided by financing activities
|
|
|
31,496 |
|
|
|
73,063 |
|
|
|
3,105 |
|
|
|
|
|
|
|
|
|
|
|
Change in cash and cash equivalents
|
|
|
(57,492 |
) |
|
|
58,152 |
|
|
|
(41,134 |
) |
Cash and cash equivalents at beginning of period
|
|
|
74,765 |
|
|
|
16,613 |
|
|
|
57,747 |
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of period
|
|
$ |
17,273 |
|
|
$ |
74,765 |
|
|
$ |
16,613 |
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosure of cash paid during the period:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash paid for interest
|
|
$ |
47 |
|
|
$ |
75 |
|
|
$ |
639 |
|
Supplemental disclosure of non-cash financing and investing
activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock in connection with net exercise of
warrants
|
|
|
204 |
|
|
|
919 |
|
|
|
|
|
(See accompanying notes)
47
TRANSMETA CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
From Transmetas inception in 1995 through its fiscal year
ended December 31, 2004, the Companys business model
was focused primarily on designing, developing and selling
highly efficient x86-compatible software-based microprocessors.
The Company currently supplies its products to a number of the
leading companies in the computer industry. The Company has
discontinued some of those products during the first quarter of
2005, and it might discontinue more or all of those products
during 2005.
In 2003, the Company initiated efforts to diversify its business
model by establishing a revenue stream based upon the licensing
of certain of its intellectual property and advanced computing
and semiconductor technologies developed in the course of
Transmetas research and development programs. In 2004, the
Company entered into and announced agreements granting licenses
to use Transmetas proprietary
LongRun2tm
technologies for power management and transistor leakage
control. Those licensing agreements include deliverable-based
technology transfer fees, maintenance and service fees, and
subsequent royalties on products incorporating the licensed
technologies.
In January 2005, the Company announced that it is critically
evaluating the economics of its microprocessor product business
during the first quarter of 2005 and that it intends to modify
its business model in 2005 to increase its efforts to license
intellectual property and advanced technologies. The Company
intends to continue its efforts to license advanced power
management technologies to other semiconductor companies, and it
is also contemplating licensing its intellectual property and
microprocessor and computing technologies to other companies in
the future in order to grow its licensing and services revenue.
Transmeta was incorporated in California as Transmeta
Corporation on March 3, 1995. Effective October 26,
2000, Transmeta reincorporated as a Delaware corporation.
The Company has historically reported negative cash flows from
its operations because the gross profit, if any, generated from
its product revenues and its license and service revenues has
not been sufficient to cover its operating cash requirements.
From its inception in 1995 through the end of fiscal year 2004,
the Company incurred a cumulative loss aggregating
$649.4 million, which included net losses of
$106.8 million in fiscal 2004, $87.6 million in fiscal
2003 and $110.0 million in fiscal 2002, which losses have
reduced stockholders equity to $58.0 million at
December 31, 2004. The Company believes that its existing
cash and cash equivalents and short-term investment balances and
cash from operations would not be sufficient to fund its
operations, planned capital and research and development
expenditures for the next twelve months under the business model
that the Company pursued during and through its fiscal year
ended December 31, 2004, which business model was primarily
focused on designing, developing and selling software-based
x86-compatible microprocessor products.
Accordingly, and as the Company announced publicly in January
2005, the Company is currently evaluating and modifying its
business model and developing a related restructuring plan, and
the Company currently expects to announce that modified business
model and related restructuring plan on or about March 31,
2005. During the first quarter of 2005, the Company began to
modify its business model to leverage its intellectual property
rights and increase its business focus on licensing its advanced
power management and other proprietary technologies to other
companies. By increasing its focus on its licensing and service
business, the Company hopes to increase revenue from its
licensing and service activities in 2005 and beyond. During the
first quarter of 2005, as part of its transition to a modified
business model, the Company also began taking action to reduce
its operating expenses by discontinuing certain of its products,
increasing prices for its products, and changing its terms and
conditions of sale, which actions the Company anticipates will
improve the negative gross margins historically associated with
its product business. The Company currently expects
48
TRANSMETA CORPORATION
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
that its modified business model will further reduce its
historic business focus on product sales, and that the Company
will further reduce operating expenses associated with its
product business as part of a restructuring plan. The Company
expects that its restructuring plan will include a reduction of
its workforce, and in January 2005 the Company gave written
notice to its employees, pursuant to federal and state Worker
Adjustment and Retraining Notification (WARN) Acts and
similar statutes applicable in other countries, that the Company
plans to restructure its business operations and to conduct a
mass layoff on or about March 31, 2005. Under the currently
anticipated restructuring plan, the Company expects to
restructure its operations so as to reduce its overall operating
expenses in accordance with a modified business model and, as a
result, the Company believes that its existing cash and cash
equivalents and short-term investment balances and cash from
operations will be sufficient to fund its operations, planned
capital and R&D expenditures for the next twelve months
under the modified business model that the Company is currently
developing and expects to announce with a related restructuring
plan on or about March 31, 2005.
The accompanying financial statements have been prepared
assuming that the Company will continue as a going concern;
however, the above conditions raise substantial doubt about the
Companys ability to continue as a going concern. The
financial statements do not include any adjustments to reflect
the possible future effects on the recoverability and
classification of assets or the amounts and classifications of
liabilities that may result should the Company be unable to
continue as a going concern.
Transmetas fiscal year ends on the last Friday in
December. For ease of presentation, the accompanying financial
statements have been shown as ending on December 31 and
calendar quarter ends for all annual and quarterly financial
statement captions. Fiscal year 2004 consisted of 53 weeks
and ended on December 31, 2004. Fiscal years 2003 and 2002
consisted of 52 weeks each and ended on December 26 and
December 27, respectively.
On February 25, 2005, the Companys Board of Directors
resolved to change the fiscal year from one ending on the last
Friday in December to a fiscal year ending the last calendar day
in December. This change is not deemed a change in fiscal year
for purposes of reporting subject to Rule 13a-10 or 15d-10
because the Companys fiscal year 2005 commenced with the
end of its fiscal year 2004.
|
|
2. |
Summary of Significant Accounting Policies |
|
|
|
Principles of Consolidation |
The accompanying consolidated financial statements include the
financial statements of Transmeta and its wholly owned
subsidiaries. All significant intercompany balances and
transactions have been eliminated in consolidation.
The preparation of financial statements in accordance with
U.S. generally accepted accounting principles requires
management to make estimates and assumptions that affect the
amounts reported in the financial statements. Actual results
could differ from those estimates. The critical accounting
policies that require management judgment and estimates include
license and service revenue recognition, inventory valuations,
long-lived and intangible asset valuations, restructuring
charges and loss contingencies.
|
|
|
Concentrations of Credit Risk |
Financial instruments that potentially subject the Company to
credit risk consist primarily of cash equivalents, short-term
investments and accounts receivable. Substantially all of the
Companys cash equivalents are invested in highly liquid
money market funds and commercial securities with high-quality
49
TRANSMETA CORPORATION
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
financial institutions in the United States. Short-term
investments consist of U.S. government and commercial bonds
and notes. The Company performs ongoing credit evaluations of
its customers, maintains an allowance for potential credit
losses and does not generally require collateral.
The Company depends on a single or limited number of outside
contractors to fabricate, assemble and test its semiconductor
devices. While the Company seeks to maintain a sufficient level
of supply and endeavors to maintain ongoing communications with
suppliers to guard against interruptions or cessation of supply,
business and results of operations could be adversely affected
by a stoppage or delay of supply from these vendors.
The Company recognizes revenue from products sold when
persuasive evidence of an arrangement exists, the price is fixed
or determinable, delivery has occurred and collectibility is
reasonably assured. The Company recognizes revenue for product
sales upon transfer of title. Transfer of title for the majority
of the Companys customers occurs upon shipment, as those
customers have terms of FOB: shipping point. For those customers
that have terms other than FOB: shipping point, transfer of
title generally occurs once products have been delivered to the
customer or the customers freight forwarder. The Company
accrues for estimated sales returns, and other allowances at the
time of shipment. Certain of the Companys product sales
are made to distributors under agreements allowing for price
protection and/or right of return on unsold products. The
Company defers recognition of revenue on these sales until the
distributors sell the products. The Company may also sell
certain products with End of Life status to its
distributors under special arrangements without price protection
or return privileges for which revenue is recognized upon
transfer of title, typically upon shipment.
The Company enters into license agreements, some of which may
contain multiple elements, including technology license and
support services, or non-standard terms and conditions. As a
result, in accordance with Emerging Issues Task Force
(EITF) Issue No. 00-21, Revenue Arrangements
with Multiple Deliverables and the Securities and Exchange
Commissions Staff Accounting Bulletin No. 104,
Revenue Recognition, significant interpretation on
these agreements is sometimes required to determine the
appropriate accounting, including whether deliverables specified
in a multiple element arrangement should be treated as separate
units of accounting for revenue recognition purposes, and if so,
how the price should be allocated among the deliverable elements
and when to recognize revenue for each element. The Company
recognizes revenue from license agreements when earned, which
generally occurs when agreed-upon deliverables are provided, or
milestones are met and confirmed by licensees and relative fair
values of multiple elements can be determined. Additionally,
license, and maintenance and service revenues are recognized if
collectibility is reasonably assured and if the Company is not
subject to any future performance obligation. The Company
recognizes revenue from maintenance agreements based on the fair
value of such agreements ratably over the period in which such
services are rendered. Royalty revenue is recognized upon
receipt of royalty payments from customers.
|
|
|
Shipping and Handling Costs |
Shipping and handling costs are expensed as incurred and
included in cost of revenue in the Companys results of
operations.
50
TRANSMETA CORPORATION
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Net comprehensive loss includes the Companys net loss, as
well as accumulated comprehensive income/(loss) on
available-for-sale investments and foreign currency translation
adjustments. Net comprehensive loss for the years ended
December 31, 2004, 2003 and 2002, respectively, is as
follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31, | |
|
|
| |
|
|
2004 | |
|
2003 | |
|
2002 | |
|
|
| |
|
| |
|
| |
|
|
(In thousands) | |
Net loss
|
|
$ |
(106,798 |
) |
|
$ |
(87,636 |
) |
|
$ |
(109,966 |
) |
Net change in unrealized gain/(loss) on investments
|
|
|
(173 |
) |
|
|
(134 |
) |
|
|
(586 |
) |
Net change in foreign currency translation adjustments
|
|
|
24 |
|
|
|
24 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net comprehensive loss
|
|
$ |
(106,947 |
) |
|
$ |
(87,746 |
) |
|
$ |
(110,552 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash Equivalents and Short-term Investments |
Highly liquid debt securities with insignificant interest rate
risk and original maturities of three months or less are
classified as cash equivalents. Debt securities with maturities
greater than three months are available-for-sale and are
classified as short-term investments.
All of Transmetas short-term investments were classified
as available-for-sale as of the balance sheet dates presented
and, accordingly, are reported at fair value with unrealized
gains and losses recorded as a component of accumulated other
comprehensive income/(loss) in stockholders equity. Fair
values of cash equivalents approximated original cost due to the
short period of time to maturity. The cost of securities sold is
based on the specific identification method. Realized gains or
losses and declines in value, if any, judged to be other than
temporary on available-for-sale securities are reported in
interest income or expense.
|
|
|
Fair Values of Financial Instruments |
The fair values of Transmetas cash equivalents, short-term
investments, accounts receivable, prepaid expenses and other
current assets, and accounts payable and accrued liabilities
approximate their carrying values due to the short-term nature
of those instruments.
The fair values of short-term and long-term capital lease
obligations are based on interest rates inherent on leasing
contracts. The carrying values of these obligations approximate
their respective fair values.
Inventories are stated at the lower of cost (first-in,
first-out) or market. Write-downs to reduce the carrying value
of excess and obsolete, slow moving and non-usable inventory to
net realizable value are charged to cost of revenue. Inventories
written down to net realizable value at the close of a fiscal
period are not marked up in subsequent periods.
In computing inventory valuation adjustments as a result of
lower of cost or market considerations, the Company reviews not
only the inventory on hand but also inventory in the supply
chain pursuant to the non-cancelable purchase orders. If the
Company becomes aware of factors that indicate that inventory
associated with these non-cancelable purchase orders will be
sold to customers below its cost, the Company accrues such loss
as an additional cost of revenue and as an additional accrued
liability on the balance sheet.
Property and equipment are recorded at cost. Depreciation and
amortization have been provided on the straight-line method over
the related assets estimated useful life ranging from
three to five years. Leasehold
51
TRANSMETA CORPORATION
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
improvements and assets recorded under capital leases are
amortized on a straight-line basis over the lesser of the
related assets estimated useful life or the remaining
lease term.
|
|
|
Valuation of Long-Lived and Intangible Assets |
Transmetas accounting policy related to the valuation and
impairment of long-lived assets is in accordance with the
Financial Accounting Standards Boards
(FASB) Statement of Financial Accounting Standards
(SFAS) 144, Accounting for the Impairment or Disposal
of Long-Lived Assets. In accordance with our policy, and
as circumstances require, we evaluate our long-lived and
intangible assets for impairment whenever events or changes in
circumstances indicate that the carrying amount of long-lived
assets may not be recoverable. The Company evaluates its
assumptions and estimates on an ongoing basis. Recoverability of
assets to be held and used is determined by comparing the
carrying amount of an asset to the future cash flows expected to
be generated by the asset. If the carrying amount of an asset
exceeds the future cash flows the asset is considered to be
impaired and the impairment charge recognized is measured by the
amount by which the carrying amount of the asset exceeds the
fair value of the asset.
Costs to develop Transmetas products and licenses are
expensed as incurred in accordance with the FASBs
SFAS 2, Accounting for Research and Development
Costs, which establishes accounting and reporting
standards for research and development costs.
Transmeta accounts for income taxes in accordance with the
FASBs SFAS 109, Accounting for Income
Taxes, which requires the use of the liability method in
accounting for income taxes. Under SFAS 109, deferred tax
assets and liabilities are measured based on differences between
the financial reporting and tax bases of assets and liabilities
using enacted tax rates and laws that will be in effect when
differences are expected to reverse.
Transmeta typically provides a warranty that includes factory
repair services or replacement as needed for replacement parts
on its products for a period of one year from shipment.
Transmeta records a provision for estimated warranty costs upon
shipment of its products. Warranty costs have been within
managements expectations to date and have not been
material.
The Company generally sells products with a limited
indemnification of customers against intellectual property
infringement claims related to the Companys products. The
Companys policy is to accrue for known indemnification
issues if a loss is probable and can be reasonably estimated and
to accrue for estimated incurred but unidentified issues based
on historical activity. To date, there are no such accruals or
related expenses.
All advertising costs are expensed as incurred. To date,
advertising costs have not been material.
Basic and diluted net loss per share is presented in conformity
with the FASBs SFAS 128, Earnings Per
Share, for all periods presented. Basic and diluted net
loss per share has been computed using the weighted-average
number of shares of common stock outstanding during each period,
less weighted-average shares subject to repurchase.
52
TRANSMETA CORPORATION
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The following table presents the computation of basic and
diluted net loss per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31, | |
|
|
| |
|
|
2004 | |
|
2003 | |
|
2002 | |
|
|
| |
|
| |
|
| |
|
|
(In thousands, except per share amounts) | |
Basic and diluted:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$ |
(106,798 |
) |
|
$ |
(87,636 |
) |
|
$ |
(109,966 |
) |
|
|
|
|
|
|
|
|
|
|
Basic and diluted:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding
|
|
|
175,989 |
|
|
|
139,698 |
|
|
|
134,902 |
|
|
Less: Weighted average shares subject to repurchase
|
|
|
|
|
|
|
(6 |
) |
|
|
(183 |
) |
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares used in computing basic and diluted net
loss per share
|
|
|
175,989 |
|
|
|
139,692 |
|
|
|
134,719 |
|
|
|
|
|
|
|
|
|
|
|
Net loss per share basic and diluted
|
|
$ |
(0.61 |
) |
|
$ |
(0.63 |
) |
|
$ |
(0.82 |
) |
|
|
|
|
|
|
|
|
|
|
The Company has excluded all outstanding warrants, stock options
and shares subject to repurchase from the calculation of basic
and diluted net loss per share because these securities are
antidilutive for all periods presented. Options and warrants to
purchase 40,301,940, 33,706,226 and 32,917,730 shares
of common stock in 2004, 2003 and 2002, respectively, determined
using the treasury stock method, were not included in the
computation of diluted net loss per share because the effect
would be antidilutive. These securities, had they been dilutive,
would have been included in the computation of diluted net loss
per share using the treasury stock method.
Transmeta has employee stock plans that are described more fully
in Note 12. The Company has elected to use the intrinsic
value method under Accounting Principles Board Opinion
No. 25, Accounting for Stock Issued to
Employee, as permitted by Statement of Financial
Accounting Standard (SFAS) No. 123, Accounting
for Stock-Based Compensation, subsequently amended by
SFAS 148, Accounting for Stock-Based
Compensation Transition and Disclosure to
account for stock options issued to its employees under its
stock option plans, and amortizes deferred compensation, if any,
ratably over the vesting period of the options. Expense
associated with stock-based compensation is amortized on an
accelerated basis over the vesting period of the individual
award consistent with the method described in FASB
Interpretation 28, Accounting for Stock Appreciation
Rights and Other Variable Stock Option or Award Plan.
Accordingly, approximately 59% of the unearned deferred
compensation is amortized in the first year, 25% in the second
year, 12% in the third year, and 4% in the fourth year following
the date of grant. Pursuant to SFAS 123, Transmeta
discloses the pro forma effect of using the fair value method of
accounting for its stock-based compensation arrangements.
53
TRANSMETA CORPORATION
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
For purposes of pro forma disclosures, the estimated fair value
of options is amortized to pro forma expense over the
options vesting period using an accelerated graded method.
Pro forma information follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31, | |
|
|
| |
|
|
2004 | |
|
2003 | |
|
2002 | |
|
|
| |
|
| |
|
| |
|
|
(In thousands, except per share data) | |
Net loss, as reported
|
|
$ |
(106,798 |
) |
|
$ |
(87,636 |
) |
|
$ |
(109,966 |
) |
Add: Stock-based employee compensation expense included in
reported net loss, net of related tax effects
|
|
$ |
1,665 |
|
|
$ |
4,529 |
|
|
$ |
1,809 |
|
Less: Total stock-based employee compensation expense under fair
value based method for all awards, net of related tax effects
|
|
$ |
(34,756 |
) |
|
$ |
(46,462 |
) |
|
$ |
(41,377 |
) |
Pro forma net loss
|
|
$ |
(139,889 |
) |
|
$ |
(129,569 |
) |
|
$ |
(149,534 |
) |
Basic and diluted net loss per share as reported
|
|
$ |
(0.61 |
) |
|
$ |
(0.63 |
) |
|
$ |
(0.82 |
) |
Basic and diluted net loss per share pro forma
|
|
$ |
(0.79 |
) |
|
$ |
(0.93 |
) |
|
$ |
(1.11 |
) |
See Note 12 for a discussion of the assumptions used in the
option pricing model and estimated fair value of employee stock
options.
Options and warrants granted to consultants and vendors are
accounted for at fair value determined by using the
Black-Scholes method in accordance with Emerging Issues Task
Force (EITF) Issue No. 96-18. The assumptions used to
value stock-based awards to consultants and vendors are similar
to those used for employees except that the respective
contractual life of the warrant or option was used instead of
the estimated life. (See Note 12).
Due to the resignation in fiscal 2001 of certain officers and
the treatment of the notes they issued to the Company in order
to early exercise their options, the Company is accounting for
all remaining stockholder notes that were issued to purchase
shares of the Companys common stock as if such notes had
terms equivalent to non-recourse notes. The Company determined
that variable accounting is to be applied to these note
arrangements as long as the notes remain outstanding. Under
variable accounting, the Company records compensation expense
for the vested shares for the excess, if any, of the current
market value of the shares over the then current principle
amount of the notes and accrued interest, determined separately
for each outstanding stockholder note.
The Company accounted for its restructuring activity during
fiscal 2002 under EITF Issue No. 94-3, Liability
Recognition for Certain Employee Termination Benefits and Other
Costs to Exit an Activity (including Certain Cots Incurred in a
Restructuring) for recognition of liabilities and expenses
associated with exit and disposal costs when the Company made a
commitment to a firm exit plan. In July 2002, the FASB issued
SFAS 146 Accounting for Costs Associated with Exit or
Disposal Activities, which addresses financial accounting
and reporting for costs associated with exit or disposal
activities and nullifies EITF Issue No. 94-3. SFAS 146
is effective for exit or disposal activities that are initiated
after December 31, 2002. Any future restructuring
activities, will be recorded in accordance with SFAS 146,
which requires that a liability for costs associated with an
exit or disposal activity be recognized when the liability is
incurred.
The Company is subject to the possibility of various loss
contingencies arising in the normal course of business. In
accordance with SFAS No. 5, Accounting for
Contingencies, the Company accrues for a loss contingency
when it is probable that a liability has been incurred and the
Company can reasonably estimate
54
TRANSMETA CORPORATION
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
the amount of loss. The Company regularly assesses current
information available to determine whether changes in such
accruals are required.
Certain reclassifications have been made to prior year balances
in order to conform to the current year presentation.
|
|
|
Recent Accounting Pronouncements |
In March 2004, the Financial Accounting Standards Board
(FASB) approved the consensus reached on the Emerging
Issues Task Force (EITF) Issue No. 03-1, The
Meaning of Other-Than-Temporary Impairment and Its Application
to Certain Investments. EITF 03-1 provides guidance
for identifying other-than-temporarily impaired investments.
EITF 03-1 also provides new disclosure requirements for
investments that are deemed to be temporarily impaired. In
September 2004, the FASB issued a FASB Staff Position
(FSP) EITF 03-1-1 that delays the effective date of
the measurement and recognition guidance in EITF 03-1 until
further notice. Once the FASB reaches a final decision on the
measurement and recognition provisions, the Company will
evaluate the impact of the adoption of the accounting provisions
of EITF 03-1.
In November 2004, the FASB issued Statement of Financial
Accounting Standards (SFAS) 151, Inventory Costs, an
amendment of ARB No. 43, Chapter 4.
SFAS 151 amends ARB No. 43, Chapter 4, to clarify
that abnormal amounts of idle facility expense, freight,
handling costs and wasted materials (spoilage) should be
recognized as current period charges. Additionally,
SFAS 151 requires that the allocation of fixed production
overheads to the costs of conversion be based on the normal
capacity of the production facilities. SFAS 151 is
effective for fiscal years beginning after June 15, 2005.
The adoption of this pronouncement is not expected to have a
material impact on the Companys statements of operations.
In December 2004, the FASB issued SFAS 123(R),
Share-Based Payment. SFAS 123(R) requires
employee stock options and rights to purchase shares under stock
participation plans to be accounted for under the fair value
method, and eliminates the ability to account for these
instruments under the intrinsic value method prescribed by APB
Opinion No. 25, and allowed under the original provisions
of SFAS 123. SFAS 123(R) requires the use of an option
pricing model for estimating fair value, which is amortized to
expense over the service periods. The requirements of
SFAS 123(R) are effective for fiscal periods beginning
after June 15, 2005. SFAS 123(R) allows for either
prospective recognition of compensation expense or retrospective
recognition, which may be back to the original issuance of
SFAS 123 or only to interim periods in the year of
adoption. The Company is currently evaluating the impact of the
adoption of SFAS 123(R).
In December 2004, the FASB issued SFAS 153, Exchanges
of Nonmonetary Assets, an amendment of APB Opinion
No. 29. SFAS 153 amends APB Opinion No. 29
to eliminate the exception for nonmonetary exchanges of similar
productive assets and replaces it with a general exception for
exchanges of nonmonetary assets that do not have commercial
substance. A nonmonetary exchange has commercial substance if
the future cash flows of the entity are expected to change
significantly as a result of the exchange. The Company is
required to adopt SFAS 153, on a prospective basis, for
nonmonetary exchanges beginning after June 15, 2005. The
adoption of SFAS 153 is not expected to have an impact on
the Companys consolidated result of operations.
55
TRANSMETA CORPORATION
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
3. |
Financial Statement Components |
|
|
|
Cash Equivalents and Short-Term Investments |
All cash equivalents and short-term investments as of
December 31, 2003 and 2002 were classified as
available-for-sale securities and consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross | |
|
Gross | |
|
|
|
|
Amortized | |
|
Unrealized | |
|
Unrealized | |
|
|
|
|
Cost | |
|
Gains | |
|
Losses | |
|
Fair Value | |
|
|
| |
|
| |
|
| |
|
| |
|
|
(In thousands) | |
As of December 31, 2004:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Money market funds
|
|
$ |
17,273 |
|
|
$ |
|
|
|
$ |
|
|
|
$ |
17,273 |
|
|
Federal agency discount notes
|
|
|
21,000 |
|
|
|
1 |
|
|
|
168 |
|
|
|
20,833 |
|
|
Commercial paper
|
|
|
15,569 |
|
|
|
|
|
|
|
7 |
|
|
|
15,562 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total available-for-sale securities
|
|
$ |
53,842 |
|
|
$ |
1 |
|
|
$ |
175 |
|
|
$ |
53,668 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Less amounts classified as cash equivalents
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(17,273 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total short-term investments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
36,395 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31, 2003:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Money market funds
|
|
$ |
72,766 |
|
|
$ |
|
|
|
$ |
|
|
|
$ |
72,766 |
|
|
Federal agency discount notes
|
|
|
22,000 |
|
|
|
21 |
|
|
|
21 |
|
|
|
22,000 |
|
|
Commercial paper
|
|
|
25,999 |
|
|
|
|
|
|
|
|
|
|
|
25,999 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total available-for-sale securities
|
|
$ |
120,765 |
|
|
$ |
21 |
|
|
$ |
21 |
|
|
$ |
120,765 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Less amounts classified as cash equivalents
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(74,765 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total short-term investments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
46,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The following is a summary of amortized costs and estimated fair
values of debt securities by contractual maturity.
|
|
|
|
|
|
|
|
|
|
|
|
Amortized | |
|
Fair | |
|
|
Cost | |
|
Value | |
|
|
| |
|
| |
|
|
(In thousands) | |
As of December 31, 2004:
|
|
|
|
|
|
|
|
|
|
Amounts maturing within one year
|
|
$ |
21,569 |
|
|
$ |
21,520 |
|
|
Amounts maturing after one year, within five years
|
|
$ |
15,000 |
|
|
$ |
14,875 |
|
The Company had a restricted cash balance of $110,000 at
December 31, 2004 and December 31, 2003 which served
as collateral for the Companys credit card program.
In fiscal 2004, the Company reclassified certain auction rate
securities of $9.0 million from Cash and cash equivalents
to Short-term investments on the Consolidated Balance Sheets as
of December 31, 2003. The Company has reclassified the
purchases and sales of these auction rate securities in the
Consolidated Statements of Cash Flows, which decreased Net cash
provided by investing activities from $58.6 million to
$49.6 million for the year ended December 31, 2003.
To date, there has been no impairment charges on its
available-for-sale securities related to other-than-temporary
declines in market value.
56
TRANSMETA CORPORATION
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Customers who accounted for more than 10% of Transmetas
accounts receivable balance at December 31, 2004 and 2003
are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
December 31, | |
|
|
| |
|
|
2004 | |
|
2003 | |
|
|
| |
|
| |
Customer:
|
|
|
|
|
|
|
|
|
|
Hewlett Packard International Pte Ltd.
|
|
|
31% |
|
|
|
66% |
|
|
Siltrontech Electronics Corporation
|
|
|
28% |
|
|
|
*% |
|
|
Sharp Trading Corporation
|
|
|
16% |
|
|
|
13% |
|
|
|
* |
represents less than 10% of accounts receivable balance |
The Company maintains an allowance for doubtful accounts
receivable based upon the expected collectibility of accounts
receivable. During fiscal 2003, the Company increased the
allowance for doubtful accounts from $90,000 at
December 31, 2002 to $215,000 at December 31, 2003,
which resulted in a charge to bad debt expense of $125,000.
During fiscal 2004, the Company wrote off a customer account and
adjusted the allowance for doubtful accounts from $215,000 at
December 31, 2003 to $9,000 at December 31, 2004.
There were no other adjustments to the allowance for bad
doubtful accounts during fiscal 2004 and 2003. Net accounts
receivable at December 31, 2004 and 2003 included a reserve
for returned material authorizations of $295,000 and $23,000,
respectively.
The components of inventories as of December 31, 2004 and
2003 are as follows:
|
|
|
|
|
|
|
|
|
|
|
December 31, | |
|
|
| |
|
|
2004 | |
|
2003 | |
|
|
| |
|
| |
|
|
(In thousands) | |
Work in progress
|
|
$ |
4,158 |
|
|
$ |
6,136 |
|
Finished goods
|
|
|
1,252 |
|
|
|
2,660 |
|
|
|
|
|
|
|
|
|
|
$ |
5,410 |
|
|
$ |
8,796 |
|
|
|
|
|
|
|
|
In fiscal 2004, the Company recorded a charge of approximately
$9.0 million to cost of revenue related to the valuation of
inventory on hand, which resulted in a reduction of the carrying
value of that inventory. As a component of this charge and in
computing inventory valuation adjustments as a result of lower
of cost or market considerations, the Company reviews the
inventory on hand and inventory on order. In estimating the net
realizable value of the inventory on hand and in determining
whether the inventory on hand was in excess of anticipated
demand, the Company took into consideration current assumptions
regarding the Companys future plans on its products and
the related potential impact on customer demand. Of the
$5.4 million and $8.8 million of net inventory on hand
at December 31, 2004 and 2003, respectively,
$2.4 million and $2.6 million of net inventory,
respectively, were adjusted to their net realizable value.
Accordingly, gross margin may be impacted from future sales of
these parts to the extent that the associated revenue exceeds or
fails to achieve their currently adjusted values. For fiscal
2004 and fiscal 2003, the Companys gross margins included
a benefit of $0.6 million and $0.5 million,
respectively, resulting from products being sold at average
selling prices (ASPs) in excess of their previously written down
values.
In addition to recording the inventory valuation adjustments
described above, the Company accrues a loss provision for any
purchase commitments if the Company becomes aware of factors
that would decrease the net realizable value of such on-order
inventory, in accordance with U.S. generally accepted
accounting
57
TRANSMETA CORPORATION
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
principles. In connection with the estimates of net realizable
value of such on-order inventory and purchase commitments, the
Company recorded an $8.4 million charge in fiscal 2004 as
additional cost of revenue. In computing the accrual for the
loss provision, the Company took into consideration current
assumptions regarding the Companys future plans on its
products and the related potential impact on customer demand.
Calculation of inventory valuation adjustments and loss
provisions for any purchase commitments requires the Company to
make estimates. Actual future results could differ from these
estimates. Accordingly, gross margin may benefit from future
sales of inventory to the extent that the associated revenues
exceed their currently adjusted values. Similarly, gross margin
may be adversely affected if the associated revenues are lower
than their currently adjusted values.
Property and equipment, net, consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
|
December 31, | |
|
|
| |
|
|
2004 | |
|
2003 | |
|
|
| |
|
| |
|
|
(In thousands) | |
Furniture and fixtures
|
|
$ |
2,019 |
|
|
$ |
2,018 |
|
Computer equipment
|
|
|
23,534 |
|
|
|
21,643 |
|
Computer software
|
|
|
11,359 |
|
|
|
11,181 |
|
Leasehold improvements
|
|
|
2,899 |
|
|
|
2,730 |
|
|
|
|
|
|
|
|
|
|
|
39,811 |
|
|
|
37,572 |
|
Less: Accumulated depreciation and amortization
|
|
|
(35,888 |
) |
|
|
(32,267 |
) |
Less: Impairment charge
|
|
|
(1,736 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
Property and equipment, net
|
|
$ |
2,187 |
|
|
$ |
5,305 |
|
|
|
|
|
|
|
|
The original cost of equipment recorded under capital lease
arrangements included in property and equipment aggregated
$1.9 million at 2004 and 2003. Related accumulated
depreciation was $1.3 million and $0.6 million as of
December 31, 2004 and 2003, respectively. Amortization
expense related to assets under capital leases is included with
depreciation expense.
In fiscal 2004, due to the emergence of indicators of
impairment, Transmeta performed an assessment of the carrying
value of certain long-lived and other assets. As a result,
during the fourth quarter of 2004, the Company recorded a charge
of $1.7 million related to property and equipment. See
Note 8 for further discussion on the impairment charge on
long-lived and other assets.
|
|
4. |
License and Service Revenue |
During fiscal 2004 the Company recognized $10.7 million in
license and service revenue. The Company recognized
$9.0 million as technology transfer and license fees
pursuant to a technology and professional services agreement
executed in March 2004 with a customer upon receiving customer
acceptance of all deliverables and when all revenue recognition
criteria have been met. Service revenue of $0.8 million
pursuant to the March 2004 agreement and $0.9 million of
service revenue from agreements signed in the prior year was
recognized over the period in which services were rendered based
on the fair value of the services. The Company did not recognize
revenue on the technology license agreement executed in November
2004 as the Company had not completed the delivery of all the
required deliverables.
58
TRANSMETA CORPORATION
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
5. |
Technology License Agreements |
In December 1997, Transmeta entered into a technology license
agreement with IBM Corporation (IBM), which was amended in 1999
and again in 2000. The term of the original agreement was five
years. In the first amendment, in November 1999, IBM
relinquished certain of the worldwide license rights previously
obtained in exchange for commitments by Transmeta. These
commitments included payments of $33.0 million to IBM in
various installments.
The then net present value of the $33.0 million commitment
(approximately $18.9 million) was recorded on the balance
sheet as an element of deferred charges under license agreements
with a corresponding liability. During the fourth quarter of
2001, as part of the Companys routine procedures and due
to the emergence of indicators of impairment, Transmeta
performed an assessment of the carrying value for its long-lived
assets. As a result, during the fourth quarter of 2001, the
Company recorded a charge to write-off the carrying value of the
deferred charges associated with this agreement.
Although the asset was impaired, the associated liability
remains on the balance sheet. The liability was accreted to its
future value using the effective interest method at a rate of
approximately 15% per annum and the accretion expense was
recorded as part of amortization of deferred charges, patents
and patent rights. Accretion expense for these payments for
fiscal 2004, 2003 and 2002 was $2.1 million,
$2.7 million and $3.2 million, respectively. During
2001, Transmeta fulfilled its obligation to pay IBM the
$4.0 million payment due on or before December 15,
2001 by negotiating a $3.5 million payment in June 2001. A
scheduled payment of $7.0 million and $6.0 million was
made to IBM in December 2003 and 2002, respectively, in
accordance with the terms of the agreement. Under the terms of a
re-negotiation of payment terms made in October 2004, the
Company made a $4.0 million payment to IBM in December
2004. The Company further re-negotiated the contract payment
obligation with IBM in December 2004 by making an additional
$7.0 million payment in December 2004 and deferred the
remaining balance and related interest payments until
June 30, 2006. The future cash commitment to IBM at
December 31, 2004 was $5.0 million. As the liability
was accreted to its future value of $5.0 million at
December 31, 2004, no further accretion expense related to
this liability will be recorded.
|
|
6. |
Patents and Patent Rights |
Patents and patent rights, net, consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
|
December 31, | |
|
|
| |
|
|
2004 | |
|
2003 | |
|
|
| |
|
| |
|
|
(In thousands) | |
Patents and patent rights
|
|
$ |
47,920 |
|
|
$ |
47,920 |
|
Less: Accumulated amortization
|
|
|
(24,994 |
) |
|
|
(18,149 |
) |
|
|
|
|
|
|
|
|
Patents and patent rights, net
|
|
$ |
22,926 |
|
|
$ |
29,771 |
|
|
|
|
|
|
|
|
Patents and patent rights for microprocessor technology were
acquired from Seiko Epson (Epson) in May 2001. Under the patents
and patent rights agreement with Epson, Transmeta agreed to pay
Epson a combination of $30.0 million in cash and shares of
the Companys common stock valued at $10.0 million
based upon the average of the closing stock price over a defined
period. The Company recorded total consideration of
$38.1 million consisting of $10.8 million of Transmeta
common stock, $26.8 million as the net present value of
cash payments and $0.5 million of acquisition costs on the
balance sheet as an element of patents and patent rights. The
Company paid Epson $7.5 million in cash and
766,930 shares of the Companys unregistered common
stock in May 2001. The number of shares issued to Epson was
calculated in accordance with the agreement; however for
accounting purposes the value of the shares was determined using
the closing price on the issuance date, or $14.10, resulting in
a recorded value of $10.8 million. The Company paid Epson
59
TRANSMETA CORPORATION
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
$7.5 million in cash in May 2004, $7.5 million in cash
in May 2003 and $7.5 million in cash in May 2002 in
accordance with the terms of the agreement. The May 2004 payment
represents the completion of the Companys obligations in
relation to this agreement.
Additional patents and patent rights for microprocessor
technology were acquired from another third party in February
2001. In exchange for the acquired patents and patent rights,
Transmeta agreed to pay a combination of $7.0 million cash
and shares of the Companys common stock valued at
$3.0 million over a three year period. The Company recorded
total consideration of $9.7 million consisting of the net
present value of cash payments of $6.7 million and
$3.0 million of Transmeta common stock. The Company paid
$1.5 million, $1.5 million and $4.0 million in
cash in February 2003, 2002 and 2001, respectively. The Company
issued 796,178 shares, 340,483 shares and
31,719 shares of the Companys unregistered common
stock in February 2003, 2002 and 2001, respectively. Each
issuance had a market value of $1.0 million calculated in
accordance with the terms of the agreement. As of
December 31, 2004, the Company has no further commitments
for these patents and patent rights.
Patents and patent rights are amortized on a straight-line basis
over their expected life of seven years. The Company believes
that a seven-year amortization period continues to be
appropriate and consistent with the Companys increased
focus on the licensing of intellectual property. Amortization
expense of $6.8 million was recorded in each of fiscal
2004, 2003 and 2002 related to patents and patent rights. Future
amortization expense related to patents and patent rights is as
follows:
|
|
|
|
|
|
|
|
|
(In thousands) | |
Years ending December 31,
|
|
|
|
|
|
2005
|
|
$ |
6,846 |
|
|
2006
|
|
|
6,846 |
|
|
2007
|
|
|
6,846 |
|
|
2008
|
|
|
2,388 |
|
|
|
|
|
|
|
Total future amortization
|
|
$ |
22,926 |
|
|
|
|
|
In the second quarter of fiscal 2002, Transmeta recorded a
$10.6 million restructuring charge as a result of the
Companys decision to cease development and productization
of the TM6000 microprocessor. The restructuring charge
consisted primarily of lease costs, equipment write-offs and
other costs as the Company identified a number of leased
facilities as well as leased and owned equipment that were no
longer required.
On July 18, 2002 and in connection with Transmetas
decision to cease the development and productization of the
TM6000 microprocessor, the Company terminated approximately
195 employees and contractors. As a result, the Company
recorded severance and termination charges of $4.1 million
in the third quarter of fiscal 2002, which excludes a credit of
$1.7 million to deferred compensation expense related to
stock option cancellations for terminated employees.
Additionally, the Company paid approximately $531,000 for
previously accrued compensation in the third quarter of fiscal
2002 in connection with the employee terminations. Of the
approximately 195 employees and contractors that were terminated
on July 18, 2002, approximately 44 were sales, marketing,
and administrative employees and approximately 151 were research
and development personnel. The Companys workforce
reduction was completed in the third quarter of fiscal 2002.
Additionally, the Company vacated all excess facilities as of
September 30, 2002.
During the fourth quarter of fiscal 2003, Transmeta reassessed
the adequacy of the remaining accrual and adjusted the accrued
restructuring costs as a result of an update in certain
underlying assumptions regarding the Companys internal use
of previously vacated space, as well as the anticipated length
of time before vacated facilities are sublet to others.
60
TRANSMETA CORPORATION
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
During the third quarter of fiscal 2004, Transmeta reassessed
the adequacy of the remaining accrual and adjusted the accrued
restructuring costs as a result of an update in certain
underlying assumptions. In view of market conditions, the
Company had no assumptions of subleasing previously vacated
space that remained unused as of September 30, 2004. As a
result of this update in assumptions, the Company adjusted the
accrued restructuring costs and recorded a charge of
$0.9 million in restructuring charges.
Accrued restructuring charges consist of the following at
December 31, 2004 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Charges | |
|
|
|
|
Charges Recorded | |
|
Recorded | |
|
|
|
|
in connection with the June 2002 | |
|
in the Quarter | |
|
|
|
|
Restructuring | |
|
Ended | |
|
|
|
|
| |
|
September 30, | |
|
|
|
|
|
|
Property and | |
|
|
|
2002 | |
|
|
|
|
Building | |
|
Equipment | |
|
|
|
| |
|
|
|
|
Leasehold | |
|
and Software | |
|
|
|
Workforce | |
|
Total | |
|
|
Costs | |
|
Costs | |
|
Other | |
|
Reduction | |
|
Balance | |
|
|
| |
|
| |
|
| |
|
| |
|
| |
Restructuring charges
|
|
$ |
8,854 |
|
|
$ |
1,629 |
|
|
$ |
141 |
|
|
$ |
4,102 |
|
|
$ |
14,726 |
|
Cash drawdowns
|
|
|
(667 |
) |
|
|
(187 |
) |
|
|
(141 |
) |
|
|
(4,000 |
) |
|
|
(4,995 |
) |
Non-cash drawdowns
|
|
|
(284 |
) |
|
|
(1,442 |
) |
|
|
|
|
|
|
|
|
|
|
(1,726 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2002
|
|
$ |
7,903 |
|
|
$ |
|
|
|
$ |
|
|
|
$ |
102 |
|
|
$ |
8,005 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring recovery
|
|
|
(244 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(244 |
) |
Cash drawdowns
|
|
|
(2,473 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2,473 |
) |
Non-cash drawdowns
|
|
|
885 |
|
|
|
|
|
|
|
|
|
|
|
(102 |
) |
|
|
783 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2003
|
|
$ |
6,071 |
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
6,071 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring charges
|
|
|
904 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
904 |
|
Cash drawdowns
|
|
|
(1,730 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1,730 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2004
|
|
$ |
5,245 |
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
5,245 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8. |
Impairment of Long-Lived and Other Assets |
During the fourth quarter of 2004, due to the emergence of
indicators of impairment, Transmeta performed an assessment of
its long-lived and other assets. The assessment was performed in
connection with the Companys internal policies and
pursuant to SFAS 144. The conclusion of the assessment was
that the carrying value of certain assets was in excess of their
expected future undiscounted cash flows. As a result, the
Company recorded a charge in operating expenses of
$2.5 million and a charge in cost of revenue of
$1.9 million to write-off such assets based on the amount
by which the carrying amount of these assets exceeded their fair
value, which was deemed to be zero. The $2.5 million charge
in operating expenses related to long-lived and other assets
associated with the product business and was comprised of
$1.7 million for property and equipment and
$0.8 million for software maintenance prepayments. The
$1.9 million charge in cost of revenue related to prepaid
tools used in the manufacture of the Companys products.
|
|
9. |
Commitments and Contingencies |
Transmeta leases its facilities and certain equipment under
noncancelable operating leases expiring through 2008. Gross
operating lease and rental expenses were $3.0 million in
2004, $2.2 million in 2003 and $3.7 million in 2002.
The facility leases provide for a 4% annual base rent increase.
During fiscal 2002, Transmeta subleased a portion of its
facilities. Sublease income was $122,000 in 2002. Of the total
operating lease commitments of $15.5 million included in
the table below, the Company has accrued $4.1 million of
the liabilities as a component of accrued restructuring costs
(See Note 7). During fiscals 2003 and 2004, Transmeta
entered into agreements that expire in 2007 and 2008 to sublease
portions of its facilities that were
61
TRANSMETA CORPORATION
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
vacated as part of the 2002 restructuring plan. Accordingly,
sublease income of $188,000 in fiscal 2004 and $128,000 in
fiscal 2003 derived from this agreement was charged to the
accrued restructuring charge balance.
The Company finances certain equipment and software under
noncancelable lease agreements that are accounted for as capital
leases.
At December 31, 2004, future minimum payments for capital
and operating lease obligations are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital | |
|
Operating | |
|
|
Leases | |
|
Leases | |
|
|
| |
|
| |
|
|
(In thousands) | |
Years ending December 31,
|
|
|
|
|
|
|
|
|
|
2005
|
|
$ |
371 |
|
|
$ |
4,602 |
|
|
2006
|
|
|
|
|
|
|
4,644 |
|
|
2007
|
|
|
|
|
|
|
4,696 |
|
|
2008
|
|
|
|
|
|
|
2,386 |
|
|
Income from subleases
|
|
|
|
|
|
|
(868 |
) |
|
|
|
|
|
|
|
|
|
Total minimum lease payments
|
|
|
371 |
|
|
$ |
15,460 |
|
|
|
|
|
|
|
|
Less amount representing interest
|
|
|
(15 |
) |
|
|
|
|
|
|
|
|
|
|
|
Present value of capital lease obligations
|
|
|
356 |
|
|
|
|
|
Less current portion
|
|
|
356 |
|
|
|
|
|
|
|
|
|
|
|
|
Non-current portion
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
|
|
Transmetas foundry relationship with Fujitsu Limited
allows the Company to cancel all outstanding purchase orders,
but requires Transmeta to pay the foundry for expenses it has
incurred in connection with the purchase orders through the date
of cancellation. As of December 31, 2004, Fujitsu Limited
had incurred approximately $2.2 million of such
manufacturing expenses on the Companys outstanding
purchase orders.
At December 31, 2004, we had the following contractual
obligations:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments Due by Period |
|
|
|
|
|
|
|
Less than | |
|
1-3 | |
|
After |
Contractual Obligations |
|
Total | |
|
1 Year | |
|
Years | |
|
4 Years |
|
|
| |
|
| |
|
| |
|
|
|
|
(In thousands) |
Capital Lease Obligations
|
|
$ |
371 |
|
|
$ |
371 |
|
|
$ |
|
|
|
$ |
|
|
Operating Leases
|
|
$ |
16,328 |
|
|
$ |
4,603 |
|
|
$ |
11,725 |
|
|
$ |
|
|
Unconditional Purchase Obligations(1)
|
|
$ |
6,173 |
|
|
$ |
4,876 |
|
|
$ |
1,297 |
|
|
$ |
|
|
Other Obligations(2)
|
|
$ |
5,000 |
|
|
$ |
|
|
|
|
5,000 |
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$ |
27,872 |
|
|
$ |
9,850 |
|
|
$ |
18,022 |
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
Purchase obligations include agreements to purchase goods or
services that are enforceable and legally binding on Transmeta
and that specify all significant terms, including: fixed or
minimum quantities to be purchased; fixed, minimum or variable
price provisions; and the approximate timing of the transaction. |
|
(2) |
Other obligations include payments to our development partner. |
The Company from time to time enters into certain types of
agreements that might contingently require the Company to
indemnify other parties against third-party claims. Such
contracts primarily relate to: (i) certain real estate
leases, under which the Company may be required to indemnify
property owners for
62
TRANSMETA CORPORATION
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
certain types of claims arising from the Companys use or
subleasing of the applicable premises; (ii) certain license
agreements, under which the Company may provide customary
indemnifications to licensees of the Companys technology;
and (iii) certain agreements with the Companys
directors, officers and employees, under which the Company may
be required to indemnify such persons for liabilities arising
out of their fiduciary or employment relationships with the
Company.
The terms of such indemnity obligations vary. Generally, a
maximum obligation is not expressly stated. Because the
obligated amounts of these types of agreements often are not
expressly stated, the overall maximum amount of these
obligations cannot be reasonably estimated. Historically, the
Company has not been obligated to make any significant payments
for any of these obligations, and no liabilities have been
recorded for these obligations on the Companys balance
sheet as of December 31, 2004.
Transmeta issued promissory notes to financing companies in the
principal amounts of $1.4 million in 1999, which mature
through January 2003. As of December 31, 2004, these notes
have been fully paid. No additional notes were issued after
1999. In connection with the notes, Transmeta issued to the note
holders warrants to purchase 735,032 shares of common
stock. Warrants to purchase 685,032 shares of common
stock were issued with an exercise price of $1.25 and expire
between March 2004 and April 2008. Warrants to
purchase 50,000 shares of common stock were issued
with an exercise price of $3.00 and expire in May 2005. These
warrants were assigned an aggregate value of $78,000 on the
basis of Black-Scholes valuation models using the contractual
lives ranging from six to ten years and a volatility of 0.80.
The value of the warrants was recorded as a discount against the
respective borrowings. In October 2003, one of the note holders,
who was issued a warrant to purchase 320,000 shares of
common stock, exercised the warrant and paid the $1.25 per
share exercise price by a net exercise of the warrant through
the surrender of shares issuable under the warrant. The note
holder was issued 222,960 shares of common stock from this
net exercise. See Note 11 for warrants outstanding to
purchase common stock at December 31, 2004.
At December 31, 2004, the total common stock amount at a
par value of $0.00001 per share is minimal. The Company
therefore reports the common stock and paid in capital amounts
in total.
In December 2003, the Company completed a public offering of
25,000,000 shares of common stock at a price of
$2.90 per share. Total net proceeds, after
$4.4 million of underwriter discounts and commissions and
$0.7 million of expenses, were $67.5 million. In
relation to this offering, in January 2004, the Companys
underwriters exercised their over-allotment option and purchased
3,750,000 shares of common stock, resulting in net proceeds
to the company, after expenses, of $10.2 million.
In November 2004, the Company completed a public offering of
11,083,333 shares of common stock at a price of
$1.50 per share. Total net proceeds, after
$1.2 million of expenses, were $15.4 million.
These shares were offered under the shelf S-3 registration
statement that was filed by Transmeta with the Securities and
Exchange Commission (the SEC) and declared effective
on July 29, 2003 by the SEC.
63
TRANSMETA CORPORATION
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
|
Common Stock Reserved for Issuance |
Shares reserved for future issuance are as follows:
|
|
|
|
|
|
|
|
|
|
|
December 31, | |
|
|
| |
|
|
2004 | |
|
2003 | |
|
|
| |
|
| |
Warrants outstanding
|
|
|
498,228 |
|
|
|
566,228 |
|
Options outstanding
|
|
|
39,803,712 |
|
|
|
33,139,998 |
|
Employee Stock Purchase Plan
|
|
|
2,026,270 |
|
|
|
4,067,421 |
|
Future option grants
|
|
|
4,177,119 |
|
|
|
4,229,540 |
|
|
|
|
|
|
|
|
|
|
|
46,505,329 |
|
|
|
42,003,187 |
|
|
|
|
|
|
|
|
Transmeta has periodically granted warrants in connection with
certain lease and bank agreements and consulting services. The
Company had the following warrants outstanding to purchase
common stock at December 31, 2004:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercise | |
|
|
|
|
Number of | |
|
Price per | |
|
|
Issuance Date |
|
Shares | |
|
Share | |
|
Expiration Date | |
|
|
| |
|
| |
|
| |
October 1995
|
|
|
60,196 |
|
|
$ |
0.41 |
|
|
|
October 2005 |
|
January 1998
|
|
|
125,032 |
|
|
$ |
1.25 |
|
|
|
December 2007 |
|
April 1998
|
|
|
240,000 |
|
|
$ |
1.25 |
|
|
|
April 2008 |
|
May 1998
|
|
|
50,000 |
|
|
$ |
3.00 |
|
|
|
May 2005 |
|
February 2000
|
|
|
8,000 |
|
|
$ |
5.00 |
|
|
|
February 2005 |
|
March 2001
|
|
|
15,000 |
|
|
$ |
5.00 |
|
|
|
March 2005 |
|
|
|
|
|
|
|
|
|
|
|
|
Total number of shares
|
|
|
498,228 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At the time of issuance, all warrants have been valued using the
Black-Scholes valuation model based on the assumptions used for
stock-based awards to employees (see Note 12) except that a
volatility of 0.80 was used through fiscal 2000. Assigned values
of $30,000 and $17,000 associated with these warrant issuances
were recorded as common stock in 2000 and 1999, respectively,
and were amortized as interest expense over the term of the
agreement or the period the services were rendered. Costs
associated with warrants issued during 2001 were immaterial.
In connection with the resignation of two officers in the fourth
quarter of fiscal 2001, the Company purchased
796,875 mature vested shares with a market value of
approximately $2.4 million held by the two officers in
exchange for cancellations of a portion of shareholder notes
held by the officers (see Note 12). Mature vested shares
are shares that have been both vested and outstanding for over
six months. As a result of this transaction, the Company
recorded $2.4 million as a contra-equity balance
representing the market value of the treasury stock at the date
the shares were acquired and the notes were cancelled.
The Company is authorized, subject to limitations imposed by
Delaware law, to issue up to a total of 5,000,000 shares of
preferred stock in one or more series, without stockholder
approval. The Board of Directors is authorized to establish from
time to time the number of shares to be included in each series,
and
64
TRANSMETA CORPORATION
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
to fix the rights, preferences and privileges of the shares of
each wholly unissued series and any of its qualifications,
limitations or restrictions. The Board of Directors can also
increase or decrease the number of shares of a series, but not
below the number of shares of that series then outstanding,
without any further vote or action by the stockholders.
The Board of Directors may authorize the issuance of preferred
stock with voting or conversion rights that could harm the
voting power or other rights of the holders of the common stock.
The issuance of preferred stock, while providing flexibility in
connection with possible acquisitions and other corporate
purposes, could, among other things, have the effect of
delaying, deferring or preventing a change in control of
Transmeta and might harm the market price of its common stock
and the voting and other rights of the holders of common stock.
As of December 31, 2004 and 2003, there were no shares of
preferred stock outstanding.
|
|
|
Stockholders Rights Agreement |
On January 10, 2002, the Company entered into a Rights
Agreement, pursuant to which the Companys Board of
Directors declared a dividend of one stock purchase right (a
Right) for each outstanding share of the
Companys common stock. The dividend was issued to
stockholders of record on January 18, 2002. In addition,
one Right shall be issued with each share of the Companys
common stock that becomes outstanding (i) between the
record date and the earliest of the Distribution Date, the
Redemption Date and the Final Expiration Date (as such
terms are defined in the Rights Agreement) or
(ii) following the Distribution Date and prior to the
Redemption Date or Final Expiration Date, pursuant to the
exercise of stock options or under any employee plan or
arrangement or upon the exercise, conversion or exchange of
other securities of the Company, which options or securities
were outstanding prior to the Distribution Date. The Rights will
become exercisable only upon the occurrence of certain events
specified in the Rights Agreement, including the acquisition of
15% of the Companys outstanding common stock by a person
or group. Each Right entitles the registered holder, other than
an acquiring person, under specified circumstances,
to purchase from the Company one one-hundredth of a share of
Series A Junior Participating Preferred Stock, par value
$0.00001 per share, of the Company, at a price of
$21.00 per one one-hundredth of a share of that preferred
stock, subject to adjustment. In addition, each Right entitles
the registered holder, other than an acquiring
person, under specified circumstances, to purchase from
the Company that number of shares of the Companys Common
Stock having a market value of two times the exercise price of
the Right.
|
|
12. |
Stock-Based Compensation |
|
|
|
2000 Equity Incentive Plan |
The 2000 Equity Incentive Plan (the Plan) was
adopted in September 2000 and became effective November 6,
2000. The Plan serves as the successor to the 1997 Equity
Incentive Plan, and authorizes the award of options, restricted
stock and stock bonuses and provides for the grant of both
incentive stock options (ISOs) that qualify
under Section 422 of the Internal Revenue Code to employees
and nonqualified stock options to employees, directors and
consultants. The exercise price of the incentive stock options
must be at least equal to the fair market value of the common
stock on the date of grant. The exercise price of incentive
stock options granted to 10% stockholders must be at least equal
to 110% of the fair market value of the common stock on the date
of grant. The maximum term of the options granted is ten years.
During any calendar year, no person will be eligible to receive
more than 4,000,000 shares, or 6,000,000 shares in the
case of a new employee.
Transmeta initially reserved 7,000,000 shares of common
stock under the Plan. The aggregate number of shares reserved
for issuance under the Plan is increased automatically on
January 1 of each year starting on January 1, 2001 by
an amount equal to 5% of the total outstanding shares of the
Company on the immediately preceding December 31. As a
result of this provision, 8,376,425, 6,804,307, 6,611,728 and
6,520,946 shares were added to the Plan in 2004, 2003, 2002
and 2001 respectively. In addition, the Plan allows for canceled
65
TRANSMETA CORPORATION
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
shares from the 1995 and 1997 Equity Incentive Plans to be
transferred into the 2000 Plan. As a result of this provision,
461,781, 728,479, 3,116,323 and 1,508,882 shares were also
added to the Plan in 2004, 2003, 2002 and 2001, respectively.
|
|
|
Non-Plan Stock Option Grants |
Transmeta has from time to time granted options outside of its
plans (non-plan stock options). Non-plan stock
options to purchase shares of common stock authorized and
granted were 7,046,000 in 2000 and 2,500,000 in 1999. No
non-plan stock options were granted in 2004, 2003, 2002 and 2001.
|
|
|
Prior Equity Incentive Plans |
The 1995 Equity Incentive Plan and the 1997 Equity Incentive
Plan (the Prior Plans) provided for the grant of
ISOs to employees and the grant of nonstatutory stock options to
employees, directors and consultants. Options granted under the
Prior Plans were designated as ISO, or
nonstatutory stock options at the discretion of
Transmeta, with exercise prices not less than the fair market
value at the date of grant. Options granted under the Prior
Plans generally vest 25% on the first anniversary of the vesting
start date and then monthly over the next three years and expire
ten years from the grant date.
The following is a summary of the Companys stock option
activity under the Plan, the Prior Plans and outside the plans,
and related information:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options Outstanding | |
|
|
|
|
| |
|
|
|
|
|
|
Weighted | |
|
Weighted | |
|
|
Shares | |
|
|
|
Average | |
|
Average | |
|
|
Available for | |
|
Number of | |
|
Exercise | |
|
Grant Date | |
|
|
Grant | |
|
Shares | |
|
Price | |
|
Fair Value | |
|
|
| |
|
| |
|
| |
|
| |
Balance at December 31, 2001
|
|
|
6,696,841 |
|
|
|
21,839,209 |
|
|
$ |
4.53 |
|
|
|
|
|
|
Additional shares reserved
|
|
|
9,728,051 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options granted
|
|
|
(22,278,100 |
) |
|
|
22,278,100 |
|
|
$ |
1.94 |
|
|
$ |
1.59 |
|
|
Options exercised
|
|
|
|
|
|
|
(1,187,191 |
) |
|
$ |
0.68 |
|
|
|
|
|
|
Options canceled
|
|
|
6,953,566 |
|
|
|
(11,058,616 |
) |
|
$ |
4.35 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2002
|
|
|
1,100,358 |
|
|
|
31,871,502 |
|
|
$ |
2.93 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional shares reserved
|
|
|
7,532,786 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options granted
|
|
|
(6,889,750 |
) |
|
|
6,889,750 |
|
|
$ |
1.65 |
|
|
$ |
1.04 |
|
|
Options exercised
|
|
|
|
|
|
|
(2,336,796 |
) |
|
$ |
1.53 |
|
|
|
|
|
|
Options canceled
|
|
|
2,486,146 |
|
|
|
(3,284,458 |
) |
|
$ |
3.27 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2003
|
|
|
4,229,540 |
|
|
|
33,139,998 |
|
|
$ |
2.73 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional shares reserved
|
|
|
8,838,206 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options granted
|
|
|
(11,775,000 |
) |
|
|
11,775,000 |
|
|
$ |
1.67 |
|
|
$ |
0.96 |
|
|
Options exercised
|
|
|
|
|
|
|
(1,685,132 |
) |
|
$ |
1.25 |
|
|
|
|
|
|
Options canceled
|
|
|
2,884,373 |
|
|
|
(3,426,154 |
) |
|
$ |
3.13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2004
|
|
|
4,177,119 |
|
|
|
39,803,712 |
|
|
$ |
2.44 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
66
TRANSMETA CORPORATION
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted | |
|
|
|
|
Average | |
|
|
Number of | |
|
Exercise | |
Shares Exercisable At: |
|
Shares | |
|
Price | |
|
|
| |
|
| |
December 31, 2002
|
|
|
8,493,708 |
|
|
$ |
3.92 |
|
December 31, 2003
|
|
|
14,876,266 |
|
|
$ |
3.36 |
|
December 31, 2004
|
|
|
19,174,403 |
|
|
$ |
3.07 |
|
The exercise prices for options outstanding and exercisable as
of December 31, 2004 and their weighted average remaining
contractual lives were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding | |
|
Exercisable | |
|
|
| |
|
| |
|
|
|
|
Weighted | |
|
|
|
|
|
|
|
|
Average | |
|
Weighted | |
|
|
|
Weighted | |
|
|
|
|
Remaining | |
|
Average | |
|
|
|
Average | |
|
|
Shares | |
|
Contractual | |
|
Exercise | |
|
Shares | |
|
Exercise | |
Range of Exercise Prices |
|
Outstanding | |
|
Life Years | |
|
Price | |
|
Exercisable | |
|
Price | |
|
|
| |
|
| |
|
| |
|
| |
|
| |
As of December 31, 2004:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$0.19-$1.15
|
|
|
6,881,552 |
|
|
|
7.5 |
|
|
$ |
0.97 |
|
|
|
4,183,055 |
|
|
$ |
0.93 |
|
|
$1.17-$1.27
|
|
|
7,366,000 |
|
|
|
9.1 |
|
|
$ |
1.22 |
|
|
|
1,199,458 |
|
|
$ |
1.27 |
|
|
$1.30-$2.15
|
|
|
9,427,455 |
|
|
|
8.9 |
|
|
$ |
1.79 |
|
|
|
2,489,658 |
|
|
$ |
1.63 |
|
|
$2.16-$2.60
|
|
|
8,089,282 |
|
|
|
7.2 |
|
|
$ |
2.46 |
|
|
|
5,026,293 |
|
|
$ |
2.46 |
|
|
$2.66-$8.25
|
|
|
6,875,752 |
|
|
|
6.3 |
|
|
$ |
4.72 |
|
|
|
5,223,357 |
|
|
$ |
4.95 |
|
|
$9.50-$27.88
|
|
|
1,163,671 |
|
|
|
5.9 |
|
|
$ |
10.58 |
|
|
|
1,052,582 |
|
|
$ |
10.60 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$0.19-$27.88
|
|
|
39,803,712 |
|
|
|
7.8 |
|
|
$ |
2.44 |
|
|
|
19,174,403 |
|
|
$ |
3.07 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2000 Employee Stock Purchase Plan |
Transmeta effected the 2000 Employee Stock Purchase Plan (the
Purchase Plan) in November 2000. The Purchase Plan
allows employees to designate up to 15% of their total
compensation to purchase shares of the Companys common
stock at 85% of fair market value. Upon effectiveness of the
Purchase Plan, the Company reserved 2,000,000 shares of
common stock under the Purchase Plan. In addition, the aggregate
number of shares reserved for issuance under the Purchase Plan
will be increased automatically on January 1 of each year
starting on January 1, 2001 by an amount equal to 1% of the
total outstanding shares of the Company on the immediately
preceding December 31. As a result of this provision,
1,675,285, 1,360,861, 1,322,346 and 1,304,189 shares were
added to the Purchase Plan in 2004, 2003, 2002 and 2001,
respectively. In May 2002, the Companys stockholders
authorized an additional 4,000,000 shares to be available
under the Purchase Plan. As of December 31, 2004,
9,636,411 shares had been issued under the Purchase Plan.
|
|
|
Deferred Stock Compensation |
Transmeta recorded deferred stock compensation of
$46.0 million during 2000, representing the aggregate
difference between the exercise prices of certain options and
the deemed fair values of common stock subject to the options as
of the respective measurement dates. This amount is being
amortized by charges to operations, using the accelerated graded
method, over the four year vesting periods of the individual
stock options, ending in fiscal 2004. During 2004, 2003, 2002
and 2001, the Company recorded $0.7 million,
$1.8 million, $3.6 million and $16.8 million,
respectively, of net amortization expense related to deferred
stock compensation. The net amortization expense recorded during
fiscal 2002 included a credit of $1.7 million for stock
option cancellations resulting from the Companys workforce
reduction in the third quarter. The Company completed its
amortization of deferred stock compensation in fiscal 2004.
67
TRANSMETA CORPORATION
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
|
Accounting for Stock-Based Compensation |
The Company has elected to follow APB Opinion 25 and
related interpretations in accounting for its employee and
director stock-based awards because, as discussed below, the
alternative fair value accounting provided for under
SFAS 123 requires use of option valuation models that were
not developed for use in valuing employee stock-based awards.
Under APB Opinion 25, the Company recognizes no
compensation expense with respect to awards if the exercise
price equals or exceeds the fair value of the underlying
security on the date of grant and other terms are fixed.
Notes Receivable from Stockholders. Transmetas
equity incentive plans permit, subject to approval by the Board
of Directors, holders of options granted prior to March 1999 and
certain holders of non-plan grants to exercise stock options
before they are vested. Shares of common stock issued in
connection with these exercises are subject to repurchase at the
exercise price. At December 31, 2004, the outstanding notes
issued by employees to exercise stock options bear interest at
rates ranging from 5.92% to 6.60% and have original terms of
five years. Prior to the fourth quarter of fiscal 2001, all
notes were full recourse and were recorded as a reduction of
stockholders equity when issued.
Officer notes. In the fourth quarter of fiscal 2001, the
employment of two officers terminated. In connection with the
termination of their employment, the Company repurchased a total
of 796,875 vested shares and 1,753,125 unvested shares
held by these officers. These shares were originally issued in
return for an aggregate of $8.0 million in recourse notes.
As a result of the repurchase of these shares and the
cancellation of the outstanding recourse notes and accrued
interest, the Company in 2001 recorded additional stock
compensation expense of $1.2 million primarily to write-off
accrued interest on the notes and an offsetting entry of
$1.9 million to reverse stock compensation expense
previously recognized on the unvested shares. The Company has
not since made any other stock repurchases from any of its
officers or directors.
Recourse notes held by other officers and employees. At
the time the above two officer notes were cancelled, other
recourse notes for a total of $8.2 million, including
$0.7 million of accrued interest, were outstanding. Because
the Company did not enforce the recourse provisions of the notes
for the officers that resigned, which would have recouped all
principal and interest, in the fourth quarter of 2001, the
Company began to account for these remaining notes as if they
had terms equivalent to non-recourse notes, even though the
terms of these notes were not in fact changed from recourse to
non-recourse.
Transmeta will continue to record stock compensation expense on
these stock awards until the notes are paid based on the current
market value of its stock at the end of each accounting period.
This variable stock compensation will be based on the excess, if
any, of the current market price of its stock as of period-end
over the purchase price of the stock award, adjusted for vesting
and prior stock compensation expense recognized on the stock
award. At December 31, 2004, the Company had
48,000 shares that are subject to variable stock
compensation at option exercise prices ranging from $0.58 to
$0.65 per share. During fiscal 2004, the Company recorded
$1.0 million of variable compensation expenses, which
included expenses of $0.5 million related to adjustments
made for certain notes receivable from stockholders that had
been fully paid and expenses of $0.5 million primarily
related to the higher market price of the Companys common
stock at the time of repayment of notes from stockholders
compared to the end of fiscal 2003. During fiscal 2003, the
Company recorded $2.7 million of variable compensation
expenses, primarily due to a higher market price of the
Companys common stock at the end of fiscal 2003 compared
to fiscal 2002. During fiscal 2002, the Company recorded a
credit of $1.8 million related to stock compensation
expense due to a lower market price of the Companys common
stock at the end of fiscal 2002 compared to fiscal 2001. Because
variable stock compensation expense is calculated based on the
current market value of the Companys common stock at the
end of each accounting period, future stock compensation expense
for these variable stock awards could increase significantly in
periods when the Companys stock price rises, and could
reverse and become a benefit in periods when the Companys
stock price falls. The market value of the Companys common
stock was $1.63, $3.24 and $1.21 per share at the end of
fiscal 2004, 2003 and 2002, respectively. The Company also has
68
TRANSMETA CORPORATION
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
an additional 1,100,000 shares that are subject to variable
accounting if its stock price increases above approximately
$11.50 per share. However, the Company has a call option on
these shares that it intends to exercise before the stock price
exceeds $11.50 per share and does not believe it will incur
variable stock compensation on these shares.
Fair value accounting for stock-based awards. The fair
value for the Companys stock-based awards is estimated at
the date of grant using a Black-Scholes option-pricing model.
The Black-Scholes option-pricing model was developed for use in
estimating the fair value of traded options that have no vesting
restrictions and are fully transferable. In addition, the
Black-Scholes option-pricing model requires the input of highly
subjective assumptions, including expected stock price
volatility. The fair value of options granted in 2000 was
determined based on estimated stock price volatility. The
weighted average assumptions used to determine fair value were
as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options | |
|
ESPP | |
|
|
| |
|
| |
|
|
Years Ended | |
|
Years Ended | |
|
|
December 31, | |
|
December 31, | |
|
|
| |
|
| |
|
|
2004 | |
|
2003 | |
|
2002 | |
|
2004 | |
|
2003 | |
|
2002 | |
|
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
Expected volatility
|
|
|
0.90 |
|
|
|
0.86 |
|
|
|
1.3 |
|
|
|
0.90 |
|
|
|
1.1 |
|
|
|
1.2 |
|
Expected life in years
|
|
|
3.7 |
|
|
|
4.0 |
|
|
|
4.0 |
|
|
|
.5 |
|
|
|
.5 |
|
|
|
.5 |
|
Risk-free interest rate
|
|
|
2.8 |
% |
|
|
2.3 |
% |
|
|
3.7 |
% |
|
|
2.0 |
% |
|
|
2.0 |
% |
|
|
2.5 |
% |
Expected dividend yield
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
13. |
Employee Benefit Plan |
Transmeta has an Employee Savings and Retirement Plan (the
Benefit Plan) under Section 401(k) of the
Internal Revenue Code for its eligible employees. The Benefit
Plan is available to all of Transmetas employees who meet
minimum age requirements, and provides employees with tax
deferred salary deductions and alternative investment options.
Employees may contribute up to 15% of their eligible earnings,
subject to certain limitations. There have been no matching
contributions by the Company under the Benefit Plan.
|
|
14. |
Related Party Transaction |
Transmeta entered into a trademark and technology licensing
agreement during fiscal 2003 with Chinese 2 Linux
(Holdings) Limited. In relation to this agreement, the Company
became a 16.6% beneficial owner of the party with which the
agreement was entered. The agreement resulted in recognition of
license and service revenue of $918,000 and $140,000 during
fiscal 2004 and 2003, respectively.
Transmeta recorded a provision for foreign income taxes of
$240,000, $32,000 and $21,000 for fiscal 2004, 2003 and 2002,
respectively, in interest income and other, net.
69
TRANSMETA CORPORATION
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The provision for income taxes differs from the amount computed
by applying the statutory federal income tax rate to income
(loss) before income taxes. The sources and tax effects of the
differences are as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31, | |
|
|
| |
|
|
2004 | |
|
2003 | |
|
2002 | |
|
|
| |
|
| |
|
| |
|
|
(In thousands) | |
Income tax expense (benefit) at U.S. statutory rate
|
|
$ |
(36,162 |
) |
|
$ |
(29,785 |
) |
|
$ |
(37,381 |
) |
Foreign income taxes
|
|
|
240 |
|
|
|
32 |
|
|
|
21 |
|
Valuation Allowance
|
|
|
36,162 |
|
|
|
29,785 |
|
|
|
37,381 |
|
|
|
|
|
|
|
|
|
|
|
Provision for income taxes
|
|
$ |
240 |
|
|
$ |
32 |
|
|
$ |
21 |
|
|
|
|
|
|
|
|
|
|
|
Deferred income taxes reflect the net tax effects of operating
losses and tax credit carryforwards and temporary differences
between the carrying amount of assets and liabilities for
financial reporting purposes and the amounts used for income tax
purposes. Significant components of the Companys deferred
tax assets are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31, | |
|
|
| |
|
|
2004 | |
|
2003 | |
|
2002 | |
|
|
| |
|
| |
|
| |
|
|
(In thousands) | |
Federal operating loss carryforwards
|
|
$ |
139,000 |
|
|
$ |
131,500 |
|
|
$ |
99,000 |
|
State operating loss carryforwards
|
|
|
9,000 |
|
|
|
6,500 |
|
|
|
5,000 |
|
Federal tax credit carryforwards
|
|
|
11,000 |
|
|
|
9,000 |
|
|
|
8,000 |
|
State tax credit carryforwards
|
|
|
8,000 |
|
|
|
7,000 |
|
|
|
6,000 |
|
Non-deductible reserves and capitalized expenses
|
|
|
59,000 |
|
|
|
28,000 |
|
|
|
35,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
226,000 |
|
|
|
182,000 |
|
|
|
153,000 |
|
Less: Valuation allowance
|
|
|
(226,000 |
) |
|
|
(182,000 |
) |
|
|
(153,000 |
) |
|
|
|
|
|
|
|
|
|
|
Net deferred taxes
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
|
Based upon the weight of available evidence, which includes the
Companys historical operating performance, the Company has
always provided a full valuation allowance against its net
deferred tax assets as it is more likely than not that the
deferred tax assets will not be realized. The valuation
allowance increased by $44.0 million in 2004,
$29.0 million in 2003 and $40.8 million in 2002.
The federal operating loss and tax credit carryforwards listed
above will expire between 2010 and 2024, if not utilized. The
state operating loss and tax credit carryforwards will expire
beginning in 2005, if not utilized. Utilization of the
Companys net operating loss and tax credits may be subject
to substantial annual limitations due to the ownership change
limitations provided by the Internal Revenue Code and similar
state provisions. Such annual limitation could result in the
expiration of the net operating loss and tax credits before
being utilized.
The Company incurred pre-tax income from foreign operations of
$0.04 million in fiscal 2004 and $0.5 million in
fiscal 2003. During fiscal 2002, pre-tax losses from foreign
operations totaled $20.7 million.
The Company has determined that, in accordance with FASBs
SFAS No. 131, Disclosure About Segments of an
Enterprise and Related Information, it operates in one
segment as it operates and is evaluated by management on a
single segment basis; the development, licensing, marketing and
sale of hardware and software technologies for the computing
market.
70
TRANSMETA CORPORATION
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Sales by geographic area are categorized based on the customers
billing address. The following is a summary of the
Companys net revenue by major geographic area:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended | |
|
|
December 31, | |
|
|
| |
|
|
2004 | |
|
2003 | |
|
2002 | |
|
|
| |
|
| |
|
| |
Japan
|
|
|
51% |
|
|
|
44% |
|
|
|
79% |
|
China/ Hong Kong
|
|
|
32% |
|
|
|
39% |
|
|
|
6% |
|
Taiwan
|
|
|
10% |
|
|
|
13% |
|
|
|
14% |
|
North America
|
|
|
5% |
|
|
|
4% |
|
|
|
1% |
|
Other
|
|
|
2% |
|
|
|
*% |
|
|
|
*% |
|
Total revenue by product is presented as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31, | |
|
|
| |
|
|
2004 | |
|
2003 | |
|
2002 | |
|
|
| |
|
| |
|
| |
|
|
(In thousands) | |
Crusoe microprocessors
|
|
$ |
13,417 |
|
|
$ |
15,874 |
|
|
$ |
24,247 |
|
Efficeon microprocessors
|
|
|
5,359 |
|
|
|
351 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product revenue
|
|
|
18,776 |
|
|
|
16,225 |
|
|
|
24,247 |
|
|
License and service revenue
|
|
|
10,668 |
|
|
|
1,090 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
$ |
29,444 |
|
|
$ |
17,315 |
|
|
$ |
24,247 |
|
|
|
|
|
|
|
|
|
|
|
Total revenue, which includes product and license revenue, for
each computing market, is presented as a percentage of total
revenue in the following table:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended | |
|
|
December 31, | |
|
|
| |
|
|
2004 | |
|
2003 | |
|
2002 | |
|
|
| |
|
| |
|
| |
Product:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Thin client desktop
|
|
|
30% |
|
|
|
17% |
|
|
|
6% |
|
|
Notebook computers
|
|
|
19% |
|
|
|
42% |
|
|
|
82% |
|
|
Embedded/ servers
|
|
|
8% |
|
|
|
6% |
|
|
|
5% |
|
|
Tablet PCs
|
|
|
4% |
|
|
|
27% |
|
|
|
6% |
|
|
UPCs
|
|
|
3% |
|
|
|
2% |
|
|
|
1% |
|
License and service:
|
|
|
36% |
|
|
|
6% |
|
|
|
n/a |
|
Long lived assets by geographical regions are presented as
follows:
|
|
|
|
|
|
|
|
|
|
|
Years Ended | |
|
|
December 31, | |
|
|
| |
|
|
2004 | |
|
2003 | |
|
|
| |
|
| |
|
|
(In thousands) | |
United States
|
|
$ |
25,908 |
|
|
$ |
35,880 |
|
Asia
|
|
|
119 |
|
|
|
759 |
|
|
|
|
|
|
|
|
Total
|
|
$ |
26,027 |
|
|
$ |
36,639 |
|
|
|
|
|
|
|
|
71
TRANSMETA CORPORATION
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The following customers accounted for more than 10% of total
revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended | |
|
|
December 31, | |
|
|
| |
|
|
2004 | |
|
2003 | |
|
2002 | |
|
|
| |
|
| |
|
| |
Customer:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NEC Electronics Corp.
|
|
|
33% |
|
|
|
*% |
|
|
|
*% |
|
|
Hewlett Packard International Pte Inc
|
|
|
27% |
|
|
|
14% |
|
|
|
% |
|
|
Sharp Trading Corporation
|
|
|
12% |
|
|
|
20% |
|
|
|
*% |
|
|
Uniquest Hong Kong**
|
|
|
*% |
|
|
|
21% |
|
|
|
*% |
|
|
Fujitsu America Inc.
|
|
|
*% |
|
|
|
16% |
|
|
|
26% |
|
|
Sony Trading International Corp.
|
|
|
% |
|
|
|
*% |
|
|
|
37% |
|
|
|
|
|
* |
represents less than 10% of total revenue |
|
|
** |
Uniquest Hong Kong made these purchases acting as the
distributor of our product for the Hewlett Packard Tablet PC
program. |
The Company is a party to one consolidated lawsuit. Beginning in
June 2001, the Company, certain of its directors and officers,
and certain of the underwriters for its initial public offering
were named as defendants in three putative shareholder class
actions that were consolidated in and by the United States
District Court for the Southern District of New York in
In re Transmeta Corporation Initial Public Offering
Securities Litigation, Case No. 01 CV 6492.
The complaints allege that the prospectus issued in connection
with the Companys initial public offering on
November 7, 2000 failed to disclose certain alleged actions
by the underwriters for that offering, and alleges claims
against the Company and several of its officers and directors
under Sections 11 and 15 of the Securities Act of 1933, as
amended, and under Sections 10(b) and Section 20(a) of
the Securities Exchange Act of 1934, as amended. Similar actions
have been filed against more than 300 other companies that
issued stock in connection with other initial public offerings
during 1999-2000. Those cases have been coordinated for pretrial
purposes as In re Initial Public Offering Securities
Litigation, Master File No. 21 MC 92 (SAS).
In July 2002, the Company joined in a coordinated motion to
dismiss filed on behalf of multiple issuers and other
defendants. In February 2003, the Court granted in part and
denied in part the coordinated motion to dismiss, and issued an
order regarding the pleading of amended complaints. Plaintiffs
subsequently proposed a settlement offer to all issuer
defendants, which settlement would provide for payments by
issuers insurance carriers if plaintiffs fail to recover a
certain amount from underwriter defendants. Although the Company
and the individual defendants believe that the complaints are
without merit and deny any liability, but because they also wish
to avoid the continuing waste of management time and expense of
litigation, they accepted plaintiffs proposal to settle
all claims that might have been brought in this action. Our
insurance carriers are part of the proposed settlement, and the
Company and the individual Transmeta defendants expect that
their share of the global settlement will be fully funded by
their director and officer liability insurance. Although the
Company and the Transmeta defendants have approved the
settlement in principle, it remains subject to several
procedural conditions, as well as formal approval by the Court.
It is possible that the parties may not reach a final written
settlement agreement or that the Court may decline to approve
the settlement in whole or part. In the event that the parties
do not reach agreement on the final settlement, the Company and
the Transmeta defendants believe that they have meritorious
defenses and intend to defend any remaining action vigorously.
72
TRANSMETA CORPORATION
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
In January 2005, the Company announced plans to modify its
existing business model of designing, developing and selling
x86-compatible microprocessor products, including its Crusoe and
Efficeon families. The Company announced that it is critically
evaluating the economics of its microprocessor product business
during the first quarter of 2005 and intends to modify its
business model in 2005 to increase efforts to license its
intellectual property and advanced technologies. The Company
also announced that, as part of its overall restructuring plan,
it expects to reorganize its operations on March 31, 2005
to align with the business prospects it has firmly identified at
that time. Accordingly, the Company timely notified its employee
base in January 2005 that it may reduce its staffing as early as
March 31, 2005. As part of its effort to retain employees
during this interim period, the Company put in place an
appropriate retention program.
In January 2005, the Company entered into and announced an
agreement granting a license to Sony Corporation to use
Transmetas proprietary LongRun2 technologies for power
management and transistor leakage control. That agreement
includes deliverable-based technology transfer fees, maintenance
and service fees, and subsequent royalties on products
incorporating the licensed technologies.
|
|
19. |
Quarterly Results of Operations (Unaudited) |
The following table presents Transmetas unaudited
quarterly statement of operations data for the four quarters of
fiscal 2004 and fiscal 2003. Each quarter consists of
13 weeks, except for the quarter ended December 31,
2004, which consists of 14 weeks. For ease of presentation,
the quarterly financial statements are shown as ending on
calendar quarters. The Company believes that this information
has been prepared on the same basis as its audited consolidated
financial statements and that all necessary adjustments,
consisting only of normal recurring adjustments, have been
included to present fairly the selected quarterly information.
Transmetas quarterly results of operations for these
periods are not necessarily indicative of future results of
operations.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarters Ended | |
|
|
| |
|
|
Dec. 31, | |
|
Sept. 30, | |
|
Jun. 30, | |
|
Mar. 31, | |
|
Dec. 31, | |
|
Sept. 30, | |
|
Jun. 30, | |
|
Mar. 31, | |
|
|
2004 | |
|
2004 | |
|
2004 | |
|
2004 | |
|
2003 | |
|
2003 | |
|
2003 | |
|
2003 | |
|
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
|
(In thousands, except for per share data) | |
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product
|
|
$ |
4,799 |
|
|
$ |
3,297 |
|
|
$ |
5,673 |
|
|
$ |
5,007 |
|
|
$ |
3,316 |
|
|
$ |
2,365 |
|
|
$ |
4,601 |
|
|
$ |
5,943 |
|
|
License
|
|
|
6,448 |
|
|
|
3,698 |
|
|
|
327 |
|
|
|
195 |
|
|
|
240 |
|
|
|
323 |
|
|
|
453 |
|
|
|
74 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
|
11,247 |
|
|
|
6,995 |
|
|
|
6,000 |
|
|
|
5,202 |
|
|
|
3,556 |
|
|
|
2,688 |
|
|
|
5,054 |
|
|
|
6,017 |
|
Cost of revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenue
|
|
|
10,843 |
|
|
|
11,344 |
|
|
|
9,264 |
|
|
|
5,614 |
|
|
|
3,801 |
|
|
|
3,073 |
|
|
|
4,998 |
|
|
|
4,452 |
|
|
Impairment charge on long-lived assets
|
|
|
1,943 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total cost of revenue
|
|
|
12,786 |
|
|
|
11,344 |
|
|
|
9,264 |
|
|
|
5,614 |
|
|
|
3,801 |
|
|
|
3,073 |
|
|
|
4,998 |
|
|
|
4,452 |
|
Gross profit (loss)
|
|
|
(1,539 |
) |
|
|
(4,349 |
) |
|
|
(3,264 |
) |
|
|
(412 |
) |
|
|
(245 |
) |
|
|
(385 |
) |
|
|
56 |
|
|
|
1,565 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development
|
|
|
12,578 |
|
|
|
13,751 |
|
|
|
13,719 |
|
|
|
12,717 |
|
|
|
11,404 |
|
|
|
12,452 |
|
|
|
12,190 |
|
|
|
12,479 |
|
|
Selling, general and administrative
|
|
|
9,292 |
|
|
|
7,424 |
|
|
|
7,418 |
|
|
|
6,721 |
|
|
|
7,240 |
|
|
|
5,978 |
|
|
|
6,347 |
|
|
|
6,634 |
|
|
Restructuring charges
|
|
|
|
|
|
|
904 |
|
|
|
|
|
|
|
|
|
|
|
(244 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of patents and patent rights
|
|
|
2,233 |
|
|
|
2,233 |
|
|
|
2,347 |
|
|
|
2,404 |
|
|
|
2,628 |
|
|
|
2,628 |
|
|
|
2,634 |
|
|
|
2,640 |
|
73
TRANSMETA CORPORATION
NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarters Ended | |
|
|
| |
|
|
Dec. 31, | |
|
Sept. 30, | |
|
Jun. 30, | |
|
Mar. 31, | |
|
Dec. 31, | |
|
Sept. 30, | |
|
Jun. 30, | |
|
Mar. 31, | |
|
|
2004 | |
|
2004 | |
|
2004 | |
|
2004 | |
|
2003 | |
|
2003 | |
|
2003 | |
|
2003 | |
|
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
|
(In thousands, except for per share data) | |
|
Impairment charge on long-lived and other assets
|
|
|
2,544 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock compensation
|
|
|
29 |
|
|
|
56 |
|
|
|
230 |
|
|
|
1,350 |
|
|
|
696 |
|
|
|
2,302 |
|
|
|
1,095 |
|
|
|
436 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
|
26,676 |
|
|
|
24,368 |
|
|
|
23,714 |
|
|
|
23,192 |
|
|
|
21,724 |
|
|
|
23,360 |
|
|
|
22,266 |
|
|
|
22,189 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating loss
|
|
|
(28,215 |
) |
|
|
(28,717 |
) |
|
|
(26,978 |
) |
|
|
(23,604 |
) |
|
|
(21,969 |
) |
|
|
(23,745 |
) |
|
|
(22,210 |
) |
|
|
(20,624 |
) |
|
Interest income and other, net
|
|
|
150 |
|
|
|
188 |
|
|
|
243 |
|
|
|
246 |
|
|
|
167 |
|
|
|
203 |
|
|
|
312 |
|
|
|
707 |
|
|
Interest expense
|
|
|
(50 |
) |
|
|
(26 |
) |
|
|
(20 |
) |
|
|
(15 |
) |
|
|
(114 |
) |
|
|
(116 |
) |
|
|
(123 |
) |
|
|
(124 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$ |
(28,115 |
) |
|
$ |
(28,555 |
) |
|
$ |
(26,755 |
) |
|
$ |
(23,373 |
) |
|
$ |
(21,916 |
) |
|
$ |
(23,658 |
) |
|
$ |
(22,021 |
) |
|
$ |
(20,041 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share basic and diluted
|
|
$ |
(0.15 |
) |
|
$ |
(0.16 |
) |
|
$ |
(0.15 |
) |
|
$ |
(0.14 |
) |
|
$ |
(0.15 |
) |
|
$ |
(0.17 |
) |
|
$ |
(0.16 |
) |
|
$ |
(0.15 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding basic and diluted
|
|
|
182,104 |
|
|
|
175,487 |
|
|
|
174,006 |
|
|
|
171,869 |
|
|
|
142,747 |
|
|
|
139,844 |
|
|
|
138,678 |
|
|
|
137,551 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
74
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board of Directors and Stockholders
Transmeta Corporation
We have audited the accompanying consolidated balance sheets of
Transmeta Corporation as of December 31, 2004 and 2003, and
the related consolidated statements of operations,
stockholders equity, and cash flows for each of the three
years in the period ended December 31, 2004. These
financial statements are the responsibility of the
Companys management. Our responsibility is to express an
opinion on these financial statements based on our audits.
We conducted our audits in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are
free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in
the financial statements. An audit also includes assessing the
accounting principles used and significant estimates made by
management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, the financial statements referred to above
present fairly, in all material respects, the consolidated
financial position of Transmeta Corporation at December 31,
2004 and 2003, and the consolidated results of its operations
and its cash flows for each of the three years in the period
ended December 31, 2004, in conformity with
U.S. generally accepted accounting principles.
As discussed in Note 1 to the consolidated financial
statements, the Companys recurring losses from operations
raise substantial doubt about its ability to continue as a going
concern. Managements plans as to these matters are also
described in Note 1. The 2004 consolidated financial
statements do not include any adjustments that might result from
the outcome of this uncertainty.
San Jose, California
March 25, 2005
75
|
|
Item 9. |
Changes in and Disagreements with Accountants on
Accounting and Financial Disclosure |
Not applicable.
|
|
Item 9A. |
Controls and Procedures |
(a) Disclosure Controls and Procedures
Our management, with the participation of our chief executive
officer and our chief financial officer, evaluated the
effectiveness of our disclosure controls and procedures as of
December 31, 2004. The term disclosure controls and
procedures, as defined in Rules 13a-15(e) and
15d-15(e) under the Securities Exchange Act, means controls and
other procedures of a company that are designed to ensure that
information required to be disclosed by the company in the
reports that it files or submits under the Securities Exchange
Act is recorded, processed, summarized and reported, within the
time periods specified in the SECs rules and forms.
Disclosure controls and procedures include, without limitation,
controls and procedures designed to ensure that information
required to be disclosed by a company in the reports that it
files or submits under the Securities Exchange Act is
accumulated and communicated to the companys management,
including its principal executive and principal financial
officers, or persons performing similar functions, as
appropriate to allow timely decisions regarding required
disclosure.
As described below under (b) Internal Control Over
Financial Reporting, we have identified and reported to our
Audit Committee of our Board of Directors and Ernst &
Young LLP, our independent registered public accounting
firm, material weaknesses in our internal control over financial
reporting. As a result of these material weaknesses, our chief
executive officer and chief financial officer have concluded
that, as of December 31, 2004, our disclosure controls and
procedures were not effective.
(b) Internal Control Over Financial Reporting
Our management is also responsible for establishing and
maintaining adequate internal control over financial reporting,
as that term is defined in Securities Exchange Act
Rules 13a-15(f) and 15d-15(f). The Sarbanes-Oxley Act of
2002 (Sarbanes-Oxley) and the SECs related
rules and regulations impose on us requirements regarding
corporate governance and financial reporting. One requirement,
arising under Section 404 of Sarbanes-Oxley and beginning
with this Annual Report on Form 10-K, is for management to
report on our internal control over financial reporting and for
our independent registered public accounting firm,
Ernst & Young LLP, to attest to managements
assessment and to the effectiveness of our internal control over
financial reporting.
On November 30, 2004, the SEC issued an exemptive order
providing a 45-day extension for the filing of these reports and
attestations by eligible companies. We have elected to utilize
this 45-day extension and, therefore, this Annual Report on
Form 10-K does not include managements report on the
effectiveness of our internal control over financial reporting
or Ernst & Young LLPs attestation report. We
intend to include our report and the attestation report of
Ernst & Young LLP in an amendment to this Annual
Report on Form 10-K, in accordance with the SECs
exemptive order.
Beginning in the third quarter of fiscal 2004, and continuing
through the first quarter of fiscal 2005, our financial
management has devoted substantial time and resources to
analyzing, documenting and testing our system of internal
control over financial reporting. During this time, however, our
financial management resources were significantly constrained by
multiple factors, including: (a) the workload necessary to
develop and support our financial and strategic planning of
potential modifications to our business model; (b) turnover
of our financial management and staff during the second half of
2004, including transitions in the positions of chief financial
officer and corporate controller in September 2004 and November
2004, respectively; and (c) existing weaknesses in our
finance organization relating to our internal control over
financial reporting, which were disclosed as material weaknesses
in Item 4 of both our report on Form 10-Q for our
third quarter of fiscal 2004 and our amended report on
Form 10-Q/ A for our second quarter of fiscal 2004, both of
which reports we filed with the Securities and Exchange
Commission in November 2004. Consequently, we have experienced
significant delays as part of our process of performing the
required management assessment of internal control over
financial reporting in accordance with Section 404 of
Sarbanes-Oxley.
76
As of the date of this report, we have identified certain
material weaknesses in internal control over financial reporting
as of December 31, 2004. We have reported both to our Audit
Committee and to Ernst & Young LLP, our
independent registered public accounting firm, the material
weaknesses in our internal control over financial reporting as
of December 31, 2004 that have been identified to date, and
certain remedial measures that we have implemented in response
to those material weaknesses. The nature of the material
weaknesses that we have identified to date and the remedial
measures being implemented by us are as follows:
Identification of material weaknesses: A material
weakness is a control deficiency, or a combination of control
deficiencies, that results in there being more than a remote
likelihood that a material misstatement of the annual or interim
financial statements will not be prevented or detected. During
2004 and as part of our work to date to perform an assessment of
the effectiveness of internal control over financial reporting,
we have identified six material weaknesses at December 31,
2004 as follows:
|
|
|
|
|
A material weakness existed in our financial statement close
process for preparing and compiling our financial statements for
external reporting, including (a) ineffective controls to
ensure timely review of all account reconciliations and
significant financial statement accounts; (b) inadequate
controls to determine that financial spreadsheets are accurately
calculated and protected against unauthorized changes; and
(c) ineffective controls over the review of financial
statements for inclusion in periodic external financial reports. |
|
|
|
A material weakness existed in our contract administration
process, including (a) lack of a centralized contract
administration function; (b) lack of a formal contract
approval process and signature authority matrix; and
(c) lack of a process to review all contractual commitments
in order to properly capture and record their effects on the
financial statements and related disclosures. |
|
|
|
A material weakness existed in our inventory cost accounting
process, including (a) ineffective control processes for
determining excess and obsolescence and lower-of-cost-or-market
inventory write-offs; (b) ineffective management review of
cost accounting processes; (c) inadequate controls over the
completeness and accuracy of information calculated using manual
spreadsheets for inventory costing and related cost-of-sales
variance calculations; and (d) inadequate controls for
verification of inventory and components held by third parties. |
|
|
|
A material weakness existed in our control environment relating
to inadequate staffing of our technical accounting function,
including a lack of sufficient personnel with skills, training
and familiarity with certain complex technical accounting
pronouncements that have or may affect the Companys
financial statements and disclosures. |
|
|
|
A material weakness existed in our processes to determine the
existence of fixed assets recorded on our balance sheet,
including inadequate controls over the monitoring and tracking
of our fixed assets and the physical verification of our fixed
assets. |
|
|
|
A material weakness existed in our segregation of duties among
our limited finance department staff, including lack of internal
controls in our accounts payable function sufficient to prevent
or timely detect error or fraud that could have had a material
impact on the financial statements of the Company. |
We have previously identified and disclosed the first and second
of these six material weaknesses, and certain aspects of the
third material weakness, in both our Form 10-Q/ A for our
second quarter of fiscal 2004 and our Form 10-Q for our
third quarter of fiscal 2004, both of which we filed in November
2004. These material weaknesses resulted in a restatement of our
previously filed financial results for the second quarter of
fiscal 2004, which were corrected in the third quarter of fiscal
2004 when we filed the Form 10-Q/ A with the Securities and
Exchange Commission. We identified the rest of our material
weaknesses in connection with conducting our evaluation and
testing as required by Section 404 of Sarbanes-Oxley.
In view of the material weaknesses described here in
Item 9A, we undertook additional processes to ensure that
our financial statements at and for the year ended
December 31, 2004 are stated fairly in all
77
material respects in accordance with U.S. generally
accepted accounting principles. These processes included
additional year-end procedures relating to our inventory and
inventory valuation, accounts receivable, open purchase orders
and related obligations, contractual obligations, and fixed
assets. In addition, as part of these processes, management
concluded that no material adjustments were needed to such
financial statements or with respect to amounts recorded in the
interim periods in the year ended December 31, 2004.
Notwithstanding the above-mentioned material weaknesses, in
light of the processes involved in our preparation of our
consolidated financial statements for the year ended
December 31, 2004, included in this Annual Report, we
believe that these financial statements fairly present our
consolidated financial position as of, and the consolidated
results of operations for the year ended, December 31,
2004. Nothing has come to the attention of management that would
cause us to believe that the material weaknesses described above
have resulted in any material inaccuracies or errors in our
publicly reported financial statements as of and for the year
ended December 31, 2004 or for any other annual financial
statements publicly reported for any prior period.
Remediation efforts. We have been, and intend to
continue, planning and implementing changes to our processes
that we believe are reasonably likely to improve and materially
affect our internal control over financial reporting. We
anticipate that remediation will be continuing throughout fiscal
2005, during which we expect to continue pursuing appropriate
corrective actions, including the following:
|
|
|
|
|
To improve our financial statement close process, we are
(a) establishing a more efficient and effective
responsibilities matrix for our close process to provide timely
and accurate completion of financial reporting as well as timely
review and approval by the controller of all balance sheet
reconciliations and account balances, respectively;
(b) assembling an inventory of financial spreadsheets used
to support preparation of our financial statements and assigning
responsibility to review all such spreadsheets for calculational
integrity and security access limitation; and (c) planning
a transition from our SAP financial system to a new financial
system which will be simpler to maintain, less costly to modify,
and better aligned with our financial statement requirements. |
|
|
|
To improve our contract administration process, we are
initiating a centralized contract administration function. The
purpose of such function will include documenting the contract
approval process and determining that all contractual
commitments are properly provided to the finance department. As
an interim measure, authorization to execute contracts on behalf
of the Company is limited to the chief executive officer, the
chief financial officer, or the general counsel. |
|
|
|
To improve our inventory cost accounting process, during the
fourth quarter of 2004, (a) we engaged an inventory cost
accounting consultant to review our significant cost accounting
entries and to assist in the re-design of the inventory analysis
and reporting process; and (b) the chief financial officer
established a product pricing committee composed of sales,
marketing, manufacturing, and finance staff with the purpose to
formally set product pricing relative to the market, costs to
build, and available inventory, and to establish standard terms
and conditions, which are all factors used in the development of
inventory valuation. Additionally, as noted above, a new
financial system will be implemented to include a re-designed
cost accounting system. |
|
|
|
To improve our technical accounting function, we are developing
technical expertise to support the development of our business
both by training our current staff and by adding, as
appropriate, permanent staff with such technical accounting
skills and internal control process background as may be
required. |
|
|
|
To improve our fixed asset system tracking, we will initiate a
formal fixed asset tagging system that can be tied to our fixed
asset register, and we will periodically conduct physical
inventories of fixed assets to verify the existence of assets
recorded our balance sheet. |
|
|
|
To improve our segregation of duties in accounts payable, we are
in the process of establishing additional controls over the
authorizations and approvals of transactions and expenditures,
and we are currently evaluating the resource requirements of the
Company in order to build a well-controlled and effective
organization and to ensure segregation of key functions within
our finance department. |
78
Although we have already taken some actions to remediate these
material weaknesses, further action is required to complete our
remediation. Our management and Audit Committee will monitor
closely the implementation of our remediation plan. The
effectiveness of the steps we have taken to date and the steps
we are still in the process of completing is subject to
continued management review, as well as Audit Committee
oversight, and we may make additional changes to our internal
control over financial reporting. Although we have undertaken
the initiatives described above, the existence of a material
weakness is an indication that there is more than a remote
likelihood that a material misstatement of our financial
statements will not be prevented or detected. While we are
undertaking our remediation plan, material weaknesses may
continue to exist that could result in material misstatements in
the Companys annual or interim financial statements not
being prevented or detected by the Companys controls in a
timely manner.
We cannot assure you that we will not in the future identify
further material weaknesses in our internal control over
financial reporting. We currently are unable to determine when
the above-mentioned material weaknesses will be fully
remediated. However, because remediation will not be completed
until we have added finance staff and strengthened pertinent
controls, we presently do not believe that we will be able to
remediate by the end of our first quarter of fiscal 2005, and we
presently anticipate that we will report in our Quarterly Report
on Form 10-Q for the first quarter of fiscal 2005 that
material weaknesses continue to exist.
Currently, we are not aware of any material weaknesses in our
internal control over financial reporting other than as
described above. However, we are continuing to evaluate and test
our internal control over financial reporting. There can be no
assurance that, as a result of our ongoing evaluation of our
internal control over financial reporting, we will not identify
additional material weaknesses, or that our evaluation and
testing of internal control over financial reporting will be
completed by the end of the 45-day extension period.
As a result of the identified material weaknesses, upon
completion of our evaluation and testing of our internal control
over financial reporting, we expect that our management will
determine that our internal control over financial reporting, as
of December 31, 2004, was not effective.
(c) Changes in Internal Control Over Financial
Reporting
Regulations under the Securities Exchange Act require public
companies to evaluate any change in internal control over
financial reporting. Other than as discussed herein, there were
no changes in our internal controls over financial reporting
that occurred during our most recent fiscal quarter that have
materially affected, or are reasonably likely to materially
affect, our internal controls over financial reporting. Other
than as set out above, there were no changes in our internal
control over financial reporting during the fiscal quarter ended
December 31, 2004 that materially affected, or are
reasonably likely to materially affect, our internal control
over financial reporting. As described above, we have determined
that the identified significant deficiencies in the
Companys internal control over financial reporting
constitute material weaknesses and, during 2005, we have made
changes and plan to continue to make changes to our internal
control over financial reporting as part of our steps to
remediate such weaknesses.
(d) Inherent Limitations on Effectiveness of Controls
Our management, including our chief executive officer and our
chief financial officer, does not expect that our disclosure
controls and procedures or our internal control over financial
reporting will prevent or detect all errors and all fraud. Any
control system, no matter how well designed and operated, can
provide only reasonable, not absolute, assurance that the
control systems objectives will be met. The design of a
control system must reflect the fact that there are resource
constraints, and the benefits of controls must be considered
relative to their costs. Further, because of the inherent
limitations in all control systems, no evaluation of controls
can provide absolute assurance that misstatements due to error
or fraud will not occur or that all control issues and instances
of fraud, if any, within the company have been detected. These
inherent limitations include the realities that judgments in
decision-making can be faulty and that breakdowns can occur
because of simple error or mistake. Controls can also be
circumvented by the individual acts of some persons, by
collusion of two or more people, or by management override of
the controls. The design of any system of controls is based in
part on certain assumptions about the likelihood of future
events, and there can be no assurance that any design will
succeed in achieving its stated goals under all potential future
conditions.
79
Projections of any evaluation of controls effectiveness to
future periods are subject to risks. Over time, controls may
become inadequate because of changes in conditions or
deterioration in the degree of compliance with policies or
procedures.
Item 9B. Other Information
Not applicable.
PART III
|
|
Item 10. |
Directors and Executive Officers of the Registrant |
The information under the captions,
Proposal No. 1 Election of
Directors, Executive Officers and
Compliance Under Section 16(a) of the Securities
Exchange Act of 1934 in our 2005 Proxy Statement is
incorporated herein by reference.
We have adopted a Code of Ethics for Chief Executive Officer and
Senior Financial Officers that applies to our chief executive
officer and senior finance professionals. We have adopted a
Corporate Code of Conduct that applies to our directors,
officers and employees. In addition, we have adopted a Policy
Regarding Accounting Complaints and Concerns. These corporate
policies are posted on our company website at
http://www.transmeta.com.
|
|
Item 11. |
Executive Compensation |
The information required by this item is incorporated by
reference to our definitive proxy statement for our 2005 Annual
Meeting of Stockholders.
|
|
Item 12. |
Security Ownership of Certain Beneficial Owners and
Management and Related Stockholder Matters |
The information required by this item is incorporated by
reference to our definitive proxy statement for our 2005 Annual
Meeting of Stockholders.
|
|
Item 13. |
Certain Relationships and Related Transactions |
The information required by this item is incorporated by
reference to our definitive proxy statement for our 2005 Annual
Meeting of Stockholders.
|
|
Item 14. |
Principal Accountant Fees and Services |
The information required by this item is incorporated by
reference to our definitive proxy statement for our 2005 Annual
Meeting of Stockholders.
PART IV
|
|
Item 15. |
Exhibits and Financial Statement Schedules |
(a) The following documents are filed as part of this
report:
1. Financial
Statements See Index to Consolidated Financial
Statements in Part II, Item 8.
2. Financial Statement
Schedules All financial statement schedules have
been omitted because the information required is not applicable
or is shown in the Consolidated Financial Statements or notes
thereto.
3. Exhibits
80
The following exhibits are filed herewith or incorporated by
reference herein:
|
|
|
|
|
Exhibit | |
|
|
Number | |
|
Exhibit Title |
| |
|
|
|
3 |
.01 |
|
Second Amended and Restated Certificate of Incorporation.
Incorporated by reference to Exhibit 3.01 to
Transmetas Form 10-K for the year ended December 31,
2000. |
|
3 |
.02 |
|
Restated Bylaws. Incorporated by reference to Exhibit 3.06
to Transmetas Form S-1 Registration Statement (File
No. 333-44030) (the IPO S-1). |
|
3 |
.03 |
|
Certificate of Designations specifying the terms of the
Series A Junior Participating Preferred Stock of Transmeta
as filed with the Secretary of State of the State of Delaware on
January 15, 2002. Incorporated by reference to
Exhibit 3.02 to Transmetas Form 8-A Registration
Statement filed on January 16, 2002. |
|
4 |
.01 |
|
Specimen common stock certificate. Incorporated by reference to
Exhibit 4.01 to the IPO S-1. |
|
4 |
.02 |
|
Fifth Restated Investors Rights Agreement dated
March 31, 2000, between Transmeta, certain stockholders of
Transmeta and a convertible note holder named therein.
Incorporated by reference to Exhibit 4.02 to the IPO S-1. |
|
4 |
.03 |
|
Form of Piggyback Registration Rights Agreement. Incorporated by
reference to Exhibit 4.03 to the IPO S-1. |
|
4 |
.04 |
|
Rights Agreement dated January 15, 2002 between Transmeta
and Mellon Investor Services LLC as Rights Agent, which includes
as Exhibit A the form of Certificate of Designations of
Series A Junior Participating Preferred Stock, as
Exhibit B the Summary of Stock Purchase Rights and as
Exhibit C the Form of Rights Certificate. Incorporated by
reference to Exhibit 4.01 to Transmetas Form 8-A
Registration Statement filed on January 16, 2002. |
|
10 |
.01 |
|
Form of Indemnity Agreement. Incorporated by reference to
Exhibit 10.01 to the IPO S-1.** |
|
10 |
.02 |
|
1995 Equity Incentive Plan. Incorporated by reference to
Exhibit 10.02 to the IPO S-1.** |
|
10 |
.03 |
|
1997 Equity Incentive Plan. Incorporated by reference to
Exhibit 10.03 to the IPO S-1.** |
|
10 |
.04 |
|
2000 Equity Incentive Plan. Incorporated by reference to
Exhibit 4.06 to Transmetas Form S-8 Registration
Statement filed January 18, 2002.** |
|
10 |
.05 |
|
2000 Employee Stock Purchase Plan. Incorporated by reference to
Exhibit 4.08 to Transmetas Form S-8 Registration
Statement filed May 28, 2002.** |
|
10 |
.06 |
|
Lease Agreement, dated November 1, 1995, between John
Arrillaga, as trustee of John Arrillaga Family Trust, Richard T.
Peery, as trustee of Richard T. Peery Separate Property Trust,
and Transmeta, as amended by Amendment No. 1, dated
January 29, 1997, and Amendment No. 2, dated
April 2, 1998, between John Arrillaga, as trustee of John
Arrillaga Survivors Trust (successor in interest to the
Arrillaga Family Trust), Richard T. Peery, as trustee of Richard
T. Peery Separate Property Trust, and Transmeta. Incorporated by
reference to Exhibit 10.08 to the IPO S-1. |
|
10 |
.07 |
|
Lease Agreement, dated January 29, 1997, between John
Arrillaga, as trustee of John Arrillaga Family Trust, Richard T.
Peery, as trustee of Richard T. Peery Separate Property Trust,
and Transmeta, as amended by Amendment No. 1, dated
April 2, 1998, between John Arrillaga, as trustee of John
Arrillaga Survivors Trust (successor in interest to the
Arrillaga Family Trust), Richard T. Peery, as trustee of Richard
T. Peery Separate Property Trust, and Transmeta. Incorporated by
reference to Exhibit 10.09 to the IPO S-1. |
|
10 |
.08 |
|
Lease Agreement, dated April 2, 1998, between John
Arrillaga, as trustee of John Arrillaga Survivors Trust,
Richard T. Peery, as trustee of Richard T. Peery Separate
Property Trust, and Transmeta. Incorporated by reference to
Exhibit 10.10 to the IPO S-1. |
|
10 |
.09 |
|
Lease Agreement, dated April 2, 1998, between John
Arrillaga, as trustee of John Arrillaga Survivors Trust,
Richard T. Peery, as trustee of Richard T. Peery Separate
Property Trust, and Transmeta. Incorporated by reference to
Exhibit 10.11 to the IPO S-1. |
|
10 |
.10 |
|
Sublease Agreement, dated as of April 28, 1999, between
Transmeta and Xuan Nguyen dba World Marketing Alliance.
Incorporated by reference to Exhibit 10.13 to the IPO S-1. |
|
10 |
.11 |
|
Form of Stock Option Agreement under Transmetas 2000
Equity Incentive Plan. Incorporated by reference to
Exhibit 10.17 to the IPO S-1.** |
81
|
|
|
|
|
Exhibit | |
|
|
Number | |
|
Exhibit Title |
| |
|
|
|
10 |
.12 |
|
Form of Stock Option Agreement (for Non-Employee Directors)
under Transmetas 2000 Equity Incentive Plan. Incorporated
by reference to Exhibit 10.18 to the IPO S-1.** |
|
10 |
.13 |
|
Form of Stock Option Agreement. Incorporated by reference to
Exhibit 10.18 to Transmetas Form 10-K for the
year ended December 31, 2000.** |
|
10 |
.14 |
|
Authorized Exclusive Distributor Agreement, dated
September 12, 2000, between Transmeta and Siltrontech
Electronics Corporation. Incorporated by reference to
Exhibit 10.15 to Transmetas Form 10-K for the
year ended December 31, 2001 (the 2001 10-K). |
|
10 |
.15 |
|
Option Amendment and Termination Agreement, dated
November 16, 2001, between Transmeta and Merle McClendon.
Incorporated by reference to Exhibit 10.17 to the 2001
10-K.** |
|
10 |
.16 |
|
Offer of Employment from Transmeta Corporation to Matthew R.
Perry dated March 21, 2002. Incorporated by reference to
Exhibit 10.22 to Transmetas Form 10-Q for the
quarterly period ended June 30, 2002.** |
|
10 |
.17* |
|
Technology Transfer Services and Technology License Agreement,
dated March 25, 2004, between Transmeta and NEC Electronics
Corporation.+ |
|
10 |
.18* |
|
LongRun2 Technology License Agreement, dated November 29,
2004, between Transmeta and Fujitsu Limited.+ |
|
10 |
.19* |
|
LongRun2 Technology License Agreement, dated January 20,
2005, between Transmeta and Sony Corporation.+ |
|
21 |
.01 |
|
Subsidiaries. Incorporated by reference to Exhibit 21.01 to
the IPO S-1. |
|
23 |
.01* |
|
Consent of Ernst & Young LLP, Independent Registered
Public Accounting Firm. |
|
24 |
.01* |
|
Power of Attorney. See Signature Page. |
|
31 |
.01* |
|
Certification by Matthew R. Perry pursuant to
Rule 13a-14(a). |
|
31 |
.02* |
|
Certification by Mark R. Kent pursuant to Rule 13a-14(a). |
|
32 |
.01* |
|
Certification by Matthew R. Perry pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002. |
|
32 |
.02* |
|
Certification by Mark R. Kent pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002. |
|
|
** |
Management contract or compensatory arrangement. |
|
|
|
|
+ |
Confidential treatment has been requested for portions of this
exhibit. These portions have been omitted from this Report and
have been filed separately with the Securities and Exchange
Commission. |
(b) Exhibits
See Item 15(a)(3) above.
(c) Financial Statement Schedules
See Item 15(a)(2) above.
82
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
|
|
Mark R. Kent |
|
Chief Financial Officer |
|
(Principal Financial Officer and |
|
Duly Authorized Officer) |
Dated: March 28, 2005
POWER OF ATTORNEY
By signing this Form 10-K below, I hereby appoint each of
Matthew R. Perry and Mark R. Kent, as my attorney-in-fact to
sign all amendments to this Form 10-K on my behalf,
and to file this Form 10-K (including all exhibits and
other documents related to the Form 10-K) with the
Securities and Exchange Commission. I authorize each of my
attorneys-in-fact to (1) appoint a substitute
attorney-in-fact for himself and (2) perform any actions
that he or she believes are necessary or appropriate to carry
out the intention and purpose of this Power of Attorney. I
ratify and confirm all lawful actions taken directly or
indirectly by my attorneys-in-fact and by any properly appointed
substitute attorneys-in-fact.
Pursuant to the requirements of the Securities Exchange Act of
1934, this report has been signed by the following persons on
behalf of the Registrant and in the capacities and on the dates
indicated.
|
|
|
|
|
|
|
Signature |
|
Title |
|
Date |
|
|
|
|
|
|
/s/ MATTHEW R. PERRY
Matthew
R. Perry |
|
Chief Executive Officer (Principal Executive Officer) |
|
March 28, 2005 |
|
/s/ MARK R. KENT
Mark
R. Kent |
|
Chief Financial Officer (Principal Financial Officer and Duly
Authorized Officer) |
|
March 25, 2005 |
|
/s/ MURRAY A. GOLDMAN
Murray
A. Goldman |
|
Director |
|
March 25, 2005 |
|
/s/ R. HUGH BARNES
R.
Hugh Barnes |
|
Director |
|
March 25, 2005 |
|
/s/ DAVID R. DITZEL
David
R. Ditzel |
|
Director |
|
March 28, 2005 |
|
/s/ WILLIAM P. TAI
William
P. Tai |
|
Director |
|
March 25, 2005 |
83
|
|
|
|
|
|
|
Signature |
|
Title |
|
Date |
|
|
|
|
|
|
/s/ T. PETER THOMAS
T.
Peter Thomas |
|
Director |
|
March 25, 2005 |
|
/s/ RICK TIMMINS
Rick
Timmins |
|
Director |
|
March 25, 2005 |
84
EXHIBIT INDEX
|
|
|
|
|
Exhibit | |
|
|
Number | |
|
Exhibit Title |
| |
|
|
|
3 |
.01 |
|
Second Amended and Restated Certificate of Incorporation.
Incorporated by reference to Exhibit 3.01 to
Transmetas Form 10-K for the year ended December 31,
2000. |
|
3 |
.02 |
|
Restated Bylaws. Incorporated by reference to Exhibit 3.06
to Transmetas Form S-1 Registration Statement (File
No. 333-44030) (the IPO S-1). |
|
3 |
.03 |
|
Certificate of Designations specifying the terms of the
Series A Junior Participating Preferred Stock of Transmeta
as filed with the Secretary of State of the State of Delaware on
January 15, 2002. Incorporated by reference to
Exhibit 3.02 to Transmetas Form 8-A Registration
Statement filed on January 16, 2002. |
|
4 |
.01 |
|
Specimen common stock certificate. Incorporated by reference to
Exhibit 4.01 to the IPO S-1. |
|
4 |
.02 |
|
Fifth Restated Investors Rights Agreement dated
March 31, 2000, between Transmeta, certain stockholders of
Transmeta and a convertible note holder named therein.
Incorporated by reference to Exhibit 4.02 to the IPO S-1. |
|
4 |
.03 |
|
Form of Piggyback Registration Rights Agreement. Incorporated by
reference to Exhibit 4.03 to the IPO S-1. |
|
4 |
.04 |
|
Rights Agreement dated January 15, 2002 between Transmeta
and Mellon Investor Services LLC as Rights Agent, which includes
as Exhibit A the form of Certificate of Designations of
Series A Junior Participating Preferred Stock, as
Exhibit B the Summary of Stock Purchase Rights and as
Exhibit C the Form of Rights Certificate. Incorporated by
reference to Exhibit 4.01 to Transmetas Form 8-A
Registration Statement filed on January 16, 2002. |
|
10 |
.01 |
|
Form of Indemnity Agreement. Incorporated by reference to
Exhibit 10.01 to the IPO S-1.** |
|
10 |
.02 |
|
1995 Equity Incentive Plan. Incorporated by reference to
Exhibit 10.02 to the IPO S-1.** |
|
10 |
.03 |
|
1997 Equity Incentive Plan. Incorporated by reference to
Exhibit 10.03 to the IPO S-1.** |
|
10 |
.04 |
|
2000 Equity Incentive Plan. Incorporated by reference to
Exhibit 4.06 to Transmetas Form S-8 Registration
Statement filed January 18, 2002.** |
|
10 |
.05 |
|
2000 Employee Stock Purchase Plan. Incorporated by reference to
Exhibit 4.08 to Transmetas Form S-8 Registration
Statement filed May 28, 2002.** |
|
10 |
.06 |
|
Lease Agreement, dated November 1, 1995, between John
Arrillaga, as trustee of John Arrillaga Family Trust, Richard T.
Peery, as trustee of Richard T. Peery Separate Property Trust,
and Transmeta, as amended by Amendment No. 1, dated
January 29, 1997, and Amendment No. 2, dated
April 2, 1998, between John Arrillaga, as trustee of John
Arrillaga Survivors Trust (successor in interest to the
Arrillaga Family Trust), Richard T. Peery, as trustee of Richard
T. Peery Separate Property Trust, and Transmeta. Incorporated by
reference to Exhibit 10.08 to the IPO S-1. |
|
10 |
.07 |
|
Lease Agreement, dated January 29, 1997, between John
Arrillaga, as trustee of John Arrillaga Family Trust, Richard T.
Peery, as trustee of Richard T. Peery Separate Property Trust,
and Transmeta, as amended by Amendment No. 1, dated
April 2, 1998, between John Arrillaga, as trustee of John
Arrillaga Survivors Trust (successor in interest to the
Arrillaga Family Trust), Richard T. Peery, as trustee of Richard
T. Peery Separate Property Trust, and Transmeta. Incorporated by
reference to Exhibit 10.09 to the IPO S-1. |
|
10 |
.08 |
|
Lease Agreement, dated April 2, 1998, between John
Arrillaga, as trustee of John Arrillaga Survivors Trust,
Richard T. Peery, as trustee of Richard T. Peery Separate
Property Trust, and Transmeta. Incorporated by reference to
Exhibit 10.10 to the IPO S-1. |
|
10 |
.09 |
|
Lease Agreement, dated April 2, 1998, between John
Arrillaga, as trustee of John Arrillaga Survivors Trust,
Richard T. Peery, as trustee of Richard T. Peery Separate
Property Trust, and Transmeta. Incorporated by reference to
Exhibit 10.11 to the IPO S-1. |
|
10 |
.10 |
|
Sublease Agreement, dated as of April 28, 1999, between
Transmeta and Xuan Nguyen dba World Marketing Alliance.
Incorporated by reference to Exhibit 10.13 to the IPO S-1. |
|
10 |
.11 |
|
Form of Stock Option Agreement under Transmetas 2000
Equity Incentive Plan. Incorporated by reference to
Exhibit 10.17 to the IPO S-1.** |
|
10 |
.12 |
|
Form of Stock Option Agreement (for Non-Employee Directors)
under Transmetas 2000 Equity Incentive Plan. Incorporated
by reference to Exhibit 10.18 to the IPO S-1.** |
|
|
|
|
|
Exhibit | |
|
|
Number | |
|
Exhibit Title |
| |
|
|
|
10 |
.13 |
|
Form of Stock Option Agreement. Incorporated by reference to
Exhibit 10.18 to Transmetas Form 10-K for the
year ended December 31, 2000.** |
|
10 |
.14 |
|
Authorized Exclusive Distributor Agreement, dated
September 12, 2000, between Transmeta and Siltrontech
Electronics Corporation. Incorporated by reference to
Exhibit 10.15 to Transmetas Form 10-K for the
year ended December 31, 2001 (the 2001 10-K). |
|
10 |
.15 |
|
Option Amendment and Termination Agreement, dated
November 16, 2001, between Transmeta and Merle McClendon.
Incorporated by reference to Exhibit 10.17 to the 2001
10-K.** |
|
10 |
.16 |
|
Offer of Employment from Transmeta Corporation to Matthew R.
Perry dated March 21, 2002. Incorporated by reference to
Exhibit 10.22 to Transmetas Form 10-Q for the
quarterly period ended June 30, 2002.** |
|
10 |
.17* |
|
Technology Transfer Services and Technology License Agreement,
dated March 25, 2004, between Transmeta and NEC Electronics
Corporation.+ |
|
10 |
.18* |
|
LongRun2 Technology License Agreement, dated November 29,
2004, between Transmeta and Fujitsu Limited.+ |
|
10 |
.19* |
|
LongRun2 Technology License Agreement, dated January 20,
2005, between Transmeta and Sony Corporation.+ |
|
21 |
.01 |
|
Subsidiaries. Incorporated by reference to Exhibit 21.01 to
the IPO S-1. |
|
23 |
.01* |
|
Consent of Ernst & Young LLP, Independent Registered
Public Accounting Firm. |
|
24 |
.01* |
|
Power of Attorney. See Signature Page. |
|
31 |
.01* |
|
Certification by Matthew R. Perry pursuant to
Rule 13a-14(a). |
|
31 |
.02* |
|
Certification by Mark R. Kent pursuant to Rule 13a-14(a). |
|
32 |
.01* |
|
Certification by Matthew R. Perry pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002. |
|
32 |
.02* |
|
Certification by Mark R. Kent pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002. |
|
|
** |
Management contract or compensatory arrangement. |
|
|
|
|
+ |
Confidential treatment has been requested for portions of this
exhibit. These portions have been omitted from this Report and
have been filed separately with the Securities and Exchange
Commission. |